[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvIky7enjbPMrcqNGJUe5pZy8dJXtpTcy3qA83LKFd5o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":84,"rows":91},"Vanderbilt University Medical Center",[4],814,false,229,23,794469,102,553,[14,17,20,22,25,27,30,33],{"name":15,"count":16},"Obesity",30,{"name":18,"count":19},"Hypertension",15,{"name":21,"count":19},"Delirium",{"name":23,"count":24},"Parkinson Disease",14,{"name":26,"count":24},"Autism Spectrum Disorder",{"name":28,"count":29},"Depression",13,{"name":31,"count":32},"Critical Illness",12,{"name":34,"count":35},"Diabetes Mellitus, Type 2",11,[37,42,47,52,56,61,66,71,76,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04417595","Omega-3 Fatty Acids for Smoking Cessation in Pregnancy","2024-11-30","Fish Oil",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05297786","Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease","2024-12-30","Lanadelumab Injection [Takhzyro]",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04050410","Autonomic Determinants of POTS - Pilot1","2025-12-31","Moxonidine",{"nctId":53,"briefTitle":54,"date":50,"intervention":55},"NCT04140721","Autonomic Determinants of POTS - Pilot 2","Moxonidine Pill",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07123350","Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease","2026-03-31","Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04801589","Goal-Directed Sedation in Mechanically Ventilated Infants and Children","2026-04-17","Dexmedetomidine",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07116421","Effect of Rose Odor Exposure on Ictal Apnea","2026-05-08","2-phenylethanol rose scent",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06057675","Tranexamic Acid in Nasal Mohs Reconstruction","2026-06","Treatment",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT05357612","Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases","Pimavanserin",{"nctId":81,"briefTitle":82,"date":74,"intervention":83},"NCT03654066","Botox or Botox With Esophageal Dilation in Patients With Achalasia","Botulinum toxin type A",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,129,147,165,183,201,219,237,260,288,318,346,368,392,410,433,505,568,646,708,734,752,778,803,829,855,900,949,992,1030,1061,1098,1120,1239,1295,1324,1370,1409,1437,1470,1492,1510,1534,1560,1578,1602,1620,1638,1656,1682,1707,1732,1754,1777,1795,1822,1840,1858,1887,1905,1923,1945,1963,1986,2010,2042,2076,2122,2147,2170,2194,2217,2235,2263,2281,2329,2363,2386,2404,2426,2444,2462,2480,2498,2527,2550,2570,2595,2614,2664,2710,2732,2754,2792,2818,2844,2871,2889,2907,2925,2947,2969,2996,3052,3093,3115,3164,3195,3232,3256,3280,3298,3316,3334,3358,3376,3401,3419,3446,3464,3491,3509,3527,3553,3577,3595,3613,3631,3655,3681,3699,3721,3746,3764,3790,3814,3832,3850,3876,3899,3917,3943,3961,3979,3997,4023,4049,4073,4091,4109,4135,4159,4186,4213,4231,4249,4267,4285,4303,4321,4348,4366,4391,4417,4440,4468,4486,4504,4528,4552,4570,4596,4620,4644,4670,4688,4712,4735,4760,4785,4803,4828,4846,4864,4887,4910,4928,4955,4973,5001,5019,5037,5055,5073,5101,5125,5143,5161,5186,5212,5230,5259,5277,5302,5333,5360,5384,5408,5429,5452,5470,5488,5512,5530,5559,5584,5607,5636,5660,5683,5708,5726,5744,5762,5785,5809,5827,5851,5877,5901,5924,5953,5978,6005,6028,6046,6070,6095,6120,6143,6167,6190,6223,6241,6265,6288,6313,6331,6349,6367,6385,6403,6426,6450,6468,6492,6510,6528,6553,6577,6601,6619,6637,6662,6686,6712,6730,6748,6766,6790,6808,6826,6849,6873,6891,6915,6940,6958,6976,7000,7018,7041,7098,7132,7168,7202,7237,7259,7281,7303,7329,7358,7380,7402,7424,7446,7469,7496,7520,7538,7556,7574,7592,7610,7628,7646,7664,7682,7700,7718,7736,7754,7772,7790,7808,7826,7844,7862,7880,7898,7916,7934,7952,7970,7988,8006,8024,8042,8066,8092,8110,8133,8157,8179,8202,8220,8243,8261,8279,8301,8319,8337,8359,8383,8405,8431,8456,8478,8500,8525,8543,8561,8579,8597,8615,8638,8656,8681,8705,8723,8749,8767,8785],{"intervention":93,"totalTrials":94,"cells":95},"Buccal Buprenorphine 300 mcg",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":127},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":120},"NCT05988710","Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia","RECRUITING",[89],"2028-01","2028-02","2023-10-19",120,[117,118,119],"Analgesia","Abuse Opioids","Pain",[93,121,122,123,124,125,126],"Buccal Buprenorphine 600 mcg","Buccal Buprenorphine 900 mcg","Buccal Placebo","Oral Placebo","Oral immediate-release oxycodone 10mg","Buccal Buprenorphine 450mcg",{"trials":128,"activeCount":98},[],{"intervention":121,"totalTrials":94,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":145},{"trials":132,"activeCount":98},[],{"trials":134,"activeCount":98},[],{"trials":136,"activeCount":98},[],{"trials":138,"activeCount":98},[],{"trials":140,"activeCount":94,"soonestReadout":112},[141],{"nctId":108,"briefTitle":109,"status":110,"phases":142,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":143,"interventions":144},[89],[117,118,119],[93,121,122,123,124,125,126],{"trials":146,"activeCount":98},[],{"intervention":122,"totalTrials":94,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":163},{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":98},[],{"trials":154,"activeCount":98},[],{"trials":156,"activeCount":98},[],{"trials":158,"activeCount":94,"soonestReadout":112},[159],{"nctId":108,"briefTitle":109,"status":110,"phases":160,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":161,"interventions":162},[89],[117,118,119],[93,121,122,123,124,125,126],{"trials":164,"activeCount":98},[],{"intervention":123,"totalTrials":94,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":181},{"trials":168,"activeCount":98},[],{"trials":170,"activeCount":98},[],{"trials":172,"activeCount":98},[],{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":94,"soonestReadout":112},[177],{"nctId":108,"briefTitle":109,"status":110,"phases":178,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":179,"interventions":180},[89],[117,118,119],[93,121,122,123,124,125,126],{"trials":182,"activeCount":98},[],{"intervention":124,"totalTrials":94,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":199},{"trials":186,"activeCount":98},[],{"trials":188,"activeCount":98},[],{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":94,"soonestReadout":112},[195],{"nctId":108,"briefTitle":109,"status":110,"phases":196,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":197,"interventions":198},[89],[117,118,119],[93,121,122,123,124,125,126],{"trials":200,"activeCount":98},[],{"intervention":125,"totalTrials":94,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":217},{"trials":204,"activeCount":98},[],{"trials":206,"activeCount":98},[],{"trials":208,"activeCount":98},[],{"trials":210,"activeCount":98},[],{"trials":212,"activeCount":94,"soonestReadout":112},[213],{"nctId":108,"briefTitle":109,"status":110,"phases":214,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":215,"interventions":216},[89],[117,118,119],[93,121,122,123,124,125,126],{"trials":218,"activeCount":98},[],{"intervention":126,"totalTrials":94,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":235},{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":98},[],{"trials":226,"activeCount":98},[],{"trials":228,"activeCount":98},[],{"trials":230,"activeCount":94,"soonestReadout":112},[231],{"nctId":108,"briefTitle":109,"status":110,"phases":232,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":233,"interventions":234},[89],[117,118,119],[93,121,122,123,124,125,126],{"trials":236,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":258},{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":98},[],{"trials":244,"activeCount":98},[],{"trials":246,"activeCount":98},[],{"trials":248,"activeCount":94,"soonestReadout":74},[249],{"nctId":77,"briefTitle":78,"status":110,"phases":250,"primaryCompletion":74,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":257},[89],"2026-08","2023-01-23",75,[255,23,256],"Neurodegenerative Diseases","Parkinson Disease Psychosis",[79],{"trials":259,"activeCount":98},[],{"intervention":261,"totalTrials":94,"cells":262},"GlyNAC",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":286},{"trials":264,"activeCount":98},[],{"trials":266,"activeCount":98},[],{"trials":268,"activeCount":98},[],{"trials":270,"activeCount":98},[],{"trials":272,"activeCount":94,"soonestReadout":277},[273],{"nctId":274,"briefTitle":275,"status":110,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":285},"NCT06083480","Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty",[89],"2028-09","2029-03","2024-12-06",148,[282,283,284],"Osteoarthritis, Knee","Total Knee Arthroplasty","Chronic Postsurgical Pain",[261],{"trials":287,"activeCount":98},[],{"intervention":289,"totalTrials":94,"cells":290},"Vericiguat",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":316},{"trials":292,"activeCount":98},[],{"trials":294,"activeCount":98},[],{"trials":296,"activeCount":98},[],{"trials":298,"activeCount":98},[],{"trials":300,"activeCount":94,"soonestReadout":305},[301],{"nctId":302,"briefTitle":303,"status":110,"phases":304,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":315},"NCT05812755","SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery",[89],"2026-12","2027-11","2023-05-19",170,[310,311,312,313,314],"Endothelial Dysfunction","Vascular Diseases","Kidney Injury","Brain Disease","Vascular Inflammation",[289],{"trials":317,"activeCount":98},[],{"intervention":319,"totalTrials":94,"cells":320},"Lidocaine HCl 0.8% in D5W",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":344},{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":94,"soonestReadout":336},[331],{"nctId":332,"briefTitle":333,"status":334,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":342},"NCT07224711","The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","NOT_YET_RECRUITING",[89],"2028-05-30","2026-07-01",2290,[119,340,341],"Post Operative Analgesia","Opioid Consumption, Postoperative",[319,343],"Sodium Chloride 0.9%",{"trials":345,"activeCount":98},[],{"intervention":83,"totalTrials":94,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":356,"NA":366},{"trials":349,"activeCount":98},[],{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":98},[],{"trials":355,"activeCount":98},[],{"trials":357,"activeCount":94,"soonestReadout":74},[358],{"nctId":81,"briefTitle":82,"status":359,"phases":360,"primaryCompletion":74,"completion":74,"start":361,"enrollment":362,"conditions":363,"interventions":365},"ENROLLING_BY_INVITATION",[89],"2019-05-13",50,[364],"Achalasia",[83],{"trials":367,"activeCount":98},[],{"intervention":369,"totalTrials":94,"cells":370},"ValACYclovir 1000 MG",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":390},{"trials":372,"activeCount":98},[],{"trials":374,"activeCount":98},[],{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":98},[],{"trials":380,"activeCount":94,"soonestReadout":251},[381],{"nctId":382,"briefTitle":383,"status":110,"phases":384,"primaryCompletion":251,"completion":251,"start":385,"enrollment":386,"conditions":387,"interventions":388},"NCT05550194","VZV in the Enteric Nervous System: Pathogenesis and Consequences",[89],"2023-03-27",40,[364],[369,389],"Shingrix",{"trials":391,"activeCount":98},[],{"intervention":389,"totalTrials":94,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":402,"NA":408},{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":94,"soonestReadout":251},[404],{"nctId":382,"briefTitle":383,"status":110,"phases":405,"primaryCompletion":251,"completion":251,"start":385,"enrollment":386,"conditions":406,"interventions":407},[89],[364],[369,389],{"trials":409,"activeCount":98},[],{"intervention":411,"totalTrials":94,"cells":412},"Botulinum Toxin Type A Injection [Botox]",{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":431},{"trials":414,"activeCount":98},[],{"trials":416,"activeCount":98},[],{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":94,"soonestReadout":427},[423],{"nctId":424,"briefTitle":425,"status":334,"phases":426,"primaryCompletion":427,"completion":427,"start":337,"enrollment":362,"conditions":428,"interventions":430},"NCT07295288","Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis",[89],"2027-06-30",[429],"Synkinesis",[411],{"trials":432,"activeCount":98},[],{"intervention":434,"totalTrials":435,"cells":436},"Hydroxyurea",5,{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":469,"PHASE4":482,"NA":494},{"trials":438,"activeCount":98},[],{"trials":440,"activeCount":98},[],{"trials":442,"activeCount":98},[443,457],{"nctId":444,"briefTitle":445,"status":446,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":455},"NCT03634488","Management of Severe Acute Malnutrition in SCD, in Northern Nigeria","COMPLETED",[87],"2022-10-05","2022-11-09","2021-08-18",132,[453,454],"Sickle Cell Anemia","Severe Acute Malnutrition",[456],"hydroxyurea",{"nctId":458,"briefTitle":459,"status":446,"phases":460,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT05142254","A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study",[87],"2023-07-10","2023-11-09","2022-04-01",64,[466],"Priapism Due to Sickle Cell Disease",[468,434],"Tadalafil",{"trials":470,"activeCount":98},[471],{"nctId":472,"briefTitle":473,"status":446,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":481},"NCT02560935","Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II",[88],"2020-03-03","2016-07-19",440,[479,480],"Sickle Cell Disease","Stroke",[434,434],{"trials":483,"activeCount":94,"soonestReadout":488},[484],{"nctId":485,"briefTitle":486,"status":110,"phases":487,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":493},"NCT06526117","Stroke Prevention in Nigeria 2 Trial",[89],"2029-12-31","2030-06-30","2024-08-05",220,[479,480],[434],{"trials":495,"activeCount":98},[496],{"nctId":497,"briefTitle":498,"status":446,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":504},"NCT01801423","Sickle Cell Disease - Stroke Prevention in Nigeria Trial",[90],"2019-01-31","2013-04-24",29,[453,479,480],[434],{"intervention":343,"totalTrials":506,"cells":507},2,{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":522},{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"trials":513,"activeCount":98},[],{"trials":515,"activeCount":98},[],{"trials":517,"activeCount":94,"soonestReadout":336},[518],{"nctId":332,"briefTitle":333,"status":334,"phases":519,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":520,"interventions":521},[89],[119,340,341],[319,343],{"trials":523,"activeCount":98},[524],{"nctId":525,"briefTitle":526,"status":446,"phases":527,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":534},"NCT02726620","Decision Support for Intraoperative Low Blood Pressure",[90],"2017-12-31","2018-12-29","2017-01-05",22435,[533],"Hypotension",[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],"Propofol","Sevoflurane","Desflurane","Isoflurane","Ephedrine","Phenylephrine","Norepinephrine","Epinephrine","Dobutamine","Dopamine","Isoproterenol","Milrinone","Atropine","Glycopyrrolate","Vasopressin","Terlipressin","Ringer's lactate","Hydroxyethyl starch solutions","Fresh Frozen Plasma","Packed Red Blood Cells","Albumin solutions","Plasma-Lyte","Lidocaine","Bupivacaine","Levobupivacaine","Ropivacaine","Mepivacaine","Tetracaine","Prilocaine","Procaine","Chloroprocaine","Benzocaine","Articaine",{"intervention":569,"totalTrials":435,"cells":570},"Icatibant",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":603,"PHASE4":615,"NA":644},{"trials":572,"activeCount":98},[],{"trials":574,"activeCount":98},[],{"trials":576,"activeCount":98},[577,592],{"nctId":578,"briefTitle":579,"status":580,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":98,"conditions":584,"interventions":588},"NCT03005184","Mechanism(s) Underlying Cardiovascular Effects of ARB\u002FNEP Inhibition - Aim 2","WITHDRAWN",[87],"2020-01","2017-09",[585,586,587],"Heart Failure NYHA Class I","Heart Failure NYHA Class II","Heart Failure NYHA Class III",[589,590,591,569],"Valsartan 80 mg bid","Enalapril 10 mg bid","Sacubitril-Valsartan 200 mg bid",{"nctId":593,"briefTitle":594,"status":446,"phases":595,"primaryCompletion":596,"completion":597,"start":598,"enrollment":35,"conditions":599,"interventions":602},"NCT03177798","Mitochondria and Chronic Kidney Disease",[87],"2018-06-30","2018-12-31","2017-08-01",[600,601],"Hemodialysis-Induced Symptom","Mitochondrial Diseases",[569],{"trials":604,"activeCount":94,"soonestReadout":337},[605],{"nctId":606,"briefTitle":607,"status":110,"phases":608,"primaryCompletion":337,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":614},"NCT05834777","Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor",[88],"2026-11-01","2023-12-11",26,[613],"Intradialytic Hypotension",[569],{"trials":616,"activeCount":98},[617,631],{"nctId":618,"briefTitle":619,"status":446,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":627},"NCT04113109","Mechanisms Underlying Hypotensive Response to ARB\u002FNEP Inhibition - Aim 2",[89],"2025-04-01","2025-07-30","2019-11-01",46,[626],"Heart Failure",[628,569,629,630],"LCZ 696","Para-aminohippurate","Iohexol",{"nctId":632,"briefTitle":633,"status":634,"phases":635,"primaryCompletion":636,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":642},"NCT01574248","Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema","TERMINATED",[89],"2015-09","2016-02","2011-08",33,[641],"ACE Inhibitor-associated Angioedema",[643],"icatibant",{"trials":645,"activeCount":98},[],{"intervention":65,"totalTrials":647,"cells":648},4,{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":664,"PHASE3":666,"PHASE4":690,"NA":706},{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[653],{"nctId":654,"briefTitle":655,"status":634,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":662},"NCT00826553","How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units",[86],"2013-12","2009-01",6,[21,661],"Respiratory Failure",[65,663],"GABA agonist",{"trials":665,"activeCount":98},[],{"trials":667,"activeCount":94,"soonestReadout":64},[668,679],{"nctId":62,"briefTitle":63,"status":110,"phases":669,"primaryCompletion":64,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":677},[88],"2026-09-16","2021-05-10",372,[21,31,674,675,676],"Sedation Complication","Executive Dysfunction","Post Traumatic Stress Disorder",[65,678],"Midazolam",{"nctId":680,"briefTitle":681,"status":446,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":689},"NCT01739933","The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure",[88],"2019-07","2013-05-15",438,[687,21,688],"Sepsis","Impaired Cognition",[65,535],{"trials":691,"activeCount":98},[692],{"nctId":693,"briefTitle":694,"status":446,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":704},"NCT00808665","Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion",[89],"2012-12","2009-06",68,[700,701,702,703],"Spinal Fusion Acquired","Spinal Stenosis","Lesions of Lumbosacral Intervertebral Disc","Spinal Diseases",[65,705],"0.9% Saline",{"trials":707,"activeCount":98},[],{"intervention":709,"totalTrials":94,"cells":710},"Deutetrabenazine",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":730,"NA":732},{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":98},[],{"trials":718,"activeCount":94,"soonestReadout":724},[719],{"nctId":720,"briefTitle":721,"status":722,"phases":723,"primaryCompletion":724,"completion":725,"start":726,"enrollment":16,"conditions":727,"interventions":729},"NCT04713982","Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease","ACTIVE_NOT_RECRUITING",[87,88],"2026-06-30","2026-10-01","2021-11-19",[728],"Huntington Disease",[709],{"trials":731,"activeCount":98},[],{"trials":733,"activeCount":98},[],{"intervention":678,"totalTrials":94,"cells":735},{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":742,"PHASE4":748,"NA":750},{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":94,"soonestReadout":64},[744],{"nctId":62,"briefTitle":63,"status":110,"phases":745,"primaryCompletion":64,"completion":670,"start":671,"enrollment":672,"conditions":746,"interventions":747},[88],[21,31,674,675,676],[65,678],{"trials":749,"activeCount":98},[],{"trials":751,"activeCount":98},[],{"intervention":753,"totalTrials":94,"cells":754},"Artificial Tears Methylcellulose",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":774,"NA":776},{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":94,"soonestReadout":767},[763],{"nctId":764,"briefTitle":765,"status":110,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":773},"NCT05999630","Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer",[88],"2027-12-31","2023-08-21",100,[771,772],"Nasolacrimal Duct Obstruction","Thyroid Cancer",[753],{"trials":775,"activeCount":98},[],{"trials":777,"activeCount":98},[],{"intervention":779,"totalTrials":94,"cells":780},"Polyethylene Glycol 3350",{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":799,"NA":801},{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":94,"soonestReadout":793},[789],{"nctId":790,"briefTitle":791,"status":359,"phases":792,"primaryCompletion":793,"completion":794,"start":795,"enrollment":16,"conditions":796,"interventions":798},"NCT05897086","Polyethylene-glycol Assisted Nerve Repair in Phalloplasty",[87,88],"2028-12-30","2029-12-01","2023-08-01",[797],"Gender Dysphoria",[779],{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":98},[],{"intervention":804,"totalTrials":94,"cells":805},"Nitric Oxide",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":825,"NA":827},{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":94,"soonestReadout":818},[814],{"nctId":815,"briefTitle":816,"status":359,"phases":817,"primaryCompletion":818,"completion":818,"start":819,"enrollment":362,"conditions":820,"interventions":824},"NCT05101746","Nitric Oxide Effect on Brain and Kidney in Pediatric Patients Undergoing Cardiopulmonary Bypass",[87,88],"2026-09","2022-04-25",[821,822,823],"Congenital Heart Disease","Congenital Heart Defect","Congenital Heart Malformations",[804],{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"intervention":830,"totalTrials":94,"cells":831},"Tirzepatide",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":851,"NA":853},{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":94,"soonestReadout":844},[840],{"nctId":841,"briefTitle":842,"status":359,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":16,"conditions":847,"interventions":850},"NCT06162715","GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial",[87,88],"2027-01-01","2027-12-01","2024-10-30",[848,15,849],"Severe Obesity","BMI Greater Than 30",[830],{"trials":852,"activeCount":98},[],{"trials":854,"activeCount":98},[],{"intervention":856,"totalTrials":857,"cells":858},"Theophylline",3,{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":860,"activeCount":98},[],{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":506,"soonestReadout":881},[865,877,886],{"nctId":866,"briefTitle":867,"status":722,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":876},"NCT04551170","Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old",[87],"2026-12-31","2020-07-13",34,[873,874,875],"Pseudohypoparathyroidism","Albright Hereditary Osteodystrophy","Pseudohypoparathyroidism Type 1a",[856],{"nctId":878,"briefTitle":879,"status":722,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":502,"conditions":883,"interventions":884},"NCT03029429","Theophylline Treatment for Pseudohypoparathyroidism",[87],"2026-12-01","2018-09-01",[873,874],[856,885],"Placebos",{"nctId":887,"briefTitle":888,"status":446,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":659,"conditions":892,"interventions":893},"NCT02463409","Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)",[87],"2016-10","2015-06",[875,874],[856],{"trials":895,"activeCount":98},[],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":98},[],{"intervention":901,"totalTrials":857,"cells":902},"2-Hydroxybenzylamine",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":506,"soonestReadout":724},[909,920,929],{"nctId":910,"briefTitle":911,"status":446,"phases":912,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":919},"NCT04433091","2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation",[87],"2022-01-30","2023-01-30","2020-05-15",95,[918],"Atrial Fibrillation",[901],{"nctId":921,"briefTitle":922,"status":110,"phases":923,"primaryCompletion":724,"completion":869,"start":924,"enrollment":925,"conditions":926,"interventions":928},"NCT04941599","2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)",[87],"2024-02-14",72,[927],"Familial Hypercholesterolemia",[901],{"nctId":930,"briefTitle":931,"status":334,"phases":932,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":936,"interventions":941},"NCT07602166","Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans",[87],"2031-07","2026-07",20,[937,938,939,940],"Salt Sensitivity of Blood Pressure","High Blood Pressure","Inflammation","Renin-Angiotensin-Aldosterone System",[942],"2-hydroxybenzylamine",{"trials":944,"activeCount":98},[],{"trials":946,"activeCount":98},[],{"trials":948,"activeCount":98},[],{"intervention":950,"totalTrials":857,"cells":951},"Transdermal Nicotine patch",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":953,"activeCount":98},[],{"trials":955,"activeCount":98},[],{"trials":957,"activeCount":506,"soonestReadout":972},[958,968,978],{"nctId":959,"briefTitle":960,"status":722,"phases":961,"primaryCompletion":962,"completion":962,"start":963,"enrollment":964,"conditions":965,"interventions":967},"NCT05746546","Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension",[87],"2026-10-31","2023-04-15",60,[966],"Depressive Disorder",[950],{"nctId":969,"briefTitle":970,"status":110,"phases":971,"primaryCompletion":972,"completion":973,"start":963,"enrollment":964,"conditions":974,"interventions":975},"NCT05746273","Depressed Mood Improvement Through Nicotine Dosing 3",[87],"2026-07-31","2026-09-30",[966],[976,977],"Transdermal Nicotine Patch","Transdermal Placebo Patch",{"nctId":979,"briefTitle":980,"status":446,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":502,"conditions":984,"interventions":985},"NCT04433767","Depressed Mood Improvement Through Nicotine Dosing 2",[87],"2022-10-07","2020-12-15",[966],[950],{"trials":987,"activeCount":98},[],{"trials":989,"activeCount":98},[],{"trials":991,"activeCount":98},[],{"intervention":993,"totalTrials":506,"cells":994},"Semaglutide",{"EARLY_PHASE1":995,"PHASE1":1007,"PHASE2":1009,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":996,"activeCount":94,"soonestReadout":1001},[997],{"nctId":998,"briefTitle":999,"status":110,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1006},"NCT06338553","GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab",[85],"2027-03","2024-06-12",24,[1005],"Type 1 Diabetes",[993],{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":94,"soonestReadout":1015},[1011],{"nctId":1012,"briefTitle":1013,"status":110,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":64,"enrollment":1017,"conditions":1018,"interventions":1023},"NCT07221214","GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV",[87],"2029-10-31","2030-01-31",200,[1019,1020,1021,1022],"HIV","Alcohol","Smoking Cigarette","Cardiovascular Disease Prevention",[993],{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[],{"intervention":51,"totalTrials":506,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1041,"PHASE2":1043,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1033,"activeCount":94,"soonestReadout":50},[1034],{"nctId":48,"briefTitle":49,"status":722,"phases":1035,"primaryCompletion":50,"completion":869,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1040},[85],"2019-08-27",48,[1039],"Postural Tachycardia Syndrome",[51],{"trials":1042,"activeCount":98},[],{"trials":1044,"activeCount":94,"soonestReadout":1049},[1045],{"nctId":1046,"briefTitle":1047,"status":110,"phases":1048,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":32,"conditions":1052,"interventions":1053},"NCT05312892","Sympathetic Mechanisms in Obesity-Crossover Design",[86,87],"2028-12-31","2030-12-31","2022-05-20",[15,18],[1054,51],"Amlodipine",{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"trials":1060,"activeCount":98},[],{"intervention":1062,"totalTrials":506,"cells":1063},"High Dose Quadrivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"trials":1069,"activeCount":506,"soonestReadout":337},[1070,1083],{"nctId":1071,"briefTitle":1072,"status":722,"phases":1073,"primaryCompletion":337,"completion":869,"start":1074,"enrollment":1075,"conditions":1076,"interventions":1081},"NCT04613206","High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients",[87],"2021-01-11",396,[1077,1078,1079,1080],"Immunization; Infection","Transplantation Infection","Influenza","Solid Organ Transplant",[1062,1082],"Standard Dose Quadrivalent Inactivated Influenza Vaccine",{"nctId":1084,"briefTitle":1085,"status":110,"phases":1086,"primaryCompletion":1087,"completion":767,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1091},"NCT05215327","High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients",[87],"2027-07-31","2022-11-08",270,[1077,1078,1079],[1062,1082],{"trials":1093,"activeCount":98},[],{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[],{"intervention":1082,"totalTrials":506,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":506,"soonestReadout":337},[1106,1110],{"nctId":1071,"briefTitle":1072,"status":722,"phases":1107,"primaryCompletion":337,"completion":869,"start":1074,"enrollment":1075,"conditions":1108,"interventions":1109},[87],[1077,1078,1079,1080],[1062,1082],{"nctId":1084,"briefTitle":1085,"status":110,"phases":1111,"primaryCompletion":1087,"completion":767,"start":1088,"enrollment":1089,"conditions":1112,"interventions":1113},[87],[1077,1078,1079],[1062,1082],{"trials":1115,"activeCount":98},[],{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":98},[],{"intervention":1121,"totalTrials":1122,"cells":1123},"Saline",9,{"EARLY_PHASE1":1124,"PHASE1":1139,"PHASE2":1151,"PHASE3":1187,"PHASE4":1205,"NA":1217},{"trials":1125,"activeCount":98},[1126],{"nctId":1127,"briefTitle":1128,"status":634,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":637,"enrollment":1131,"conditions":1132,"interventions":1137},"NCT02591173","Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure",[85],"2020-07",7,[1133,1134,1135,1136],"Autonomic Nervous System Disorders","Pure Autonomic Failure","Shy-Drager Syndrome","Orthostatic Hypotension, Dysautonomic",[1138,1121],"Angiotensin-",{"trials":1140,"activeCount":98},[1141],{"nctId":1142,"briefTitle":1143,"status":446,"phases":1144,"primaryCompletion":1145,"completion":914,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1149},"NCT02953587","Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery",[86],"2019-08-21","2016-09",70,[15],[1150,1121],"Human Ghrelin",{"trials":1152,"activeCount":94,"soonestReadout":74},[1153,1167,1178],{"nctId":1154,"briefTitle":1155,"status":446,"phases":1156,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1165},"NCT00310401","The Effect of Nebulized Albuterol on Donor Oxygenation",[87],"2011-05","2011-06","2007-04",506,[1162,1163,1164],"Brain Death","Organ Donor","Pulmonary Edema",[1166,1121],"Albuterol",{"nctId":1168,"briefTitle":1169,"status":634,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":857,"conditions":1174,"interventions":1176},"NCT03935594","Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars",[87],"2021-05-24","2022-10-19","2020-09-18",[1175],"Hypertrophic Scar",[1177,1121],"PRP",{"nctId":1179,"briefTitle":1180,"status":110,"phases":1181,"primaryCompletion":74,"completion":74,"start":621,"enrollment":386,"conditions":1182,"interventions":1185},"NCT06634030","Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction",[87],[1183,1184],"Wound Healing","Surgical Wound",[1186,1121],"RhPDGF-BB",{"trials":1188,"activeCount":98},[1189],{"nctId":1190,"briefTitle":1191,"status":446,"phases":1192,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1202},"NCT02809131","Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.",[88],"2021-03-31","2021-09-30","2016-04-01",1010,[1198,1199,1200,1201],"Sick Sinus Syndrome","Complete Heart Block","Syncope","Chronic Systolic Heart Failure",[1203,1204,1121],"polymixin\u002Fbacitracin","cephalexin, or levofloxacin, or clindamycin",{"trials":1206,"activeCount":98},[1207],{"nctId":1208,"briefTitle":1209,"status":634,"phases":1210,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":857,"conditions":1213,"interventions":1215},"NCT04738318","Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)",[89],"2023-03-10","2022-06-16",[1214],"Elbow Fracture",[1216,1121],"Glucocorticoids",{"trials":1218,"activeCount":94,"soonestReadout":1223},[1219,1227],{"nctId":1220,"briefTitle":1221,"status":722,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":386,"conditions":1225,"interventions":1226},"NCT01000350","Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)",[90],"2028-06","2009-10",[1039],[1121],{"nctId":1228,"briefTitle":1229,"status":446,"phases":1230,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":253,"conditions":1234,"interventions":1236},"NCT00179127","Use of Insulin Glargine to Treat Diabetic Ketoacidosis",[90],"2009-07","2012-09","2004-08",[1235],"Diabetic Ketoacidosis",[1237,1238],"glargine","saline",{"intervention":885,"totalTrials":647,"cells":1240},{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1256,"PHASE3":1276,"PHASE4":1278,"NA":1293},{"trials":1242,"activeCount":98},[],{"trials":1244,"activeCount":98},[1245],{"nctId":1246,"briefTitle":1247,"status":634,"phases":1248,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":506,"conditions":1251,"interventions":1254},"NCT03201952","Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans",[86],"2020-05-01","2018-02-01",[1252,1253],"Glucose Intolerance","Gastric Bypass Surgery",[1255,885],"Ursodeoxycholic Acid",{"trials":1257,"activeCount":94,"soonestReadout":881},[1258,1272],{"nctId":1259,"briefTitle":1260,"status":446,"phases":1261,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1270},"NCT03077724","Fish Oil to Reduce Tobacco Use iN Expectant Mothers Study",[87],"2018-01-23","2018-09-05","2017-03-02",28,[1267,1268,1269],"Tobacco Use in Childbirth","Smoking Cessation","Pregnancy Related",[1271,885],"Fish oil",{"nctId":878,"briefTitle":879,"status":722,"phases":1273,"primaryCompletion":881,"completion":881,"start":882,"enrollment":502,"conditions":1274,"interventions":1275},[87],[873,874],[856,885],{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[1280],{"nctId":1281,"briefTitle":1282,"status":446,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1289},"NCT03101930","Cardiovascular Effects of GLP-1 Receptor Activation",[89],"2021-06-24","2017-05-01",329,[15,1288],"PreDiabetes",[1290,1291,885,1292],"Liraglutide","Sitagliptin","Exendin",{"trials":1294,"activeCount":98},[],{"intervention":1054,"totalTrials":506,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1307,"PHASE4":1309,"NA":1322},{"trials":1298,"activeCount":98},[],{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":94,"soonestReadout":1049},[1303],{"nctId":1046,"briefTitle":1047,"status":110,"phases":1304,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":32,"conditions":1305,"interventions":1306},[86,87],[15,18],[1054,51],{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[1311],{"nctId":1312,"briefTitle":1313,"status":446,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT02034435","Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism",[89],"2019-12","2013-10",44,[1319],"Metabolic Syndrome",[1321,1054],"Epleronone",{"trials":1323,"activeCount":98},[],{"intervention":1325,"totalTrials":857,"cells":1326},"Galantamine",{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1342,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[1331],{"nctId":1332,"briefTitle":1333,"status":580,"phases":1334,"primaryCompletion":1335,"completion":1336,"start":1337,"enrollment":98,"conditions":1338,"interventions":1341},"NCT03014323","Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study",[86],"2018-11","2018-12","2017-01",[1339,1340],"Insulin Sensitivity","Oxidative Stress",[1325],{"trials":1343,"activeCount":94,"soonestReadout":1358},[1344,1354],{"nctId":1345,"briefTitle":1346,"status":446,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":9,"conditions":1350,"interventions":1351},"NCT02365285","Racial Differences in Vagal Control of Glucose Homeostasis",[86,87],"2017-10-05","2015-03",[15],[1325,1352,1353],"Intralipid","Heparin",{"nctId":1355,"briefTitle":1356,"status":110,"phases":1357,"primaryCompletion":1358,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1363},"NCT04769206","Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans",[86,87],"2027-05-31","2028-06-01","2021-12-20",160,[310],[1325],{"trials":1365,"activeCount":98},[],{"trials":1367,"activeCount":98},[],{"trials":1369,"activeCount":98},[],{"intervention":1371,"totalTrials":506,"cells":1372},"Montelukast Oral Granules",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"trials":1378,"activeCount":94,"soonestReadout":724},[1379,1393],{"nctId":1380,"briefTitle":1381,"status":580,"phases":1382,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":98,"conditions":1386,"interventions":1392},"NCT03277170","Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations",[87],"2028-08-31","2029-09-05","2025-09-01",[1387,1388,1389,1390,1391],"Asthma; Status","Asthma in Children","Asthma Acute","Asthma Attack","Acute Asthma Exacerbation",[1371],{"nctId":1394,"briefTitle":1395,"status":110,"phases":1396,"primaryCompletion":724,"completion":724,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1401},"NCT05819541","Treating Exacerbations of Asthma With Oral Montelukast in Children",[87],"2023-10-20",90,[1400],"Status Asthmaticus",[1371,1166,1402],"Corticosteroid",{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"intervention":1271,"totalTrials":506,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":94,"soonestReadout":40},[1417,1421],{"nctId":1259,"briefTitle":1260,"status":446,"phases":1418,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":1265,"conditions":1419,"interventions":1420},[87],[1267,1268,1269],[1271,885],{"nctId":38,"briefTitle":39,"status":722,"phases":1422,"primaryCompletion":40,"completion":1423,"start":1424,"enrollment":1425,"conditions":1426,"interventions":1429},[87],"2026-01-08","2020-11-10",400,[1427,1428],"Preterm Labor","Tobacco Use Disorder",[41,1430],"Olive Oil",{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[],{"intervention":1438,"totalTrials":506,"cells":1439},"Empagliflozin 25 MG",{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1464,"PHASE4":1466,"NA":1468},{"trials":1441,"activeCount":98},[],{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":94,"soonestReadout":973},[1446,1455],{"nctId":1447,"briefTitle":1448,"status":446,"phases":1449,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":502,"conditions":1452,"interventions":1454},"NCT04907214","SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot",[86,87],"2023-12-08","2021-07-29",[15,1453],"Pre-diabetes",[1438],{"nctId":1456,"briefTitle":1457,"status":110,"phases":1458,"primaryCompletion":973,"completion":1459,"start":1460,"enrollment":1461,"conditions":1462,"interventions":1463},"NCT05972564","The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function",[86,87],"2026-12-30","2023-09-06",74,[15,1319],[1438],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[],{"trials":1469,"activeCount":98},[],{"intervention":75,"totalTrials":94,"cells":1471},{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1476,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":94,"soonestReadout":74},[1478],{"nctId":72,"briefTitle":73,"status":110,"phases":1479,"primaryCompletion":74,"completion":74,"start":1480,"enrollment":769,"conditions":1481,"interventions":1484},[87],"2024-03-19",[1482,1483],"Postoperative Bleeding","Skin Cancer Face",[75,1485],"Control",{"trials":1487,"activeCount":98},[],{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"intervention":1485,"totalTrials":94,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1504,"PHASE4":1506,"NA":1508},{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":94,"soonestReadout":74},[1500],{"nctId":72,"briefTitle":73,"status":110,"phases":1501,"primaryCompletion":74,"completion":74,"start":1480,"enrollment":769,"conditions":1502,"interventions":1503},[87],[1482,1483],[75,1485],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[],{"trials":1509,"activeCount":98},[],{"intervention":1511,"totalTrials":94,"cells":1512},"Intravenous iron",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[],{"trials":1518,"activeCount":94,"soonestReadout":1523},[1519],{"nctId":1520,"briefTitle":1521,"status":110,"phases":1522,"primaryCompletion":1523,"completion":305,"start":1524,"enrollment":32,"conditions":1525,"interventions":1527},"NCT07197905","Restoring Iron Deficiency in POTS",[87],"2026-10","2025-11-24",[1526],"POTS - Postural Orthostatic Tachycardia Syndrome",[1511],{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[],{"trials":1533,"activeCount":98},[],{"intervention":1535,"totalTrials":94,"cells":1536},"Fluzone High Dose Inactivated Influenza Vaccine",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":94,"soonestReadout":1547},[1543],{"nctId":1544,"briefTitle":1545,"status":110,"phases":1546,"primaryCompletion":1547,"completion":1548,"start":1549,"enrollment":964,"conditions":1550,"interventions":1552},"NCT07192458","High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)",[87],"2028-12","2029-12","2025-09-17",[1551,1079],"Immunization; Infection|Transplantation Infection|Influenza",[1535,1553],"Fluzone Standard Dose Inactivated Influenza Vaccine",{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"intervention":1553,"totalTrials":94,"cells":1561},{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1572,"PHASE4":1574,"NA":1576},{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":94,"soonestReadout":1547},[1568],{"nctId":1544,"briefTitle":1545,"status":110,"phases":1569,"primaryCompletion":1547,"completion":1548,"start":1549,"enrollment":964,"conditions":1570,"interventions":1571},[87],[1551,1079],[1535,1553],{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[],{"trials":1577,"activeCount":98},[],{"intervention":1579,"totalTrials":94,"cells":1580},"Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2",{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1582,"activeCount":98},[],{"trials":1584,"activeCount":98},[],{"trials":1586,"activeCount":94,"soonestReadout":1358},[1587],{"nctId":1588,"briefTitle":1589,"status":110,"phases":1590,"primaryCompletion":1358,"completion":1359,"start":1591,"enrollment":362,"conditions":1592,"interventions":1594},"NCT05375968","Splanchnic Venous Capacitance in Postural Tachycardia Syndrome",[87],"2023-02-25",[1593],"Postural Tachycardia Syndrome (POTS)",[1579,1595],"Compare change is SVC and SMA flow due to saline",{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[],{"intervention":1595,"totalTrials":94,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1614,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":94,"soonestReadout":1358},[1610],{"nctId":1588,"briefTitle":1589,"status":110,"phases":1611,"primaryCompletion":1358,"completion":1359,"start":1591,"enrollment":362,"conditions":1612,"interventions":1613},[87],[1593],[1579,1595],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"trials":1619,"activeCount":98},[],{"intervention":977,"totalTrials":94,"cells":1621},{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":94,"soonestReadout":972},[1628],{"nctId":969,"briefTitle":970,"status":110,"phases":1629,"primaryCompletion":972,"completion":973,"start":963,"enrollment":964,"conditions":1630,"interventions":1631},[87],[966],[976,977],{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[],{"intervention":1402,"totalTrials":94,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[],{"trials":1645,"activeCount":94,"soonestReadout":724},[1646],{"nctId":1394,"briefTitle":1395,"status":110,"phases":1647,"primaryCompletion":724,"completion":724,"start":1397,"enrollment":1398,"conditions":1648,"interventions":1649},[87],[1400],[1371,1166,1402],{"trials":1651,"activeCount":98},[],{"trials":1653,"activeCount":98},[],{"trials":1655,"activeCount":98},[],{"intervention":1657,"totalTrials":94,"cells":1658},"[18F]-FEOBV Radiotracer",{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":94,"soonestReadout":1669},[1665],{"nctId":1666,"briefTitle":1667,"status":110,"phases":1668,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":16,"conditions":1671,"interventions":1675},"NCT05231798","Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition",[87],"2027-04-30","2021-08-19",[1672,1673,1674],"Down Syndrome","Down Syndrome, Partial Trisomy 21","Alzheimer Disease",[1657],{"trials":1677,"activeCount":98},[],{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[],{"intervention":1683,"totalTrials":94,"cells":1684},"Furosemide 40 mg",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1686,"activeCount":98},[],{"trials":1688,"activeCount":98},[],{"trials":1690,"activeCount":94,"soonestReadout":1695},[1691],{"nctId":1692,"briefTitle":1693,"status":722,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":935,"conditions":1698,"interventions":1700},"NCT03753204","Salt-Sensitivity and Immunity Cell Activation",[86,87],"2026-09-01","2026-09-15","2021-09-01",[938,1699,939],"Salt; Excess",[1683],{"trials":1702,"activeCount":98},[],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"intervention":1708,"totalTrials":94,"cells":1709},"2-HOBA acetate",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":94,"soonestReadout":1720},[1716],{"nctId":1717,"briefTitle":1718,"status":110,"phases":1719,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":1722,"conditions":1723,"interventions":1725},"NCT07225543","2-HOBA in Systemic Lupus Erythematosus",[87],"2030-07-31","2026-05-15",42,[1724],"Systemic Lupus Erthematosus (SLE)",[1708],{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[],{"intervention":46,"totalTrials":94,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1735,"activeCount":98},[],{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":94,"soonestReadout":45},[1740],{"nctId":43,"briefTitle":44,"status":722,"phases":1741,"primaryCompletion":45,"completion":1742,"start":1743,"enrollment":1265,"conditions":1744,"interventions":1747},[87],"2026-01-31","2022-07-27",[1745,1746],"Hemodialysis Complication","Hypotension of Hemodialysis",[46],{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[],{"intervention":1755,"totalTrials":94,"cells":1756},"Budesonide and Azithromycin",{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[],{"trials":1762,"activeCount":94,"soonestReadout":1459},[1763],{"nctId":1764,"briefTitle":1765,"status":722,"phases":1766,"primaryCompletion":1459,"completion":1459,"start":1767,"enrollment":464,"conditions":1768,"interventions":1770},"NCT03250975","Incidence of Acute Laryngeal Injury Following Endotracheal Intubation",[86,87],"2017-08-19",[1769],"Intubation Complication",[1755],{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"intervention":1430,"totalTrials":94,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":94,"soonestReadout":40},[1785],{"nctId":38,"briefTitle":39,"status":722,"phases":1786,"primaryCompletion":40,"completion":1423,"start":1424,"enrollment":1425,"conditions":1787,"interventions":1788},[87],[1427,1428],[41,1430],{"trials":1790,"activeCount":98},[],{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"intervention":1796,"totalTrials":94,"cells":1797},"Amoxicillin-Clavulanate 875 Mg-125 Mg Oral",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1816,"PHASE4":1818,"NA":1820},{"trials":1799,"activeCount":98},[],{"trials":1801,"activeCount":98},[],{"trials":1803,"activeCount":94,"soonestReadout":1808},[1804],{"nctId":1805,"briefTitle":1806,"status":334,"phases":1807,"primaryCompletion":1808,"completion":1809,"start":1810,"enrollment":769,"conditions":1811,"interventions":1813},"NCT07492134","APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)",[87],"2028-04-01","2028-10-01","2026-04-01",[1812],"Acute Uncomplicated Diverticulitis",[1796,1814,1815],"Metronidazole","Cefuroxime",{"trials":1817,"activeCount":98},[],{"trials":1819,"activeCount":98},[],{"trials":1821,"activeCount":98},[],{"intervention":1814,"totalTrials":94,"cells":1823},{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1825,"activeCount":98},[],{"trials":1827,"activeCount":98},[],{"trials":1829,"activeCount":94,"soonestReadout":1808},[1830],{"nctId":1805,"briefTitle":1806,"status":334,"phases":1831,"primaryCompletion":1808,"completion":1809,"start":1810,"enrollment":769,"conditions":1832,"interventions":1833},[87],[1812],[1796,1814,1815],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"intervention":1815,"totalTrials":94,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":94,"soonestReadout":1808},[1848],{"nctId":1805,"briefTitle":1806,"status":334,"phases":1849,"primaryCompletion":1808,"completion":1809,"start":1810,"enrollment":769,"conditions":1850,"interventions":1851},[87],[1812],[1796,1814,1815],{"trials":1853,"activeCount":98},[],{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"intervention":1859,"totalTrials":94,"cells":1860},"To Measure levels of circulating monocyte\u002F T cell doublets at Baseline",{"EARLY_PHASE1":1861,"PHASE1":1863,"PHASE2":1865,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1862,"activeCount":98},[],{"trials":1864,"activeCount":98},[],{"trials":1866,"activeCount":94,"soonestReadout":1871},[1867],{"nctId":1868,"briefTitle":1869,"status":110,"phases":1870,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":362,"conditions":1874,"interventions":1878},"NCT07189936","Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS",[87],"2028-06-30","2029-06-30","2025-12-18",[1875,1593,1876,1877],"Post-Acute COVID-19 Syndrome","SARS CoV 2 Infection","Long COVID19",[1859,1879,1880],"To measure levels of circulating monocyte\u002F T cell doublets after 28 days of 2 HOBA treatment","To measure levels of circulating monocyte\u002F T cell doublets after 28 days of Placebo treatment",{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":98},[],{"trials":1886,"activeCount":98},[],{"intervention":1879,"totalTrials":94,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1899,"PHASE4":1901,"NA":1903},{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":94,"soonestReadout":1871},[1895],{"nctId":1868,"briefTitle":1869,"status":110,"phases":1896,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":362,"conditions":1897,"interventions":1898},[87],[1875,1593,1876,1877],[1859,1879,1880],{"trials":1900,"activeCount":98},[],{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"intervention":1880,"totalTrials":94,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[],{"trials":1912,"activeCount":94,"soonestReadout":1871},[1913],{"nctId":1868,"briefTitle":1869,"status":110,"phases":1914,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":362,"conditions":1915,"interventions":1916},[87],[1875,1593,1876,1877],[1859,1879,1880],{"trials":1918,"activeCount":98},[],{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"intervention":1924,"totalTrials":94,"cells":1925},"CO2 gel mask",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":94,"soonestReadout":427},[1932],{"nctId":1933,"briefTitle":1934,"status":334,"phases":1935,"primaryCompletion":427,"completion":427,"start":337,"enrollment":935,"conditions":1936,"interventions":1938},"NCT07431541","Topical Carboxytherapy Paste Following Microneedling",[86,87],[1937],"Skin",[1924],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[],{"intervention":1186,"totalTrials":94,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":94,"soonestReadout":74},[1953],{"nctId":1179,"briefTitle":1180,"status":110,"phases":1954,"primaryCompletion":74,"completion":74,"start":621,"enrollment":386,"conditions":1955,"interventions":1956},[87],[1183,1184],[1186,1121],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[],{"intervention":1964,"totalTrials":94,"cells":1965},"Semaglutide Pen Injector 2.4mg weekly",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1980,"PHASE4":1982,"NA":1984},{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[],{"trials":1971,"activeCount":94,"soonestReadout":818},[1972],{"nctId":1973,"briefTitle":1974,"status":110,"phases":1975,"primaryCompletion":818,"completion":305,"start":1976,"enrollment":769,"conditions":1977,"interventions":1979},"NCT05254314","Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)",[87],"2022-10-11",[1978],"Asthma",[1964],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[],{"trials":1985,"activeCount":98},[],{"intervention":1987,"totalTrials":94,"cells":1988},"Protocolized diuretic therapy",{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":2004,"PHASE4":2006,"NA":2008},{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":94,"soonestReadout":973},[1995],{"nctId":1996,"briefTitle":1997,"status":722,"phases":1998,"primaryCompletion":973,"completion":869,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2003},"NCT04481919","Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)",[87],"2022-05-01",474,[626,2002],"Acute Heart Failure",[1987],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[],{"intervention":1166,"totalTrials":857,"cells":2011},{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":94,"soonestReadout":724},[2018,2022],{"nctId":1394,"briefTitle":1395,"status":110,"phases":2019,"primaryCompletion":724,"completion":724,"start":1397,"enrollment":1398,"conditions":2020,"interventions":2021},[87],[1400],[1371,1166,1402],{"nctId":1154,"briefTitle":1155,"status":446,"phases":2023,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":2024,"interventions":2025},[87],[1162,1163,1164],[1166,1121],{"trials":2027,"activeCount":98},[],{"trials":2029,"activeCount":98},[],{"trials":2031,"activeCount":98},[2032],{"nctId":2033,"briefTitle":2034,"status":446,"phases":2035,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2041},"NCT01196377","Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study",[90],"2010-10","2010-09",16,[2040],"Acute Asthma",[1166],{"intervention":2043,"totalTrials":506,"cells":2044},"Droxidopa",{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2059,"PHASE3":2061,"PHASE4":2063,"NA":2074},{"trials":2046,"activeCount":98},[],{"trials":2048,"activeCount":94,"soonestReadout":818},[2049],{"nctId":2050,"briefTitle":2051,"status":110,"phases":2052,"primaryCompletion":818,"completion":305,"start":1146,"enrollment":871,"conditions":2053,"interventions":2057},"NCT02897063","Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure",[86],[2054,1134,2055,23,2056],"Autonomic Failure","Multiple System Atrophy","Orthostatic Hypotension",[2043,2058],"Midodrine",{"trials":2060,"activeCount":98},[],{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[2065],{"nctId":2066,"briefTitle":2067,"status":446,"phases":2068,"primaryCompletion":2069,"completion":2069,"start":2070,"enrollment":19,"conditions":2071,"interventions":2072},"NCT03115827","Norepinephrine-targeted Therapy for Action Control in Parkinson Disease",[89],"2018-12-21","2017-04-18",[23],[2043,2073],"Carbidopa",{"trials":2075,"activeCount":98},[],{"intervention":2058,"totalTrials":647,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2091,"PHASE2":2106,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2079,"activeCount":98},[2080],{"nctId":2081,"briefTitle":2082,"status":446,"phases":2083,"primaryCompletion":2084,"completion":2085,"start":2086,"enrollment":2087,"conditions":2088,"interventions":2090},"NCT04620382","Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients",[85],"2025-07-01","2025-12-01","2020-11-09",31,[2089,2054,1134,2055,23],"Neurogenic Orthostatic Hypotension",[2058],{"trials":2092,"activeCount":94,"soonestReadout":818},[2093,2102],{"nctId":2094,"briefTitle":2095,"status":446,"phases":2096,"primaryCompletion":50,"completion":50,"start":2097,"enrollment":2098,"conditions":2099,"interventions":2100},"NCT02429557","Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure",[86],"2015-04",21,[2056,1134,2055,2054],[2101],"midodrine",{"nctId":2050,"briefTitle":2051,"status":110,"phases":2103,"primaryCompletion":818,"completion":305,"start":1146,"enrollment":871,"conditions":2104,"interventions":2105},[86],[2054,1134,2055,23,2056],[2043,2058],{"trials":2107,"activeCount":98},[2108],{"nctId":2109,"briefTitle":2110,"status":446,"phases":2111,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":1265,"conditions":2114,"interventions":2115},"NCT03482297","Automated Abdominal Binder for Orthostatic Hypotension",[86,87],"2025-11-19","2018-03-01",[2056,2054,1134,2055],[2058],{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"intervention":2123,"totalTrials":94,"cells":2124},"Tranexamic acid",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2126,"activeCount":98},[],{"trials":2128,"activeCount":94,"soonestReadout":2133},[2129],{"nctId":2130,"briefTitle":2131,"status":110,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":964,"conditions":2135,"interventions":2138},"NCT05774717","Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis",[86],"2029-04-01","2023-04-01",[2136,2137],"Surgery","Postoperative Blood Loss",[2123],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"intervention":2148,"totalTrials":94,"cells":2149},"Ketone monoester",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":94,"soonestReadout":869},[2154],{"nctId":2155,"briefTitle":2156,"status":334,"phases":2157,"primaryCompletion":869,"completion":767,"start":2158,"enrollment":386,"conditions":2159,"interventions":2161},"NCT07364162","Exogenous Ketone Supplementation in ICU Delirium",[86],"2026-04-06",[2160,31],"ICU Delirium",[2148],{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"trials":2169,"activeCount":98},[],{"intervention":2171,"totalTrials":94,"cells":2172},"Tacrolimus ointment",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":94,"soonestReadout":845},[2177],{"nctId":2178,"briefTitle":2179,"status":110,"phases":2180,"primaryCompletion":845,"completion":1359,"start":2181,"enrollment":2182,"conditions":2183,"interventions":2185},"NCT05856994","Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns",[86],"2024-09-19",18,[2184],"Burn Injury",[2171],{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[],{"intervention":2195,"totalTrials":94,"cells":2196},"Pyridostigmine Pill",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2209,"PHASE3":2211,"PHASE4":2213,"NA":2215},{"trials":2198,"activeCount":98},[],{"trials":2200,"activeCount":94,"soonestReadout":74},[2201],{"nctId":2202,"briefTitle":2203,"status":722,"phases":2204,"primaryCompletion":74,"completion":305,"start":2205,"enrollment":35,"conditions":2206,"interventions":2207},"NCT03124355","Vagal Stimulation in POTS",[86],"2017-09-30",[1039],[2195,2208],"Galantamine Pill",{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[],{"intervention":2208,"totalTrials":94,"cells":2218},{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":94,"soonestReadout":74},[2223],{"nctId":2202,"briefTitle":2203,"status":722,"phases":2224,"primaryCompletion":74,"completion":305,"start":2205,"enrollment":35,"conditions":2225,"interventions":2226},[86],[1039],[2195,2208],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"intervention":2236,"totalTrials":94,"cells":2237},"Phentolamine",{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2255,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2239,"activeCount":98},[],{"trials":2241,"activeCount":94,"soonestReadout":2246},[2242],{"nctId":2243,"briefTitle":2244,"status":722,"phases":2245,"primaryCompletion":2246,"completion":2247,"start":2248,"enrollment":2249,"conditions":2250,"interventions":2253},"NCT03318094","Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity",[86],"2026-11-30","2027-11-30","2017-10-24",36,[2251,2252,15],"Insulin Resistance","Healthy",[2236,2254],"Sodium Nitroprusside",{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"intervention":2254,"totalTrials":94,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2273,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":94,"soonestReadout":2246},[2269],{"nctId":2243,"briefTitle":2244,"status":722,"phases":2270,"primaryCompletion":2246,"completion":2247,"start":2248,"enrollment":2249,"conditions":2271,"interventions":2272},[86],[2251,2252,15],[2236,2254],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[],{"intervention":2282,"totalTrials":857,"cells":2283},"Prednisone",{"EARLY_PHASE1":2284,"PHASE1":2298,"PHASE2":2311,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2285,"activeCount":94,"soonestReadout":427},[2286],{"nctId":2287,"briefTitle":2288,"status":110,"phases":2289,"primaryCompletion":427,"completion":767,"start":2290,"enrollment":1037,"conditions":2291,"interventions":2293},"NCT04469842","Early Use of Long-acting Tacrolimus in Lung Transplant Recipients",[85],"2023-12-01",[2292],"Lung Transplant; Complications",[2294,2295,2296,2282,2297],"Tacrolimus Extended Release Oral Tablet [Envarsus]","Tacrolimus","Mycophenolate Mofetil Hydrochloride","Azathioprine",{"trials":2299,"activeCount":98},[2300],{"nctId":2301,"briefTitle":2302,"status":446,"phases":2303,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2310},"NCT03023891","Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids",[86],"2019-01-10","2019-12-31","2017-02-15",25,[2309,1252],"Glucocorticoids Toxicity",[2282],{"trials":2312,"activeCount":98},[2313],{"nctId":2314,"briefTitle":2315,"status":580,"phases":2316,"primaryCompletion":2317,"completion":2317,"start":2318,"enrollment":98,"conditions":2319,"interventions":2322},"NCT04652414","Corticosteroids in Community Acquired Pneumonia",[87],"2022-07-30","2020-12-01",[2320,2321],"Community-acquired Pneumonia","Cognition Disorder",[2282],{"trials":2324,"activeCount":98},[],{"trials":2326,"activeCount":98},[],{"trials":2328,"activeCount":98},[],{"intervention":2330,"totalTrials":506,"cells":2331},"Mecamylamine Challenge",{"EARLY_PHASE1":2332,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2333,"activeCount":94,"soonestReadout":1871},[2334,2343],{"nctId":2335,"briefTitle":2336,"status":110,"phases":2337,"primaryCompletion":1871,"completion":1871,"start":2338,"enrollment":2339,"conditions":2340,"interventions":2342},"NCT06002477","Attentional Mechanisms in SCD",[85],"2025-03-27",80,[2341],"Subjective Cognitive Decline",[2330],{"nctId":2344,"briefTitle":2345,"status":446,"phases":2346,"primaryCompletion":2347,"completion":2348,"start":2349,"enrollment":2350,"conditions":2351,"interventions":2352},"NCT04756232","Cholinergic Mechanisms of Attention in Aging",[85],"2025-04-30","2025-05-01","2022-04-21",19,[2341],[2330],{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[],{"trials":2360,"activeCount":98},[],{"trials":2362,"activeCount":98},[],{"intervention":2364,"totalTrials":94,"cells":2365},"Modafinil",{"EARLY_PHASE1":2366,"PHASE1":2376,"PHASE2":2378,"PHASE3":2380,"PHASE4":2382,"NA":2384},{"trials":2367,"activeCount":94,"soonestReadout":305},[2368],{"nctId":2369,"briefTitle":2370,"status":722,"phases":2371,"primaryCompletion":305,"completion":305,"start":2372,"enrollment":935,"conditions":2373,"interventions":2374},"NCT01988883","Modafinil and Cognitive Function in POTS",[85],"2014-10",[1039],[2364,2375],"Propranolol",{"trials":2377,"activeCount":98},[],{"trials":2379,"activeCount":98},[],{"trials":2381,"activeCount":98},[],{"trials":2383,"activeCount":98},[],{"trials":2385,"activeCount":98},[],{"intervention":2375,"totalTrials":94,"cells":2387},{"EARLY_PHASE1":2388,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2400,"NA":2402},{"trials":2389,"activeCount":94,"soonestReadout":305},[2390],{"nctId":2369,"briefTitle":2370,"status":722,"phases":2391,"primaryCompletion":305,"completion":305,"start":2372,"enrollment":935,"conditions":2392,"interventions":2393},[85],[1039],[2364,2375],{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[],{"trials":2401,"activeCount":98},[],{"trials":2403,"activeCount":98},[],{"intervention":2405,"totalTrials":94,"cells":2406},"Donepezil",{"EARLY_PHASE1":2407,"PHASE1":2416,"PHASE2":2418,"PHASE3":2420,"PHASE4":2422,"NA":2424},{"trials":2408,"activeCount":94,"soonestReadout":1695},[2409],{"nctId":2410,"briefTitle":2411,"status":722,"phases":2412,"primaryCompletion":1695,"completion":1695,"start":1211,"enrollment":362,"conditions":2413,"interventions":2415},"NCT05438264","Effect of Donepezil on Speech Recognition in Cochlear Implant Users",[85],[2414],"Bilateral Sensorineural Hearing Loss",[2405],{"trials":2417,"activeCount":98},[],{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[],{"intervention":2294,"totalTrials":94,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2434,"PHASE2":2436,"PHASE3":2438,"PHASE4":2440,"NA":2442},{"trials":2429,"activeCount":94,"soonestReadout":427},[2430],{"nctId":2287,"briefTitle":2288,"status":110,"phases":2431,"primaryCompletion":427,"completion":767,"start":2290,"enrollment":1037,"conditions":2432,"interventions":2433},[85],[2292],[2294,2295,2296,2282,2297],{"trials":2435,"activeCount":98},[],{"trials":2437,"activeCount":98},[],{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[],{"intervention":2295,"totalTrials":94,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2458,"NA":2460},{"trials":2447,"activeCount":94,"soonestReadout":427},[2448],{"nctId":2287,"briefTitle":2288,"status":110,"phases":2449,"primaryCompletion":427,"completion":767,"start":2290,"enrollment":1037,"conditions":2450,"interventions":2451},[85],[2292],[2294,2295,2296,2282,2297],{"trials":2453,"activeCount":98},[],{"trials":2455,"activeCount":98},[],{"trials":2457,"activeCount":98},[],{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[],{"intervention":2296,"totalTrials":94,"cells":2463},{"EARLY_PHASE1":2464,"PHASE1":2470,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2478},{"trials":2465,"activeCount":94,"soonestReadout":427},[2466],{"nctId":2287,"briefTitle":2288,"status":110,"phases":2467,"primaryCompletion":427,"completion":767,"start":2290,"enrollment":1037,"conditions":2468,"interventions":2469},[85],[2292],[2294,2295,2296,2282,2297],{"trials":2471,"activeCount":98},[],{"trials":2473,"activeCount":98},[],{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[],{"intervention":2297,"totalTrials":94,"cells":2481},{"EARLY_PHASE1":2482,"PHASE1":2488,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2483,"activeCount":94,"soonestReadout":427},[2484],{"nctId":2287,"briefTitle":2288,"status":110,"phases":2485,"primaryCompletion":427,"completion":767,"start":2290,"enrollment":1037,"conditions":2486,"interventions":2487},[85],[2292],[2294,2295,2296,2282,2297],{"trials":2489,"activeCount":98},[],{"trials":2491,"activeCount":98},[],{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"intervention":2499,"totalTrials":94,"cells":2500},"Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor",{"EARLY_PHASE1":2501,"PHASE1":2517,"PHASE2":2519,"PHASE3":2521,"PHASE4":2523,"NA":2525},{"trials":2502,"activeCount":94,"soonestReadout":2507},[2503],{"nctId":2504,"briefTitle":2505,"status":110,"phases":2506,"primaryCompletion":2507,"completion":2508,"start":2509,"enrollment":2510,"conditions":2511,"interventions":2516},"NCT06609356","Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes",[85],"2027-07","2027-12","2025-07-03",27,[2512,2513,2514,2515],"Type 1 Diabetes Mellitus","Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)","MODY2 Diabetes","Healthy Volunteer",[2499],{"trials":2518,"activeCount":98},[],{"trials":2520,"activeCount":98},[],{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"intervention":2528,"totalTrials":94,"cells":2529},"[11C]-PIB",{"EARLY_PHASE1":2530,"PHASE1":2540,"PHASE2":2542,"PHASE3":2544,"PHASE4":2546,"NA":2548},{"trials":2531,"activeCount":94,"soonestReadout":869},[2532],{"nctId":2533,"briefTitle":2534,"status":722,"phases":2535,"primaryCompletion":869,"completion":869,"start":2536,"enrollment":2537,"conditions":2538,"interventions":2539},"NCT04768101","Quantitative Imaging of Brain Glymphatic Function in Humans",[85],"2020-04-15",140,[23],[2528],{"trials":2541,"activeCount":98},[],{"trials":2543,"activeCount":98},[],{"trials":2545,"activeCount":98},[],{"trials":2547,"activeCount":98},[],{"trials":2549,"activeCount":98},[],{"intervention":70,"totalTrials":94,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2560,"PHASE2":2562,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2553,"activeCount":94,"soonestReadout":69},[2554],{"nctId":67,"briefTitle":68,"status":110,"phases":2555,"primaryCompletion":69,"completion":69,"start":2084,"enrollment":386,"conditions":2556,"interventions":2559},[85],[2557,2558],"Epilepsy","Sudden Unexpected Death in Epilepsy",[70],{"trials":2561,"activeCount":98},[],{"trials":2563,"activeCount":98},[],{"trials":2565,"activeCount":98},[],{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"intervention":2571,"totalTrials":94,"cells":2572},"Vaginal Seeding",{"EARLY_PHASE1":2573,"PHASE1":2585,"PHASE2":2587,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2574,"activeCount":94,"soonestReadout":2579},[2575],{"nctId":2576,"briefTitle":2577,"status":110,"phases":2578,"primaryCompletion":2579,"completion":2579,"start":449,"enrollment":935,"conditions":2580,"interventions":2584},"NCT05505110","MOdification Of THe Early-Life Respiratory Microbiome Through Vaginal SEEDing",[85],"2028-08-10",[2581,2571,2582,2583],"C-section","Respiratory","Microbiome",[2571],{"trials":2586,"activeCount":98},[],{"trials":2588,"activeCount":98},[],{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"intervention":55,"totalTrials":94,"cells":2596},{"EARLY_PHASE1":2597,"PHASE1":2604,"PHASE2":2606,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2598,"activeCount":94,"soonestReadout":50},[2599],{"nctId":53,"briefTitle":54,"status":722,"phases":2600,"primaryCompletion":50,"completion":869,"start":2601,"enrollment":1037,"conditions":2602,"interventions":2603},[85],"2021-08-31",[1039],[55],{"trials":2605,"activeCount":98},[],{"trials":2607,"activeCount":98},[],{"trials":2609,"activeCount":98},[],{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":98},[],{"intervention":2615,"totalTrials":857,"cells":2616},"Ketamine",{"EARLY_PHASE1":2617,"PHASE1":2619,"PHASE2":2621,"PHASE3":2623,"PHASE4":2625,"NA":2652},{"trials":2618,"activeCount":98},[],{"trials":2620,"activeCount":98},[],{"trials":2622,"activeCount":98},[],{"trials":2624,"activeCount":98},[],{"trials":2626,"activeCount":98},[2627,2641],{"nctId":2628,"briefTitle":2629,"status":446,"phases":2630,"primaryCompletion":2631,"completion":2632,"start":2633,"enrollment":2634,"conditions":2635,"interventions":2640},"NCT04625283","The Impact of Perioperative Ketamine Infusion on Surgical Recovery",[89],"2024-01-26","2024-02-01","2021-04-12",1570,[2636,2637,2638,2615,2639],"Opioid Use","Enhanced Recovery After Surgery","Anesthesia","Pain, Postoperative",[2615],{"nctId":2642,"briefTitle":2643,"status":446,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":2648,"interventions":2650},"NCT05277896","Randomized Trial of Sedative Choice for Intubation",[89],"2025-09-06","2022-04-06",2367,[2649],"Acute Respiratory Failure",[2615,2651],"Etomidate",{"trials":2653,"activeCount":94,"soonestReadout":2658},[2654],{"nctId":2655,"briefTitle":2656,"status":359,"phases":2657,"primaryCompletion":2658,"completion":2659,"start":2646,"enrollment":2660,"conditions":2661,"interventions":2663},"NCT06179485","Effect of Ketamine and Etomidate During RSI on Long Term Outcomes",[],"2027-01","2028-03",1756,[2662,2649],"Post-Traumatic Stress Disorder",[2615,2651],{"intervention":540,"totalTrials":857,"cells":2665},{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2674,"NA":2689},{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[],{"trials":2671,"activeCount":98},[],{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[2676],{"nctId":2677,"briefTitle":2678,"status":634,"phases":2679,"primaryCompletion":2680,"completion":2680,"start":2681,"enrollment":2682,"conditions":2683,"interventions":2688},"NCT02203630","Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients",[89],"2016-01","2014-08",17,[2684,687,2685,2686,2687],"Septic Shock","Shock","Tachycardia","Arrhythmia",[540,541],{"trials":2690,"activeCount":94,"soonestReadout":1523},[2691,2695],{"nctId":525,"briefTitle":526,"status":446,"phases":2692,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":2693,"interventions":2694},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"nctId":2696,"briefTitle":2697,"status":359,"phases":2698,"primaryCompletion":1523,"completion":305,"start":637,"enrollment":2699,"conditions":2700,"interventions":2707},"NCT02725060","Autoimmune Basis for Postural Tachycardia Syndrome",[90],58,[2701,1039,2686,2702,2703,2704,2705,2706],"Postural Orthostatic Tachycardia Syndrome","Arrhythmias, Cardiac","Autonomic Nervous System Diseases","Orthostatic Intolerance","Cardiovascular Diseases","Primary Dysautonomias",[2708,2709],"phenylephrine","isoproterenol",{"intervention":2651,"totalTrials":506,"cells":2711},{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2718,"PHASE4":2720,"NA":2726},{"trials":2713,"activeCount":98},[],{"trials":2715,"activeCount":98},[],{"trials":2717,"activeCount":98},[],{"trials":2719,"activeCount":98},[],{"trials":2721,"activeCount":98},[2722],{"nctId":2642,"briefTitle":2643,"status":446,"phases":2723,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":2724,"interventions":2725},[89],[2649],[2615,2651],{"trials":2727,"activeCount":94,"soonestReadout":2658},[2728],{"nctId":2655,"briefTitle":2656,"status":359,"phases":2729,"primaryCompletion":2658,"completion":2659,"start":2646,"enrollment":2660,"conditions":2730,"interventions":2731},[],[2662,2649],[2615,2651],{"intervention":545,"totalTrials":506,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2735,"activeCount":98},[],{"trials":2737,"activeCount":98},[],{"trials":2739,"activeCount":98},[],{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":98},[],{"trials":2745,"activeCount":94,"soonestReadout":1523},[2746,2750],{"nctId":525,"briefTitle":526,"status":446,"phases":2747,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":2748,"interventions":2749},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"nctId":2696,"briefTitle":2697,"status":359,"phases":2751,"primaryCompletion":1523,"completion":305,"start":637,"enrollment":2699,"conditions":2752,"interventions":2753},[90],[2701,1039,2686,2702,2703,2704,2705,2706],[2708,2709],{"intervention":2755,"totalTrials":506,"cells":2756},"Naloxone",{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2765,"NA":2767},{"trials":2758,"activeCount":98},[],{"trials":2760,"activeCount":98},[],{"trials":2762,"activeCount":98},[],{"trials":2764,"activeCount":98},[],{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":94,"soonestReadout":972},[2769,2780],{"nctId":2770,"briefTitle":2771,"status":110,"phases":2772,"primaryCompletion":972,"completion":972,"start":2773,"enrollment":115,"conditions":2774,"interventions":2778},"NCT05142267","Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms",[90],"2022-03-02",[2775,2776,2777],"Opioid Use Disorder","Back Pain","Stress",[2779,2755],"Oxycodone",{"nctId":2781,"briefTitle":2782,"status":446,"phases":2783,"primaryCompletion":2784,"completion":2784,"start":2785,"enrollment":2786,"conditions":2787,"interventions":2789},"NCT02469077","Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function",[90],"2019-09","2015-08",117,[2788],"Chronic Pain",[2790,2791],"Morphine","naloxone",{"intervention":2793,"totalTrials":94,"cells":2794},"Midodrine or atomoxetine pill",{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2796,"activeCount":98},[],{"trials":2798,"activeCount":98},[],{"trials":2800,"activeCount":98},[],{"trials":2802,"activeCount":98},[],{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":94,"soonestReadout":2811},[2807],{"nctId":2808,"briefTitle":2809,"status":110,"phases":2810,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":502,"conditions":2814,"interventions":2817},"NCT04782830","Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms",[90],"2027-06-01","2027-10-01","2021-02-05",[2815,2054,1134,2055,2816],"Orthostatic; Hypotension, Neurogenic","Orthostatic; Hypotension, Parkinsonism",[2793],{"intervention":2819,"totalTrials":94,"cells":2820},"13C6-Glucose",{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2825,"PHASE3":2827,"PHASE4":2829,"NA":2831},{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[],{"trials":2826,"activeCount":98},[],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":94,"soonestReadout":427},[2833],{"nctId":2834,"briefTitle":2835,"status":110,"phases":2836,"primaryCompletion":427,"completion":427,"start":2837,"enrollment":32,"conditions":2838,"interventions":2843},"NCT06930976","Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells",[90],"2025-10-01",[2839,2840,2841,2842],"Glucose","Metabolism","Isotope Labeling","Immune System and Related Disorders",[2819],{"intervention":2845,"totalTrials":94,"cells":2846},"0.9% Sodium Chloride",{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2848,"activeCount":98},[],{"trials":2850,"activeCount":98},[],{"trials":2852,"activeCount":98},[],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"trials":2858,"activeCount":94,"soonestReadout":488},[2859],{"nctId":2860,"briefTitle":2861,"status":722,"phases":2862,"primaryCompletion":488,"completion":488,"start":2863,"enrollment":2864,"conditions":2865,"interventions":2868},"NCT04036305","Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers",[],"2019-07-26",230,[2866,2867],"Ehlers-Danlos Syndrome","Anesthesia, Local",[2845,2869,2870],"Lidocaine Injection 2%","Bupivacaine Injection 0.5%",{"intervention":2869,"totalTrials":94,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2879,"PHASE4":2881,"NA":2883},{"trials":2874,"activeCount":98},[],{"trials":2876,"activeCount":98},[],{"trials":2878,"activeCount":98},[],{"trials":2880,"activeCount":98},[],{"trials":2882,"activeCount":98},[],{"trials":2884,"activeCount":94,"soonestReadout":488},[2885],{"nctId":2860,"briefTitle":2861,"status":722,"phases":2886,"primaryCompletion":488,"completion":488,"start":2863,"enrollment":2864,"conditions":2887,"interventions":2888},[],[2866,2867],[2845,2869,2870],{"intervention":2870,"totalTrials":94,"cells":2890},{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":98},[],{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"trials":2902,"activeCount":94,"soonestReadout":488},[2903],{"nctId":2860,"briefTitle":2861,"status":722,"phases":2904,"primaryCompletion":488,"completion":488,"start":2863,"enrollment":2864,"conditions":2905,"interventions":2906},[],[2866,2867],[2845,2869,2870],{"intervention":2779,"totalTrials":94,"cells":2908},{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2910,"activeCount":98},[],{"trials":2912,"activeCount":98},[],{"trials":2914,"activeCount":98},[],{"trials":2916,"activeCount":98},[],{"trials":2918,"activeCount":98},[],{"trials":2920,"activeCount":94,"soonestReadout":972},[2921],{"nctId":2770,"briefTitle":2771,"status":110,"phases":2922,"primaryCompletion":972,"completion":972,"start":2773,"enrollment":115,"conditions":2923,"interventions":2924},[90],[2775,2776,2777],[2779,2755],{"intervention":2926,"totalTrials":94,"cells":2927},"GLP-1 receptor agonist",{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2932,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":98},[],{"trials":2933,"activeCount":98},[],{"trials":2935,"activeCount":98},[],{"trials":2937,"activeCount":98},[],{"trials":2939,"activeCount":94,"soonestReadout":818},[2940],{"nctId":2941,"briefTitle":2942,"status":110,"phases":2943,"primaryCompletion":818,"completion":2658,"start":2944,"enrollment":964,"conditions":2945,"interventions":2946},"NCT07115069","Comparison of Body Composition Changes With Weight Loss Interventions",[],"2025-08-09",[15],[2926],{"intervention":60,"totalTrials":94,"cells":2948},{"EARLY_PHASE1":2949,"PHASE1":2951,"PHASE2":2953,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2950,"activeCount":98},[],{"trials":2952,"activeCount":98},[],{"trials":2954,"activeCount":98},[],{"trials":2956,"activeCount":98},[],{"trials":2958,"activeCount":98},[],{"trials":2960,"activeCount":94,"soonestReadout":59},[2961],{"nctId":57,"briefTitle":58,"status":722,"phases":2962,"primaryCompletion":59,"completion":869,"start":2963,"enrollment":115,"conditions":2964,"interventions":2968},[],"2025-10-16",[2965,2966,2967],"Inflammatory Bowel Disease (IBD)","Crohn&Amp;#39;s Disease (CD)","Ulcerative Colitis (UC)",[60],{"intervention":2970,"totalTrials":94,"cells":2971},"Hydroxyurea therapy per standard care",{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2978,"PHASE4":2980,"NA":2982},{"trials":2973,"activeCount":98},[],{"trials":2975,"activeCount":98},[],{"trials":2977,"activeCount":98},[],{"trials":2979,"activeCount":98},[],{"trials":2981,"activeCount":98},[],{"trials":2983,"activeCount":94,"soonestReadout":2988},[2984],{"nctId":2985,"briefTitle":2986,"status":722,"phases":2987,"primaryCompletion":2988,"completion":2988,"start":2989,"enrollment":2990,"conditions":2991,"interventions":2995},"NCT04808778","Stroke Prevention in Young Adults With Sickle Cell Anemia",[],"2029-06-01","2021-05-17",250,[479,453,2992,2993,2994,480],"Stroke, Ischemic","Silent Stroke","Silent Cerebral Infarct",[2970],{"intervention":2997,"totalTrials":647,"cells":2998},"Normal saline",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3022,"PHASE3":3024,"PHASE4":3036,"NA":3050},{"trials":3000,"activeCount":98},[],{"trials":3002,"activeCount":98},[3003,3012],{"nctId":3004,"briefTitle":3005,"status":446,"phases":3006,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":506,"conditions":3009,"interventions":3010},"NCT03063476","The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)",[86],"2017-05-18","2017-03-01",[2252],[3011,2997],"C-13 labeled Lysine",{"nctId":3013,"briefTitle":3014,"status":446,"phases":3015,"primaryCompletion":3016,"completion":3016,"start":3017,"enrollment":9,"conditions":3018,"interventions":3019},"NCT05210504","Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3",[86],"2023-01-27","2022-03-09",[34],[3020,3021],"L-Lysine","Normal Saline",{"trials":3023,"activeCount":98},[],{"trials":3025,"activeCount":98},[3026],{"nctId":3027,"briefTitle":3028,"status":446,"phases":3029,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":115,"conditions":3032,"interventions":3034},"NCT00678379","Pediatric Tonsillectomy Pain Reduction Study",[88],"2009-11","2008-04",[3033],"Postoperative Pain",[3035,2997,557],"lidocaine",{"trials":3037,"activeCount":98},[3038],{"nctId":3039,"briefTitle":3040,"status":580,"phases":3041,"primaryCompletion":3042,"completion":3043,"start":3044,"enrollment":98,"conditions":3045,"interventions":3049},"NCT03143530","Effect of Pectoralis Block on Analgesia After Simple Mastectomy",[89],"2019-03-01","2019-04-01","2017-12",[3046,3047,3048],"Mastectomy","Nerve Block","Analgesia, Postoperative",[2997,560],{"trials":3051,"activeCount":98},[],{"intervention":3053,"totalTrials":506,"cells":3054},"Aliskiren 150 mg",{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3077,"PHASE3":3079,"PHASE4":3081,"NA":3091},{"trials":3056,"activeCount":98},[],{"trials":3058,"activeCount":98},[3059],{"nctId":3060,"briefTitle":3061,"status":446,"phases":3062,"primaryCompletion":3063,"completion":3064,"start":3065,"enrollment":3066,"conditions":3067,"interventions":3072},"NCT01103245","Aldosterone and the Metabolic Syndrome",[86],"2012-07","2013-09","2010-03",69,[3068,3069,3070,3071],"Metabolic Diseases","Diabetes Mellitus","Endocrine System Diseases","Glucose Metabolism Disorders",[3073,3053,3074,3075,3076],"Hydrochlorothiazide","Spironolactone","Aliskiren 300 mg","Spironolactone 50 mg",{"trials":3078,"activeCount":98},[],{"trials":3080,"activeCount":98},[],{"trials":3082,"activeCount":98},[3083],{"nctId":3084,"briefTitle":3085,"status":446,"phases":3086,"primaryCompletion":3087,"completion":3087,"start":697,"enrollment":2087,"conditions":3088,"interventions":3089},"NCT03115853","The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function",[89],"2012-01",[938],[3053,3090,3075],"HCTZ",{"trials":3092,"activeCount":98},[],{"intervention":3075,"totalTrials":506,"cells":3094},{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3103,"PHASE3":3105,"PHASE4":3107,"NA":3113},{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[3099],{"nctId":3060,"briefTitle":3061,"status":446,"phases":3100,"primaryCompletion":3063,"completion":3064,"start":3065,"enrollment":3066,"conditions":3101,"interventions":3102},[86],[3068,3069,3070,3071],[3073,3053,3074,3075,3076],{"trials":3104,"activeCount":98},[],{"trials":3106,"activeCount":98},[],{"trials":3108,"activeCount":98},[3109],{"nctId":3084,"briefTitle":3085,"status":446,"phases":3110,"primaryCompletion":3087,"completion":3087,"start":697,"enrollment":2087,"conditions":3111,"interventions":3112},[89],[938],[3053,3090,3075],{"trials":3114,"activeCount":98},[],{"intervention":3116,"totalTrials":506,"cells":3117},"Corticosteroid with normal saline",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3126,"NA":3162},{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":98},[],{"trials":3125,"activeCount":98},[],{"trials":3127,"activeCount":98},[3128,3151],{"nctId":3129,"briefTitle":3130,"status":446,"phases":3131,"primaryCompletion":3132,"completion":3132,"start":3133,"enrollment":2087,"conditions":3134,"interventions":3149},"NCT03630198","Pain Outcomes Following Intralesional Corticosteroid Injections",[89],"2019-09-01","2018-10-01",[3135,3136,3137,1175,3138,3139,3140,3141,3142,3143,3144,3145,3146,3147,3148],"Keloid","Alopecia Areata","Acne","Epidermal Inclusion Cyst","Frontal Fibrosing Alopecia","Lichen Plano-Pilaris","Keratoacanthoma","Plaque Psoriasis","Lichen Simplex Chronicus","Prurigo Nodularis","Nummular Eczema","Granuloma Annulare","Morphea","Lichen Planus",[3150,3116],"Corticosteroid with lidocaine",{"nctId":3152,"briefTitle":3153,"status":446,"phases":3154,"primaryCompletion":3155,"completion":3155,"start":3156,"enrollment":3157,"conditions":3158,"interventions":3160},"NCT04023695","Trigger Finger Corticosteroid Injection With and Without Local Anesthetic",[89],"2018-08-30","2017-10-01",110,[3159],"Trigger Finger",[3161,3116],"Corticosteroid with lidocaine with epinephrine",{"trials":3163,"activeCount":98},[],{"intervention":1291,"totalTrials":506,"cells":3165},{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3172,"PHASE4":3174,"NA":3193},{"trials":3167,"activeCount":98},[],{"trials":3169,"activeCount":98},[],{"trials":3171,"activeCount":98},[],{"trials":3173,"activeCount":98},[],{"trials":3175,"activeCount":98},[3176,3180],{"nctId":1281,"briefTitle":1282,"status":446,"phases":3177,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":3178,"interventions":3179},[89],[15,1288],[1290,1291,885,1292],{"nctId":3181,"briefTitle":3182,"status":634,"phases":3183,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":647,"conditions":3186,"interventions":3187},"NCT03738878","Mechanism(s) Underlying Hypotensive Response to ARB\u002FNEP Inhibition - Aim 1",[89],"2024-12-01","2018-11-15",[18],[3188,3189,3190,3191,3192,1291],"Valsartan","LCZ696","Bradykinin","Substance P","BNP",{"trials":3194,"activeCount":98},[],{"intervention":3196,"totalTrials":506,"cells":3197},"Dexamethasone",{"EARLY_PHASE1":3198,"PHASE1":3200,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3230},{"trials":3199,"activeCount":98},[],{"trials":3201,"activeCount":98},[3202],{"nctId":3203,"briefTitle":3204,"status":446,"phases":3205,"primaryCompletion":3206,"completion":3207,"start":3208,"enrollment":3209,"conditions":3210,"interventions":3212},"NCT03035929","Diagnosing Natriuretic Peptide Deficiency",[86],"2017-06-08","2018-01-01","2017-01-01",10,[2252,3211],"Lean",[3196],{"trials":3214,"activeCount":98},[],{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[3219],{"nctId":3220,"briefTitle":3221,"status":634,"phases":3222,"primaryCompletion":3223,"completion":3223,"start":3224,"enrollment":3225,"conditions":3226,"interventions":3228},"NCT03166761","Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection",[89],"2023-02-28","2017-09-14",41,[3227],"Sacro-Iliac Spondylosis",[3196,3229],"Triamcinolone Acetonide",{"trials":3231,"activeCount":98},[],{"intervention":3233,"totalTrials":94,"cells":3234},"diltiazem",{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3239,"PHASE3":3241,"PHASE4":3243,"NA":3254},{"trials":3236,"activeCount":98},[],{"trials":3238,"activeCount":98},[],{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[3245],{"nctId":3246,"briefTitle":3247,"status":446,"phases":3248,"primaryCompletion":3249,"completion":3249,"start":3250,"enrollment":94,"conditions":3251,"interventions":3253},"NCT06534671","Diltiazem in Jervell and Lange-Nielsen Syndrome",[89],"2024-10-23","2024-10-16",[3252],"Jervell and Lange Nielsen Syndrome",[3233],{"trials":3255,"activeCount":98},[],{"intervention":3257,"totalTrials":94,"cells":3258},"levetiracetam",{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3263,"PHASE3":3265,"PHASE4":3267,"NA":3278},{"trials":3260,"activeCount":98},[],{"trials":3262,"activeCount":98},[],{"trials":3264,"activeCount":98},[],{"trials":3266,"activeCount":98},[],{"trials":3268,"activeCount":98},[3269],{"nctId":3270,"briefTitle":3271,"status":580,"phases":3272,"primaryCompletion":3273,"completion":3273,"start":3273,"enrollment":98,"conditions":3274,"interventions":3277},"NCT01935908","Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study",[89],"2013-05",[3275,3276],"Subarachnoid Hemorrhage","Seizures",[3257],{"trials":3279,"activeCount":98},[],{"intervention":628,"totalTrials":94,"cells":3281},{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3288,"PHASE4":3290,"NA":3296},{"trials":3283,"activeCount":98},[],{"trials":3285,"activeCount":98},[],{"trials":3287,"activeCount":98},[],{"trials":3289,"activeCount":98},[],{"trials":3291,"activeCount":98},[3292],{"nctId":618,"briefTitle":619,"status":446,"phases":3293,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":3294,"interventions":3295},[89],[626],[628,569,629,630],{"trials":3297,"activeCount":98},[],{"intervention":629,"totalTrials":94,"cells":3299},{"EARLY_PHASE1":3300,"PHASE1":3302,"PHASE2":3304,"PHASE3":3306,"PHASE4":3308,"NA":3314},{"trials":3301,"activeCount":98},[],{"trials":3303,"activeCount":98},[],{"trials":3305,"activeCount":98},[],{"trials":3307,"activeCount":98},[],{"trials":3309,"activeCount":98},[3310],{"nctId":618,"briefTitle":619,"status":446,"phases":3311,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":3312,"interventions":3313},[89],[626],[628,569,629,630],{"trials":3315,"activeCount":98},[],{"intervention":630,"totalTrials":94,"cells":3317},{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3322,"PHASE3":3324,"PHASE4":3326,"NA":3332},{"trials":3319,"activeCount":98},[],{"trials":3321,"activeCount":98},[],{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[],{"trials":3327,"activeCount":98},[3328],{"nctId":618,"briefTitle":619,"status":446,"phases":3329,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":3330,"interventions":3331},[89],[626],[628,569,629,630],{"trials":3333,"activeCount":98},[],{"intervention":3335,"totalTrials":94,"cells":3336},"dabigatran etexilate mesylate",{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3356},{"trials":3338,"activeCount":98},[],{"trials":3340,"activeCount":98},[],{"trials":3342,"activeCount":98},[],{"trials":3344,"activeCount":98},[],{"trials":3346,"activeCount":98},[3347],{"nctId":3348,"briefTitle":3349,"status":446,"phases":3350,"primaryCompletion":3351,"completion":3351,"start":1316,"enrollment":3352,"conditions":3353,"interventions":3355},"NCT01976507","Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism",[89],"2016-12",101,[918,3354],"Atrial Flutter",[3335],{"trials":3357,"activeCount":98},[],{"intervention":1216,"totalTrials":94,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3374},{"trials":3361,"activeCount":98},[],{"trials":3363,"activeCount":98},[],{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[3370],{"nctId":1208,"briefTitle":1209,"status":634,"phases":3371,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":857,"conditions":3372,"interventions":3373},[89],[1214],[1216,1121],{"trials":3375,"activeCount":98},[],{"intervention":3377,"totalTrials":94,"cells":3378},"Dexamethasone IV for PO",{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3387,"NA":3399},{"trials":3380,"activeCount":98},[],{"trials":3382,"activeCount":98},[],{"trials":3384,"activeCount":98},[],{"trials":3386,"activeCount":98},[],{"trials":3388,"activeCount":98},[3389],{"nctId":3390,"briefTitle":3391,"status":634,"phases":3392,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":386,"conditions":3395,"interventions":3397},"NCT03705273","Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup",[89],"2020-10-02","2018-10-23",[1978,3396],"Croup",[3377,3398],"Dexamethasone crushed",{"trials":3400,"activeCount":98},[],{"intervention":3398,"totalTrials":94,"cells":3402},{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3409,"PHASE4":3411,"NA":3417},{"trials":3404,"activeCount":98},[],{"trials":3406,"activeCount":98},[],{"trials":3408,"activeCount":98},[],{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[3413],{"nctId":3390,"briefTitle":3391,"status":634,"phases":3414,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":386,"conditions":3415,"interventions":3416},[89],[1978,3396],[3377,3398],{"trials":3418,"activeCount":98},[],{"intervention":3420,"totalTrials":94,"cells":3421},"Liposomal bupivacaine",{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3428,"PHASE4":3430,"NA":3444},{"trials":3423,"activeCount":98},[],{"trials":3425,"activeCount":98},[],{"trials":3427,"activeCount":98},[],{"trials":3429,"activeCount":98},[],{"trials":3431,"activeCount":98},[3432],{"nctId":3433,"briefTitle":3434,"status":446,"phases":3435,"primaryCompletion":3436,"completion":3437,"start":3438,"enrollment":964,"conditions":3439,"interventions":3442},"NCT03700970","Comparing Local Anesthetics for TAP Block During Abdominally-based Free Flap for Breast Reconstruction",[89],"2021-03-15","2021-03-30","2019-06-13",[3440,2638,3441],"Breast Reconstruction","Transverse Abdominis Plane Block",[3420,3443],"Regular bupivacaine",{"trials":3445,"activeCount":98},[],{"intervention":3443,"totalTrials":94,"cells":3447},{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3454,"PHASE4":3456,"NA":3462},{"trials":3449,"activeCount":98},[],{"trials":3451,"activeCount":98},[],{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[],{"trials":3457,"activeCount":98},[3458],{"nctId":3433,"briefTitle":3434,"status":446,"phases":3459,"primaryCompletion":3436,"completion":3437,"start":3438,"enrollment":964,"conditions":3460,"interventions":3461},[89],[3440,2638,3441],[3420,3443],{"trials":3463,"activeCount":98},[],{"intervention":3465,"totalTrials":94,"cells":3466},"anti-pseudomonal cephalosporin",{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3473,"PHASE4":3475,"NA":3489},{"trials":3468,"activeCount":98},[],{"trials":3470,"activeCount":98},[],{"trials":3472,"activeCount":98},[],{"trials":3474,"activeCount":98},[],{"trials":3476,"activeCount":98},[3477],{"nctId":3478,"briefTitle":3479,"status":446,"phases":3480,"primaryCompletion":3481,"completion":3481,"start":3482,"enrollment":3483,"conditions":3484,"interventions":3487},"NCT05094154","Effect of Antibiotic Choice On ReNal Outcomes (ACORN)",[89],"2022-10-21","2021-11-10",2634,[687,3485,3486],"AKI","Neurotoxicity",[3465,3488],"anti-pseudomonal penicillin",{"trials":3490,"activeCount":98},[],{"intervention":3488,"totalTrials":94,"cells":3492},{"EARLY_PHASE1":3493,"PHASE1":3495,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3507},{"trials":3494,"activeCount":98},[],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[],{"trials":3502,"activeCount":98},[3503],{"nctId":3478,"briefTitle":3479,"status":446,"phases":3504,"primaryCompletion":3481,"completion":3481,"start":3482,"enrollment":3483,"conditions":3505,"interventions":3506},[89],[687,3485,3486],[3465,3488],{"trials":3508,"activeCount":98},[],{"intervention":2073,"totalTrials":94,"cells":3510},{"EARLY_PHASE1":3511,"PHASE1":3513,"PHASE2":3515,"PHASE3":3517,"PHASE4":3519,"NA":3525},{"trials":3512,"activeCount":98},[],{"trials":3514,"activeCount":98},[],{"trials":3516,"activeCount":98},[],{"trials":3518,"activeCount":98},[],{"trials":3520,"activeCount":98},[3521],{"nctId":2066,"briefTitle":2067,"status":446,"phases":3522,"primaryCompletion":2069,"completion":2069,"start":2070,"enrollment":19,"conditions":3523,"interventions":3524},[89],[23],[2043,2073],{"trials":3526,"activeCount":98},[],{"intervention":3528,"totalTrials":94,"cells":3529},"Change from Prograf to Envarsus XR",{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3536,"PHASE4":3538,"NA":3551},{"trials":3531,"activeCount":98},[],{"trials":3533,"activeCount":98},[],{"trials":3535,"activeCount":98},[],{"trials":3537,"activeCount":98},[],{"trials":3539,"activeCount":98},[3540],{"nctId":3541,"briefTitle":3542,"status":446,"phases":3543,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":3548,"interventions":3550},"NCT04838288","Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™",[89],"2025-01-01","2025-10-22","2021-06-22",56,[3549],"Renal Transplant",[3528],{"trials":3552,"activeCount":98},[],{"intervention":3554,"totalTrials":94,"cells":3555},"Omegaven",{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3562,"PHASE4":3564,"NA":3575},{"trials":3557,"activeCount":98},[],{"trials":3559,"activeCount":98},[],{"trials":3561,"activeCount":98},[],{"trials":3563,"activeCount":98},[],{"trials":3565,"activeCount":98},[3566],{"nctId":3567,"briefTitle":3568,"status":446,"phases":3569,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":1037,"conditions":3572,"interventions":3574},"NCT00862446","Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease",[89],"2019-10","2009-03",[3573],"Parenteral Nutrition Associated Liver Disease",[3554],{"trials":3576,"activeCount":98},[],{"intervention":3150,"totalTrials":94,"cells":3578},{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3583,"PHASE3":3585,"PHASE4":3587,"NA":3593},{"trials":3580,"activeCount":98},[],{"trials":3582,"activeCount":98},[],{"trials":3584,"activeCount":98},[],{"trials":3586,"activeCount":98},[],{"trials":3588,"activeCount":98},[3589],{"nctId":3129,"briefTitle":3130,"status":446,"phases":3590,"primaryCompletion":3132,"completion":3132,"start":3133,"enrollment":2087,"conditions":3591,"interventions":3592},[89],[3135,3136,3137,1175,3138,3139,3140,3141,3142,3143,3144,3145,3146,3147,3148],[3150,3116],{"trials":3594,"activeCount":98},[],{"intervention":1290,"totalTrials":94,"cells":3596},{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3603,"PHASE4":3605,"NA":3611},{"trials":3598,"activeCount":98},[],{"trials":3600,"activeCount":98},[],{"trials":3602,"activeCount":98},[],{"trials":3604,"activeCount":98},[],{"trials":3606,"activeCount":98},[3607],{"nctId":1281,"briefTitle":1282,"status":446,"phases":3608,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":3609,"interventions":3610},[89],[15,1288],[1290,1291,885,1292],{"trials":3612,"activeCount":98},[],{"intervention":1292,"totalTrials":94,"cells":3614},{"EARLY_PHASE1":3615,"PHASE1":3617,"PHASE2":3619,"PHASE3":3621,"PHASE4":3623,"NA":3629},{"trials":3616,"activeCount":98},[],{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":98},[],{"trials":3622,"activeCount":98},[],{"trials":3624,"activeCount":98},[3625],{"nctId":1281,"briefTitle":1282,"status":446,"phases":3626,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":3627,"interventions":3628},[89],[15,1288],[1290,1291,885,1292],{"trials":3630,"activeCount":98},[],{"intervention":3632,"totalTrials":94,"cells":3633},"Comparison of Risperidone and Aripiprazole",{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3640,"PHASE4":3642,"NA":3653},{"trials":3635,"activeCount":98},[],{"trials":3637,"activeCount":98},[],{"trials":3639,"activeCount":98},[],{"trials":3641,"activeCount":98},[],{"trials":3643,"activeCount":98},[3644],{"nctId":3645,"briefTitle":3646,"status":446,"phases":3647,"primaryCompletion":2085,"completion":2085,"start":3648,"enrollment":16,"conditions":3649,"interventions":3652},"NCT04903353","Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole",[89],"2022-02-01",[3650,26,3651],"Weight Gain","Medication Side Effect",[3632],{"trials":3654,"activeCount":98},[],{"intervention":3656,"totalTrials":94,"cells":3657},"Empiric Therapy: Drug",{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3662,"PHASE3":3664,"PHASE4":3666,"NA":3679},{"trials":3659,"activeCount":98},[],{"trials":3661,"activeCount":98},[],{"trials":3663,"activeCount":98},[],{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[3668],{"nctId":3669,"briefTitle":3670,"status":446,"phases":3671,"primaryCompletion":3672,"completion":3672,"start":3673,"enrollment":3547,"conditions":3674,"interventions":3677},"NCT05365477","Empiric Versus Selective Prevention Strategies for Kidney Stone Disease",[89],"2025-10-17","2022-08-04",[3675,3676],"Kidney Stones","Nephrolithiasis",[3656,3678],"Selective Therapy: Drug",{"trials":3680,"activeCount":98},[],{"intervention":3678,"totalTrials":94,"cells":3682},{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3697},{"trials":3684,"activeCount":98},[],{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[],{"trials":3690,"activeCount":98},[],{"trials":3692,"activeCount":98},[3693],{"nctId":3669,"briefTitle":3670,"status":446,"phases":3694,"primaryCompletion":3672,"completion":3672,"start":3673,"enrollment":3547,"conditions":3695,"interventions":3696},[89],[3675,3676],[3656,3678],{"trials":3698,"activeCount":98},[],{"intervention":3700,"totalTrials":94,"cells":3701},"Sildenafil citrate",{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3708,"PHASE4":3710,"NA":3719},{"trials":3703,"activeCount":98},[],{"trials":3705,"activeCount":98},[],{"trials":3707,"activeCount":98},[],{"trials":3709,"activeCount":98},[],{"trials":3711,"activeCount":98},[3712],{"nctId":3713,"briefTitle":3714,"status":446,"phases":3715,"primaryCompletion":890,"completion":3351,"start":3716,"enrollment":19,"conditions":3717,"interventions":3718},"NCT02129725","Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.",[89],"2014-04",[1319],[3700],{"trials":3720,"activeCount":98},[],{"intervention":3722,"totalTrials":94,"cells":3723},"ccIIV4",{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3730,"PHASE4":3732,"NA":3744},{"trials":3725,"activeCount":98},[],{"trials":3727,"activeCount":98},[],{"trials":3729,"activeCount":98},[],{"trials":3731,"activeCount":98},[],{"trials":3733,"activeCount":98},[3734],{"nctId":3735,"briefTitle":3736,"status":446,"phases":3737,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":386,"conditions":3740,"interventions":3742},"NCT02967393","Influenza Vaccine Feasibility Study in Children With Persistent Asthma",[89],"2017-02-01","2016-10-10",[3741],"Asthmatic",[3722,3743],"IIV4",{"trials":3745,"activeCount":98},[],{"intervention":3743,"totalTrials":94,"cells":3747},{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3752,"PHASE3":3754,"PHASE4":3756,"NA":3762},{"trials":3749,"activeCount":98},[],{"trials":3751,"activeCount":98},[],{"trials":3753,"activeCount":98},[],{"trials":3755,"activeCount":98},[],{"trials":3757,"activeCount":98},[3758],{"nctId":3735,"briefTitle":3736,"status":446,"phases":3759,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":386,"conditions":3760,"interventions":3761},[89],[3741],[3722,3743],{"trials":3763,"activeCount":98},[],{"intervention":3765,"totalTrials":94,"cells":3766},"Prevacid",{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3771,"PHASE3":3773,"PHASE4":3775,"NA":3788},{"trials":3768,"activeCount":98},[],{"trials":3770,"activeCount":98},[],{"trials":3772,"activeCount":98},[],{"trials":3774,"activeCount":98},[],{"trials":3776,"activeCount":98},[3777],{"nctId":3778,"briefTitle":3779,"status":446,"phases":3780,"primaryCompletion":3571,"completion":3781,"start":3782,"enrollment":3783,"conditions":3784,"interventions":3787},"NCT00444145","Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?",[89],"2009-12","2007-03",38,[3785,3786],"Larynx Disease","Gastroesophageal Reflux",[3765],{"trials":3789,"activeCount":98},[],{"intervention":3791,"totalTrials":94,"cells":3792},"Escitalopram",{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3797,"PHASE3":3799,"PHASE4":3801,"NA":3812},{"trials":3794,"activeCount":98},[],{"trials":3796,"activeCount":98},[],{"trials":3798,"activeCount":98},[],{"trials":3800,"activeCount":98},[],{"trials":3802,"activeCount":98},[3803],{"nctId":3804,"briefTitle":3805,"status":446,"phases":3806,"primaryCompletion":3807,"completion":3807,"start":2097,"enrollment":916,"conditions":3808,"interventions":3810},"NCT02332291","Connectivity Affecting the Antidepressant REsponse Study",[89],"2020-08",[3809],"Major Depressive Disorder",[3791,3811],"Bupropion XL",{"trials":3813,"activeCount":98},[],{"intervention":3811,"totalTrials":94,"cells":3815},{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3830},{"trials":3817,"activeCount":98},[],{"trials":3819,"activeCount":98},[],{"trials":3821,"activeCount":98},[],{"trials":3823,"activeCount":98},[],{"trials":3825,"activeCount":98},[3826],{"nctId":3804,"briefTitle":3805,"status":446,"phases":3827,"primaryCompletion":3807,"completion":3807,"start":2097,"enrollment":916,"conditions":3828,"interventions":3829},[89],[3809],[3791,3811],{"trials":3831,"activeCount":98},[],{"intervention":1321,"totalTrials":94,"cells":3833},{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3848},{"trials":3835,"activeCount":98},[],{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"trials":3841,"activeCount":98},[],{"trials":3843,"activeCount":98},[3844],{"nctId":1312,"briefTitle":1313,"status":446,"phases":3845,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":1317,"conditions":3846,"interventions":3847},[89],[1319],[1321,1054],{"trials":3849,"activeCount":98},[],{"intervention":3851,"totalTrials":94,"cells":3852},"Ulipristal Acetate",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3859,"PHASE4":3861,"NA":3874},{"trials":3854,"activeCount":98},[],{"trials":3856,"activeCount":98},[],{"trials":3858,"activeCount":98},[],{"trials":3860,"activeCount":98},[],{"trials":3862,"activeCount":98},[3863],{"nctId":3864,"briefTitle":3865,"status":580,"phases":3866,"primaryCompletion":3867,"completion":3867,"start":3868,"enrollment":98,"conditions":3869,"interventions":3873},"NCT03325868","Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis",[89],"2019-05","2018-02",[3870,3871,3872],"Adenomyosis","Heavy Uterine Bleeding","Dysmenorrhea",[3851],{"trials":3875,"activeCount":98},[],{"intervention":3877,"totalTrials":94,"cells":3878},"Rapamycin",{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3885,"PHASE4":3887,"NA":3897},{"trials":3880,"activeCount":98},[],{"trials":3882,"activeCount":98},[],{"trials":3884,"activeCount":98},[],{"trials":3886,"activeCount":98},[],{"trials":3888,"activeCount":98},[3889],{"nctId":3890,"briefTitle":3891,"status":446,"phases":3892,"primaryCompletion":1224,"completion":1224,"start":3893,"enrollment":935,"conditions":3894,"interventions":3896},"NCT00223678","Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure",[89],"2000-06",[3895],"Kidney Transplant",[3877],{"trials":3898,"activeCount":98},[],{"intervention":3090,"totalTrials":94,"cells":3900},{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3907,"PHASE4":3909,"NA":3915},{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"trials":3908,"activeCount":98},[],{"trials":3910,"activeCount":98},[3911],{"nctId":3084,"briefTitle":3085,"status":446,"phases":3912,"primaryCompletion":3087,"completion":3087,"start":697,"enrollment":2087,"conditions":3913,"interventions":3914},[89],[938],[3053,3090,3075],{"trials":3916,"activeCount":98},[],{"intervention":3918,"totalTrials":94,"cells":3919},"Fluzone-High Dose Quadrivalent",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3926,"PHASE4":3928,"NA":3941},{"trials":3921,"activeCount":98},[],{"trials":3923,"activeCount":98},[],{"trials":3925,"activeCount":98},[],{"trials":3927,"activeCount":98},[],{"trials":3929,"activeCount":98},[3930],{"nctId":3931,"briefTitle":3932,"status":446,"phases":3933,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":3209,"conditions":3936,"interventions":3938},"NCT04077424","Senescent Immunity in Elders and Vaccine Responses (SILVER)",[89],"2020-02-01","2019-10-21",[3937],"Flu Vaccine",[3918,3939,3940],"Fluad","Flublock",{"trials":3942,"activeCount":98},[],{"intervention":3939,"totalTrials":94,"cells":3944},{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3951,"PHASE4":3953,"NA":3959},{"trials":3946,"activeCount":98},[],{"trials":3948,"activeCount":98},[],{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[3955],{"nctId":3931,"briefTitle":3932,"status":446,"phases":3956,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":3209,"conditions":3957,"interventions":3958},[89],[3937],[3918,3939,3940],{"trials":3960,"activeCount":98},[],{"intervention":3940,"totalTrials":94,"cells":3962},{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3969,"PHASE4":3971,"NA":3977},{"trials":3964,"activeCount":98},[],{"trials":3966,"activeCount":98},[],{"trials":3968,"activeCount":98},[],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[3973],{"nctId":3931,"briefTitle":3932,"status":446,"phases":3974,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":3209,"conditions":3975,"interventions":3976},[89],[3937],[3918,3939,3940],{"trials":3978,"activeCount":98},[],{"intervention":3161,"totalTrials":94,"cells":3980},{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3987,"PHASE4":3989,"NA":3995},{"trials":3982,"activeCount":98},[],{"trials":3984,"activeCount":98},[],{"trials":3986,"activeCount":98},[],{"trials":3988,"activeCount":98},[],{"trials":3990,"activeCount":98},[3991],{"nctId":3152,"briefTitle":3153,"status":446,"phases":3992,"primaryCompletion":3155,"completion":3155,"start":3156,"enrollment":3157,"conditions":3993,"interventions":3994},[89],[3159],[3161,3116],{"trials":3996,"activeCount":98},[],{"intervention":3998,"totalTrials":94,"cells":3999},"adalimumab",{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4004,"PHASE3":4006,"PHASE4":4008,"NA":4021},{"trials":4001,"activeCount":98},[],{"trials":4003,"activeCount":98},[],{"trials":4005,"activeCount":98},[],{"trials":4007,"activeCount":98},[],{"trials":4009,"activeCount":98},[4010],{"nctId":4011,"briefTitle":4012,"status":446,"phases":4013,"primaryCompletion":4014,"completion":4015,"start":4016,"enrollment":2098,"conditions":4017,"interventions":4020},"NCT00517296","Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas",[89],"2014-12","2015-12","2008-01",[4018,4019],"Crohn Disease","Rectal Fistula",[3998],{"trials":4022,"activeCount":98},[],{"intervention":4024,"totalTrials":94,"cells":4025},"Hylenex",{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4047},{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[],{"trials":4031,"activeCount":98},[],{"trials":4033,"activeCount":98},[],{"trials":4035,"activeCount":98},[4036],{"nctId":4037,"briefTitle":4038,"status":446,"phases":4039,"primaryCompletion":4040,"completion":4040,"start":4041,"enrollment":2682,"conditions":4042,"interventions":4046},"NCT01139294","Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics",[89],"2011-11","2010-02",[4043,4044,4045],"Dehydration","Cardiac Output","Pediatrics",[4024],{"trials":4048,"activeCount":98},[],{"intervention":4050,"totalTrials":94,"cells":4051},"Rivaroxaban 2.5 Mg Oral",{"EARLY_PHASE1":4052,"PHASE1":4054,"PHASE2":4056,"PHASE3":4058,"PHASE4":4060,"NA":4071},{"trials":4053,"activeCount":98},[],{"trials":4055,"activeCount":98},[],{"trials":4057,"activeCount":98},[],{"trials":4059,"activeCount":98},[],{"trials":4061,"activeCount":98},[4062],{"nctId":4063,"briefTitle":4064,"status":446,"phases":4065,"primaryCompletion":2084,"completion":2084,"start":4066,"enrollment":964,"conditions":4067,"interventions":4069},"NCT05009862","The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease",[89],"2022-04-19",[4068],"Peripheral Arterial Disease",[4050,4070],"Aspirin 81Mg Ec Tab",{"trials":4072,"activeCount":98},[],{"intervention":4070,"totalTrials":94,"cells":4074},{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4079,"PHASE3":4081,"PHASE4":4083,"NA":4089},{"trials":4076,"activeCount":98},[],{"trials":4078,"activeCount":98},[],{"trials":4080,"activeCount":98},[],{"trials":4082,"activeCount":98},[],{"trials":4084,"activeCount":98},[4085],{"nctId":4063,"briefTitle":4064,"status":446,"phases":4086,"primaryCompletion":2084,"completion":2084,"start":4066,"enrollment":964,"conditions":4087,"interventions":4088},[89],[4068],[4050,4070],{"trials":4090,"activeCount":98},[],{"intervention":705,"totalTrials":94,"cells":4092},{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4097,"PHASE3":4099,"PHASE4":4101,"NA":4107},{"trials":4094,"activeCount":98},[],{"trials":4096,"activeCount":98},[],{"trials":4098,"activeCount":98},[],{"trials":4100,"activeCount":98},[],{"trials":4102,"activeCount":98},[4103],{"nctId":693,"briefTitle":694,"status":446,"phases":4104,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":4105,"interventions":4106},[89],[700,701,702,703],[65,705],{"trials":4108,"activeCount":98},[],{"intervention":4110,"totalTrials":94,"cells":4111},"Dabigatran Etexilate Oral",{"EARLY_PHASE1":4112,"PHASE1":4114,"PHASE2":4116,"PHASE3":4118,"PHASE4":4120,"NA":4133},{"trials":4113,"activeCount":98},[],{"trials":4115,"activeCount":98},[],{"trials":4117,"activeCount":98},[],{"trials":4119,"activeCount":98},[],{"trials":4121,"activeCount":98},[4122],{"nctId":4123,"briefTitle":4124,"status":446,"phases":4125,"primaryCompletion":4126,"completion":4127,"start":882,"enrollment":769,"conditions":4128,"interventions":4132},"NCT03539055","Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).",[89],"2023-12-31","2024-02-29",[918,4129,4130,4131],"Device Related Thrombus","Left Atrial Appendage Thrombosis","Watchman LAA Closure Device",[4110],{"trials":4134,"activeCount":98},[],{"intervention":4136,"totalTrials":94,"cells":4137},"sertraline",{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4144,"PHASE4":4146,"NA":4157},{"trials":4139,"activeCount":98},[],{"trials":4141,"activeCount":98},[],{"trials":4143,"activeCount":98},[],{"trials":4145,"activeCount":98},[],{"trials":4147,"activeCount":98},[4148],{"nctId":4149,"briefTitle":4150,"status":446,"phases":4151,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":1722,"conditions":4154,"interventions":4155},"NCT00178828","Dynamic Measures of Neurochemistry in Mood Disorders",[89],"2013-04","2002-10",[28],[4136,4156],"bupropion",{"trials":4158,"activeCount":98},[],{"intervention":4160,"totalTrials":94,"cells":4161},"Medrol 4 MG Oral Tablet Includes Medrol Dosepak",{"EARLY_PHASE1":4162,"PHASE1":4164,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4184},{"trials":4163,"activeCount":98},[],{"trials":4165,"activeCount":98},[],{"trials":4167,"activeCount":98},[],{"trials":4169,"activeCount":98},[],{"trials":4171,"activeCount":98},[4172],{"nctId":4173,"briefTitle":4174,"status":580,"phases":4175,"primaryCompletion":2658,"completion":2658,"start":4176,"enrollment":98,"conditions":4177,"interventions":4183},"NCT06483204","Steroids for Rhinoplasty: Pain, Nausea, Edema and Ecchymosis",[89],"2026-01",[4178,4179,4180,3033,4181,4182],"Edema","Bruising","Nasal Obstruction","Postoperative Nausea","Postoperative Complications",[4160],{"trials":4185,"activeCount":98},[],{"intervention":4187,"totalTrials":94,"cells":4188},"Methylprednisolone Injectable Product",{"EARLY_PHASE1":4189,"PHASE1":4191,"PHASE2":4193,"PHASE3":4195,"PHASE4":4197,"NA":4211},{"trials":4190,"activeCount":98},[],{"trials":4192,"activeCount":98},[],{"trials":4194,"activeCount":98},[],{"trials":4196,"activeCount":98},[],{"trials":4198,"activeCount":98},[4199],{"nctId":4200,"briefTitle":4201,"status":446,"phases":4202,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":94,"conditions":4205,"interventions":4209},"NCT03479502","Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis",[89],"2022-02-08","2018-03-05",[4206,4207,4208],"Adhesive Capsulitis","Adhesive Capsulitis of Unspecified Shoulder","Frozen Shoulder",[4187,4210],"Doxycycline",{"trials":4212,"activeCount":98},[],{"intervention":4210,"totalTrials":94,"cells":4214},{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4221,"PHASE4":4223,"NA":4229},{"trials":4216,"activeCount":98},[],{"trials":4218,"activeCount":98},[],{"trials":4220,"activeCount":98},[],{"trials":4222,"activeCount":98},[],{"trials":4224,"activeCount":98},[4225],{"nctId":4200,"briefTitle":4201,"status":446,"phases":4226,"primaryCompletion":4203,"completion":4203,"start":4204,"enrollment":94,"conditions":4227,"interventions":4228},[89],[4206,4207,4208],[4187,4210],{"trials":4230,"activeCount":98},[],{"intervention":3188,"totalTrials":94,"cells":4232},{"EARLY_PHASE1":4233,"PHASE1":4235,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4247},{"trials":4234,"activeCount":98},[],{"trials":4236,"activeCount":98},[],{"trials":4238,"activeCount":98},[],{"trials":4240,"activeCount":98},[],{"trials":4242,"activeCount":98},[4243],{"nctId":3181,"briefTitle":3182,"status":634,"phases":4244,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":647,"conditions":4245,"interventions":4246},[89],[18],[3188,3189,3190,3191,3192,1291],{"trials":4248,"activeCount":98},[],{"intervention":3189,"totalTrials":94,"cells":4250},{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4257,"PHASE4":4259,"NA":4265},{"trials":4252,"activeCount":98},[],{"trials":4254,"activeCount":98},[],{"trials":4256,"activeCount":98},[],{"trials":4258,"activeCount":98},[],{"trials":4260,"activeCount":98},[4261],{"nctId":3181,"briefTitle":3182,"status":634,"phases":4262,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":647,"conditions":4263,"interventions":4264},[89],[18],[3188,3189,3190,3191,3192,1291],{"trials":4266,"activeCount":98},[],{"intervention":3190,"totalTrials":94,"cells":4268},{"EARLY_PHASE1":4269,"PHASE1":4271,"PHASE2":4273,"PHASE3":4275,"PHASE4":4277,"NA":4283},{"trials":4270,"activeCount":98},[],{"trials":4272,"activeCount":98},[],{"trials":4274,"activeCount":98},[],{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[4279],{"nctId":3181,"briefTitle":3182,"status":634,"phases":4280,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":647,"conditions":4281,"interventions":4282},[89],[18],[3188,3189,3190,3191,3192,1291],{"trials":4284,"activeCount":98},[],{"intervention":3191,"totalTrials":94,"cells":4286},{"EARLY_PHASE1":4287,"PHASE1":4289,"PHASE2":4291,"PHASE3":4293,"PHASE4":4295,"NA":4301},{"trials":4288,"activeCount":98},[],{"trials":4290,"activeCount":98},[],{"trials":4292,"activeCount":98},[],{"trials":4294,"activeCount":98},[],{"trials":4296,"activeCount":98},[4297],{"nctId":3181,"briefTitle":3182,"status":634,"phases":4298,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":647,"conditions":4299,"interventions":4300},[89],[18],[3188,3189,3190,3191,3192,1291],{"trials":4302,"activeCount":98},[],{"intervention":3192,"totalTrials":94,"cells":4304},{"EARLY_PHASE1":4305,"PHASE1":4307,"PHASE2":4309,"PHASE3":4311,"PHASE4":4313,"NA":4319},{"trials":4306,"activeCount":98},[],{"trials":4308,"activeCount":98},[],{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[],{"trials":4314,"activeCount":98},[4315],{"nctId":3181,"briefTitle":3182,"status":634,"phases":4316,"primaryCompletion":3184,"completion":3184,"start":3185,"enrollment":647,"conditions":4317,"interventions":4318},[89],[18],[3188,3189,3190,3191,3192,1291],{"trials":4320,"activeCount":98},[],{"intervention":4322,"totalTrials":94,"cells":4323},"Periprocedural Antibiotics",{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4330,"PHASE4":4332,"NA":4346},{"trials":4325,"activeCount":98},[],{"trials":4327,"activeCount":98},[],{"trials":4329,"activeCount":98},[],{"trials":4331,"activeCount":98},[],{"trials":4333,"activeCount":98},[4334],{"nctId":4335,"briefTitle":4336,"status":634,"phases":4337,"primaryCompletion":4338,"completion":4338,"start":4339,"enrollment":4340,"conditions":4341,"interventions":4344},"NCT03508921","Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection",[89],"2022-06-01","2018-07-01",22,[4342,4343],"Overactive Bladder","Urinary Tract Infections",[4322,4345],"Extended Antibiotics",{"trials":4347,"activeCount":98},[],{"intervention":4345,"totalTrials":94,"cells":4349},{"EARLY_PHASE1":4350,"PHASE1":4352,"PHASE2":4354,"PHASE3":4356,"PHASE4":4358,"NA":4364},{"trials":4351,"activeCount":98},[],{"trials":4353,"activeCount":98},[],{"trials":4355,"activeCount":98},[],{"trials":4357,"activeCount":98},[],{"trials":4359,"activeCount":98},[4360],{"nctId":4335,"briefTitle":4336,"status":634,"phases":4361,"primaryCompletion":4338,"completion":4338,"start":4339,"enrollment":4340,"conditions":4362,"interventions":4363},[89],[4342,4343],[4322,4345],{"trials":4365,"activeCount":98},[],{"intervention":4367,"totalTrials":94,"cells":4368},"4% liposomal lidocaine cream",{"EARLY_PHASE1":4369,"PHASE1":4371,"PHASE2":4373,"PHASE3":4375,"PHASE4":4377,"NA":4389},{"trials":4370,"activeCount":98},[],{"trials":4372,"activeCount":98},[],{"trials":4374,"activeCount":98},[],{"trials":4376,"activeCount":98},[],{"trials":4378,"activeCount":98},[4379],{"nctId":4380,"briefTitle":4381,"status":446,"phases":4382,"primaryCompletion":4383,"completion":4383,"start":4384,"enrollment":4385,"conditions":4386,"interventions":4388},"NCT04766684","Clubfoot Tenotomy Trial",[89],"2024-08-01","2021-06-01",107,[4387],"Clubfoot",[4367],{"trials":4390,"activeCount":98},[],{"intervention":4392,"totalTrials":94,"cells":4393},"Aprepitant",{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4398,"PHASE3":4400,"PHASE4":4402,"NA":4415},{"trials":4395,"activeCount":98},[],{"trials":4397,"activeCount":98},[],{"trials":4399,"activeCount":98},[],{"trials":4401,"activeCount":98},[],{"trials":4403,"activeCount":98},[4404],{"nctId":4405,"briefTitle":4406,"status":634,"phases":4407,"primaryCompletion":4408,"completion":4409,"start":4410,"enrollment":1131,"conditions":4411,"interventions":4414},"NCT01625455","Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome",[89],"2015-07","2016-07","2012-02",[4412,4413],"Sezary Syndrome","Pruritus",[4392],{"trials":4416,"activeCount":98},[],{"intervention":4418,"totalTrials":94,"cells":4419},"Nicotine",{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4426,"PHASE4":4428,"NA":4438},{"trials":4421,"activeCount":98},[],{"trials":4423,"activeCount":98},[],{"trials":4425,"activeCount":98},[],{"trials":4427,"activeCount":98},[],{"trials":4429,"activeCount":98},[4430],{"nctId":4431,"briefTitle":4432,"status":446,"phases":4433,"primaryCompletion":4434,"completion":4435,"start":890,"enrollment":19,"conditions":4436,"interventions":4437},"NCT02816138","Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)",[89],"2017-08-23","2017-09-12",[3809],[4418],{"trials":4439,"activeCount":98},[],{"intervention":4441,"totalTrials":94,"cells":4442},"Live Attenuated Influenza Vaccine",{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4466},{"trials":4444,"activeCount":98},[],{"trials":4446,"activeCount":98},[],{"trials":4448,"activeCount":98},[],{"trials":4450,"activeCount":98},[],{"trials":4452,"activeCount":98},[4453],{"nctId":4454,"briefTitle":4455,"status":446,"phases":4456,"primaryCompletion":4457,"completion":4457,"start":4458,"enrollment":4459,"conditions":4460,"interventions":4464},"NCT03600428","Safety of LAIV4 in Children With Asthma",[89],"2020-03-20","2018-10-15",152,[1388,4461,4462,1978,4463,1079],"Vaccine Adverse Reaction","Vaccine Reaction","Wheezing",[4441,4465],"Inactivated Influenza Vaccine",{"trials":4467,"activeCount":98},[],{"intervention":4465,"totalTrials":94,"cells":4469},{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4476,"PHASE4":4478,"NA":4484},{"trials":4471,"activeCount":98},[],{"trials":4473,"activeCount":98},[],{"trials":4475,"activeCount":98},[],{"trials":4477,"activeCount":98},[],{"trials":4479,"activeCount":98},[4480],{"nctId":4454,"briefTitle":4455,"status":446,"phases":4481,"primaryCompletion":4457,"completion":4457,"start":4458,"enrollment":4459,"conditions":4482,"interventions":4483},[89],[1388,4461,4462,1978,4463,1079],[4441,4465],{"trials":4485,"activeCount":98},[],{"intervention":3229,"totalTrials":94,"cells":4487},{"EARLY_PHASE1":4488,"PHASE1":4490,"PHASE2":4492,"PHASE3":4494,"PHASE4":4496,"NA":4502},{"trials":4489,"activeCount":98},[],{"trials":4491,"activeCount":98},[],{"trials":4493,"activeCount":98},[],{"trials":4495,"activeCount":98},[],{"trials":4497,"activeCount":98},[4498],{"nctId":3220,"briefTitle":3221,"status":634,"phases":4499,"primaryCompletion":3223,"completion":3223,"start":3224,"enrollment":3225,"conditions":4500,"interventions":4501},[89],[3227],[3196,3229],{"trials":4503,"activeCount":98},[],{"intervention":4505,"totalTrials":94,"cells":4506},"Dapsone gel, 5%",{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4511,"PHASE3":4513,"PHASE4":4515,"NA":4526},{"trials":4508,"activeCount":98},[],{"trials":4510,"activeCount":98},[],{"trials":4512,"activeCount":98},[],{"trials":4514,"activeCount":98},[],{"trials":4516,"activeCount":98},[4517],{"nctId":4518,"briefTitle":4519,"status":634,"phases":4520,"primaryCompletion":4521,"completion":4521,"start":4522,"enrollment":94,"conditions":4523,"interventions":4525},"NCT01115244","Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis",[89],"2012-03","2010-07",[4524],"Dermatitis Herpetiformis",[4505],{"trials":4527,"activeCount":98},[],{"intervention":4529,"totalTrials":94,"cells":4530},"Transforaminal Epidural Steroid Injection with Dexamethasone",{"EARLY_PHASE1":4531,"PHASE1":4533,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4550},{"trials":4532,"activeCount":98},[],{"trials":4534,"activeCount":98},[],{"trials":4536,"activeCount":98},[],{"trials":4538,"activeCount":98},[],{"trials":4540,"activeCount":98},[4541],{"nctId":4542,"briefTitle":4543,"status":580,"phases":4544,"primaryCompletion":2784,"completion":3570,"start":4545,"enrollment":98,"conditions":4546,"interventions":4548},"NCT03165825","Cervical Interlaminar Versus Transforaminal Epidural Steroid Injection",[89],"2018-01",[4547],"Cervical Radiculopathy",[4529,4549],"Interlaminar Epidural Steroid Injection with Betamethasone",{"trials":4551,"activeCount":98},[],{"intervention":4549,"totalTrials":94,"cells":4553},{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4558,"PHASE3":4560,"PHASE4":4562,"NA":4568},{"trials":4555,"activeCount":98},[],{"trials":4557,"activeCount":98},[],{"trials":4559,"activeCount":98},[],{"trials":4561,"activeCount":98},[],{"trials":4563,"activeCount":98},[4564],{"nctId":4542,"briefTitle":4543,"status":580,"phases":4565,"primaryCompletion":2784,"completion":3570,"start":4545,"enrollment":98,"conditions":4566,"interventions":4567},[89],[4547],[4529,4549],{"trials":4569,"activeCount":98},[],{"intervention":4571,"totalTrials":94,"cells":4572},"Gabapentin",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4594},{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[],{"trials":4578,"activeCount":98},[],{"trials":4580,"activeCount":98},[],{"trials":4582,"activeCount":98},[4583],{"nctId":4584,"briefTitle":4585,"status":580,"phases":4586,"primaryCompletion":4587,"completion":4588,"start":4589,"enrollment":98,"conditions":4590,"interventions":4593},"NCT03335436","Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient",[89],"2020-11","2020-12","2018-04-01",[4591,4592],"Cesarean Delivery","Pain Management",[4571],{"trials":4595,"activeCount":98},[],{"intervention":4597,"totalTrials":94,"cells":4598},"Risperidone",{"EARLY_PHASE1":4599,"PHASE1":4601,"PHASE2":4603,"PHASE3":4605,"PHASE4":4607,"NA":4618},{"trials":4600,"activeCount":98},[],{"trials":4602,"activeCount":98},[],{"trials":4604,"activeCount":98},[],{"trials":4606,"activeCount":98},[],{"trials":4608,"activeCount":98},[4609],{"nctId":4610,"briefTitle":4611,"status":580,"phases":4612,"primaryCompletion":4613,"completion":4613,"start":4614,"enrollment":98,"conditions":4615,"interventions":4617},"NCT00178854","Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment",[89],"2006-03","2004-05",[4616],"Treatment Resistant Depression",[4597],{"trials":4619,"activeCount":98},[],{"intervention":4621,"totalTrials":94,"cells":4622},"Valproic Acid",{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4627,"PHASE3":4629,"PHASE4":4631,"NA":4642},{"trials":4624,"activeCount":98},[],{"trials":4626,"activeCount":98},[],{"trials":4628,"activeCount":98},[],{"trials":4630,"activeCount":98},[],{"trials":4632,"activeCount":98},[4633],{"nctId":4634,"briefTitle":4635,"status":446,"phases":4636,"primaryCompletion":4637,"completion":4637,"start":4638,"enrollment":29,"conditions":4639,"interventions":4641},"NCT00609245","Effect of Valproic Acid Concentration on Photic Response",[89],"2008-12","2007-12",[4640],"Photosensitive Epilepsy",[4621],{"trials":4643,"activeCount":98},[],{"intervention":4645,"totalTrials":94,"cells":4646},"Vitamin E",{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4651,"PHASE3":4653,"PHASE4":4655,"NA":4668},{"trials":4648,"activeCount":98},[],{"trials":4650,"activeCount":98},[],{"trials":4652,"activeCount":98},[],{"trials":4654,"activeCount":98},[],{"trials":4656,"activeCount":98},[4657],{"nctId":4658,"briefTitle":4659,"status":446,"phases":4660,"primaryCompletion":4661,"completion":4661,"start":4662,"enrollment":2087,"conditions":4663,"interventions":4666},"NCT03176966","Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis",[89],"2021-10-22","2016-09-02",[4664,4665],"Muscle Cramp","Cirrhosis",[4645,4667],"Ropinirole",{"trials":4669,"activeCount":98},[],{"intervention":4667,"totalTrials":94,"cells":4671},{"EARLY_PHASE1":4672,"PHASE1":4674,"PHASE2":4676,"PHASE3":4678,"PHASE4":4680,"NA":4686},{"trials":4673,"activeCount":98},[],{"trials":4675,"activeCount":98},[],{"trials":4677,"activeCount":98},[],{"trials":4679,"activeCount":98},[],{"trials":4681,"activeCount":98},[4682],{"nctId":4658,"briefTitle":4659,"status":446,"phases":4683,"primaryCompletion":4661,"completion":4661,"start":4662,"enrollment":2087,"conditions":4684,"interventions":4685},[89],[4664,4665],[4645,4667],{"trials":4687,"activeCount":98},[],{"intervention":4689,"totalTrials":94,"cells":4690},"Natalizumab 300 MG in 15 ML",{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4695,"PHASE3":4697,"PHASE4":4699,"NA":4710},{"trials":4692,"activeCount":98},[],{"trials":4694,"activeCount":98},[],{"trials":4696,"activeCount":98},[],{"trials":4698,"activeCount":98},[],{"trials":4700,"activeCount":98},[4701],{"nctId":4702,"briefTitle":4703,"status":634,"phases":4704,"primaryCompletion":4705,"completion":4705,"start":4706,"enrollment":94,"conditions":4707,"interventions":4709},"NCT05177718","Natalizumab and Chronic Inflammation",[89],"2023-04-05","2022-09-16",[4708],"Multiple Sclerosis",[4689],{"trials":4711,"activeCount":98},[],{"intervention":4713,"totalTrials":94,"cells":4714},"Eplerenone",{"EARLY_PHASE1":4715,"PHASE1":4717,"PHASE2":4719,"PHASE3":4721,"PHASE4":4723,"NA":4733},{"trials":4716,"activeCount":98},[],{"trials":4718,"activeCount":98},[],{"trials":4720,"activeCount":98},[],{"trials":4722,"activeCount":98},[],{"trials":4724,"activeCount":98},[4725],{"nctId":4726,"briefTitle":4727,"status":446,"phases":4728,"primaryCompletion":4729,"completion":4729,"start":1159,"enrollment":2098,"conditions":4730,"interventions":4732},"NCT00515021","Diurnal Variation of Plasminogen Activator Inhibitor-1",[89],"2010-04",[4731],"Metabolic Syndrome X",[4713,4713],{"trials":4734,"activeCount":98},[],{"intervention":4736,"totalTrials":94,"cells":4737},"Fluid Bolus",{"EARLY_PHASE1":4738,"PHASE1":4740,"PHASE2":4742,"PHASE3":4744,"PHASE4":4746,"NA":4758},{"trials":4739,"activeCount":98},[],{"trials":4741,"activeCount":98},[],{"trials":4743,"activeCount":98},[],{"trials":4745,"activeCount":98},[],{"trials":4747,"activeCount":98},[4748],{"nctId":4749,"briefTitle":4750,"status":446,"phases":4751,"primaryCompletion":1171,"completion":4752,"start":4753,"enrollment":4754,"conditions":4755,"interventions":4757},"NCT03787732","Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation",[89],"2021-06-21","2019-02-01",1067,[2649,1769,4756],"Hypotension on Induction",[4736],{"trials":4759,"activeCount":98},[],{"intervention":4761,"totalTrials":94,"cells":4762},"Opioid Analgesic",{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4767,"PHASE3":4769,"PHASE4":4771,"NA":4783},{"trials":4764,"activeCount":98},[],{"trials":4766,"activeCount":98},[],{"trials":4768,"activeCount":98},[],{"trials":4770,"activeCount":98},[],{"trials":4772,"activeCount":98},[4773],{"nctId":4774,"briefTitle":4775,"status":634,"phases":4776,"primaryCompletion":3648,"completion":3648,"start":4777,"enrollment":4778,"conditions":4779,"interventions":4781},"NCT04990804","Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery",[89],"2021-08-01",8,[2636,703,4780,2136,3033],"Surgery--Complications",[4761,4782],"Opioid-Free Postoperative Pain Regimen",{"trials":4784,"activeCount":98},[],{"intervention":4782,"totalTrials":94,"cells":4786},{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4793,"PHASE4":4795,"NA":4801},{"trials":4788,"activeCount":98},[],{"trials":4790,"activeCount":98},[],{"trials":4792,"activeCount":98},[],{"trials":4794,"activeCount":98},[],{"trials":4796,"activeCount":98},[4797],{"nctId":4774,"briefTitle":4775,"status":634,"phases":4798,"primaryCompletion":3648,"completion":3648,"start":4777,"enrollment":4778,"conditions":4799,"interventions":4800},[89],[2636,703,4780,2136,3033],[4761,4782],{"trials":4802,"activeCount":98},[],{"intervention":4804,"totalTrials":94,"cells":4805},"Dexmedetomidine Hydrochloride - Cycling",{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4810,"PHASE3":4812,"PHASE4":4814,"NA":4826},{"trials":4807,"activeCount":98},[],{"trials":4809,"activeCount":98},[],{"trials":4811,"activeCount":98},[],{"trials":4813,"activeCount":98},[],{"trials":4815,"activeCount":98},[4816],{"nctId":4817,"briefTitle":4818,"status":580,"phases":4819,"primaryCompletion":4820,"completion":4820,"start":4821,"enrollment":98,"conditions":4822,"interventions":4823},"NCT05003102","Dexmedetomidine Cycling and Sleep in the Pediatric ICU",[89],"2023-06-30","2023-02-20",[31,674,21],[4804,4824,4825],"Fentanyl - PICU Standard","Dexmedetomidine Hydrochloride - PICU Standard",{"trials":4827,"activeCount":98},[],{"intervention":4824,"totalTrials":94,"cells":4829},{"EARLY_PHASE1":4830,"PHASE1":4832,"PHASE2":4834,"PHASE3":4836,"PHASE4":4838,"NA":4844},{"trials":4831,"activeCount":98},[],{"trials":4833,"activeCount":98},[],{"trials":4835,"activeCount":98},[],{"trials":4837,"activeCount":98},[],{"trials":4839,"activeCount":98},[4840],{"nctId":4817,"briefTitle":4818,"status":580,"phases":4841,"primaryCompletion":4820,"completion":4820,"start":4821,"enrollment":98,"conditions":4842,"interventions":4843},[89],[31,674,21],[4804,4824,4825],{"trials":4845,"activeCount":98},[],{"intervention":4825,"totalTrials":94,"cells":4847},{"EARLY_PHASE1":4848,"PHASE1":4850,"PHASE2":4852,"PHASE3":4854,"PHASE4":4856,"NA":4862},{"trials":4849,"activeCount":98},[],{"trials":4851,"activeCount":98},[],{"trials":4853,"activeCount":98},[],{"trials":4855,"activeCount":98},[],{"trials":4857,"activeCount":98},[4858],{"nctId":4817,"briefTitle":4818,"status":580,"phases":4859,"primaryCompletion":4820,"completion":4820,"start":4821,"enrollment":98,"conditions":4860,"interventions":4861},[89],[31,674,21],[4804,4824,4825],{"trials":4863,"activeCount":98},[],{"intervention":4865,"totalTrials":94,"cells":4866},"Baricitinib 4 MG",{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4871,"PHASE3":4873,"PHASE4":4883,"NA":4885},{"trials":4868,"activeCount":98},[],{"trials":4870,"activeCount":98},[],{"trials":4872,"activeCount":98},[],{"trials":4874,"activeCount":98},[4875],{"nctId":4876,"briefTitle":4877,"status":580,"phases":4878,"primaryCompletion":767,"completion":4879,"start":4880,"enrollment":98,"conditions":4881,"interventions":4882},"NCT05858515","REVERSE-Long COVID-19 With Baricitinib Study",[88],"2029-12-30","2024-10-21",[1875],[4865],{"trials":4884,"activeCount":98},[],{"trials":4886,"activeCount":98},[],{"intervention":4888,"totalTrials":94,"cells":4889},"Moderate Dose Hydroxyurea",{"EARLY_PHASE1":4890,"PHASE1":4892,"PHASE2":4894,"PHASE3":4896,"PHASE4":4906,"NA":4908},{"trials":4891,"activeCount":98},[],{"trials":4893,"activeCount":98},[],{"trials":4895,"activeCount":98},[],{"trials":4897,"activeCount":98},[4898],{"nctId":4899,"briefTitle":4900,"status":446,"phases":4901,"primaryCompletion":4902,"completion":4902,"start":1337,"enrollment":115,"conditions":4903,"interventions":4904},"NCT02675790","Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa",[88],"2020-03-31",[479,453,480],[4888,4905],"Low Dose Hydroxyurea",{"trials":4907,"activeCount":98},[],{"trials":4909,"activeCount":98},[],{"intervention":4905,"totalTrials":94,"cells":4911},{"EARLY_PHASE1":4912,"PHASE1":4914,"PHASE2":4916,"PHASE3":4918,"PHASE4":4924,"NA":4926},{"trials":4913,"activeCount":98},[],{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[],{"trials":4919,"activeCount":98},[4920],{"nctId":4899,"briefTitle":4900,"status":446,"phases":4921,"primaryCompletion":4902,"completion":4902,"start":1337,"enrollment":115,"conditions":4922,"interventions":4923},[88],[479,453,480],[4888,4905],{"trials":4925,"activeCount":98},[],{"trials":4927,"activeCount":98},[],{"intervention":4929,"totalTrials":94,"cells":4930},"Haloperidol",{"EARLY_PHASE1":4931,"PHASE1":4933,"PHASE2":4935,"PHASE3":4937,"PHASE4":4951,"NA":4953},{"trials":4932,"activeCount":98},[],{"trials":4934,"activeCount":98},[],{"trials":4936,"activeCount":98},[],{"trials":4938,"activeCount":98},[4939],{"nctId":4940,"briefTitle":4941,"status":446,"phases":4942,"primaryCompletion":4943,"completion":4944,"start":4945,"enrollment":4946,"conditions":4947,"interventions":4949},"NCT01211522","The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study",[88],"2017-08-28","2018-07-19","2011-12-14",566,[21,688,4948],"Long Term Psychologic Disorders",[4929,4950],"Ziprasidone",{"trials":4952,"activeCount":98},[],{"trials":4954,"activeCount":98},[],{"intervention":4950,"totalTrials":94,"cells":4956},{"EARLY_PHASE1":4957,"PHASE1":4959,"PHASE2":4961,"PHASE3":4963,"PHASE4":4969,"NA":4971},{"trials":4958,"activeCount":98},[],{"trials":4960,"activeCount":98},[],{"trials":4962,"activeCount":98},[],{"trials":4964,"activeCount":98},[4965],{"nctId":4940,"briefTitle":4941,"status":446,"phases":4966,"primaryCompletion":4943,"completion":4944,"start":4945,"enrollment":4946,"conditions":4967,"interventions":4968},[88],[21,688,4948],[4929,4950],{"trials":4970,"activeCount":98},[],{"trials":4972,"activeCount":98},[],{"intervention":4974,"totalTrials":94,"cells":4975},"Placebos for acetaminophen and N-acetylcysteine",{"EARLY_PHASE1":4976,"PHASE1":4978,"PHASE2":4980,"PHASE3":4982,"PHASE4":4997,"NA":4999},{"trials":4977,"activeCount":98},[],{"trials":4979,"activeCount":98},[],{"trials":4981,"activeCount":98},[],{"trials":4983,"activeCount":98},[4984],{"nctId":4985,"briefTitle":4986,"status":634,"phases":4987,"primaryCompletion":4988,"completion":4988,"start":1159,"enrollment":1317,"conditions":4989,"interventions":4992},"NCT00585559","Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm",[88],"2023-10-26",[4990,4991],"Aneurysmal Subarachnoid Hemorrhage","Cerebral Vasospasm",[4974,4993,4994,4995,4996],"APAP 1 gm every 6 hours and N-acetylcysteine placebo","NAC IV infusion at 0.5 gm hourly and APAP placebo","APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly","APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",{"trials":4998,"activeCount":98},[],{"trials":5000,"activeCount":98},[],{"intervention":4993,"totalTrials":94,"cells":5002},{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5007,"PHASE3":5009,"PHASE4":5015,"NA":5017},{"trials":5004,"activeCount":98},[],{"trials":5006,"activeCount":98},[],{"trials":5008,"activeCount":98},[],{"trials":5010,"activeCount":98},[5011],{"nctId":4985,"briefTitle":4986,"status":634,"phases":5012,"primaryCompletion":4988,"completion":4988,"start":1159,"enrollment":1317,"conditions":5013,"interventions":5014},[88],[4990,4991],[4974,4993,4994,4995,4996],{"trials":5016,"activeCount":98},[],{"trials":5018,"activeCount":98},[],{"intervention":4994,"totalTrials":94,"cells":5020},{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5025,"PHASE3":5027,"PHASE4":5033,"NA":5035},{"trials":5022,"activeCount":98},[],{"trials":5024,"activeCount":98},[],{"trials":5026,"activeCount":98},[],{"trials":5028,"activeCount":98},[5029],{"nctId":4985,"briefTitle":4986,"status":634,"phases":5030,"primaryCompletion":4988,"completion":4988,"start":1159,"enrollment":1317,"conditions":5031,"interventions":5032},[88],[4990,4991],[4974,4993,4994,4995,4996],{"trials":5034,"activeCount":98},[],{"trials":5036,"activeCount":98},[],{"intervention":4995,"totalTrials":94,"cells":5038},{"EARLY_PHASE1":5039,"PHASE1":5041,"PHASE2":5043,"PHASE3":5045,"PHASE4":5051,"NA":5053},{"trials":5040,"activeCount":98},[],{"trials":5042,"activeCount":98},[],{"trials":5044,"activeCount":98},[],{"trials":5046,"activeCount":98},[5047],{"nctId":4985,"briefTitle":4986,"status":634,"phases":5048,"primaryCompletion":4988,"completion":4988,"start":1159,"enrollment":1317,"conditions":5049,"interventions":5050},[88],[4990,4991],[4974,4993,4994,4995,4996],{"trials":5052,"activeCount":98},[],{"trials":5054,"activeCount":98},[],{"intervention":4996,"totalTrials":94,"cells":5056},{"EARLY_PHASE1":5057,"PHASE1":5059,"PHASE2":5061,"PHASE3":5063,"PHASE4":5069,"NA":5071},{"trials":5058,"activeCount":98},[],{"trials":5060,"activeCount":98},[],{"trials":5062,"activeCount":98},[],{"trials":5064,"activeCount":98},[5065],{"nctId":4985,"briefTitle":4986,"status":634,"phases":5066,"primaryCompletion":4988,"completion":4988,"start":1159,"enrollment":1317,"conditions":5067,"interventions":5068},[88],[4990,4991],[4974,4993,4994,4995,4996],{"trials":5070,"activeCount":98},[],{"trials":5072,"activeCount":98},[],{"intervention":5074,"totalTrials":94,"cells":5075},"pathogen reduced SARS-CoV-2 convalescent plasma",{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5080,"PHASE3":5082,"PHASE4":5097,"NA":5099},{"trials":5077,"activeCount":98},[],{"trials":5079,"activeCount":98},[],{"trials":5081,"activeCount":98},[],{"trials":5083,"activeCount":98},[5084],{"nctId":5085,"briefTitle":5086,"status":446,"phases":5087,"primaryCompletion":5088,"completion":5089,"start":5090,"enrollment":5091,"conditions":5092,"interventions":5096},"NCT04362176","Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults",[88],"2021-07-06","2021-08-06","2020-04-24",974,[5093,5094,5095],"COVID-19","Coronavirus","SARS-CoV-2",[5074],{"trials":5098,"activeCount":98},[],{"trials":5100,"activeCount":98},[],{"intervention":5102,"totalTrials":94,"cells":5103},"Dapagliflozin 10 MG",{"EARLY_PHASE1":5104,"PHASE1":5106,"PHASE2":5108,"PHASE3":5110,"PHASE4":5121,"NA":5123},{"trials":5105,"activeCount":98},[],{"trials":5107,"activeCount":98},[],{"trials":5109,"activeCount":98},[],{"trials":5111,"activeCount":98},[5112],{"nctId":5113,"briefTitle":5114,"status":446,"phases":5115,"primaryCompletion":5116,"completion":5116,"start":5117,"enrollment":5118,"conditions":5119,"interventions":5120},"NCT04298229","Efficacy and Safety of Dapagliflozin in Acute Heart Failure",[88],"2023-05-17","2020-04-01",240,[626,34],[5102],{"trials":5122,"activeCount":98},[],{"trials":5124,"activeCount":98},[],{"intervention":1203,"totalTrials":94,"cells":5126},{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5139,"NA":5141},{"trials":5128,"activeCount":98},[],{"trials":5130,"activeCount":98},[],{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[5135],{"nctId":1190,"briefTitle":1191,"status":446,"phases":5136,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":1196,"conditions":5137,"interventions":5138},[88],[1198,1199,1200,1201],[1203,1204,1121],{"trials":5140,"activeCount":98},[],{"trials":5142,"activeCount":98},[],{"intervention":1204,"totalTrials":94,"cells":5144},{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5151,"PHASE4":5157,"NA":5159},{"trials":5146,"activeCount":98},[],{"trials":5148,"activeCount":98},[],{"trials":5150,"activeCount":98},[],{"trials":5152,"activeCount":98},[5153],{"nctId":1190,"briefTitle":1191,"status":446,"phases":5154,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":1196,"conditions":5155,"interventions":5156},[88],[1198,1199,1200,1201],[1203,1204,1121],{"trials":5158,"activeCount":98},[],{"trials":5160,"activeCount":98},[],{"intervention":5162,"totalTrials":94,"cells":5163},"Antiarrhythmic drug",{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5168,"PHASE3":5170,"PHASE4":5182,"NA":5184},{"trials":5165,"activeCount":98},[],{"trials":5167,"activeCount":98},[],{"trials":5169,"activeCount":98},[],{"trials":5171,"activeCount":98},[5172],{"nctId":5173,"briefTitle":5174,"status":634,"phases":5175,"primaryCompletion":5176,"completion":5176,"start":5177,"enrollment":435,"conditions":5178,"interventions":5181},"NCT04208997","Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation",[88],"2021-06-30","2019-12-19",[5179,5180],"Tachycardia, Ventricular","Catheter Ablation",[5162],{"trials":5183,"activeCount":98},[],{"trials":5185,"activeCount":98},[],{"intervention":5187,"totalTrials":94,"cells":5188},"Harmonized supportive care",{"EARLY_PHASE1":5189,"PHASE1":5191,"PHASE2":5193,"PHASE3":5195,"PHASE4":5208,"NA":5210},{"trials":5190,"activeCount":98},[],{"trials":5192,"activeCount":98},[],{"trials":5194,"activeCount":98},[],{"trials":5196,"activeCount":98},[5197],{"nctId":5198,"briefTitle":5199,"status":446,"phases":5200,"primaryCompletion":5201,"completion":5201,"start":5202,"enrollment":506,"conditions":5203,"interventions":5206},"NCT02987257","NATIENS: Optimal Management and Mechanisms of SJS\u002FTEN",[88],"2025-10-31","2023-03-21",[5204,5205],"Stevens-Johnson Syndrome","Toxic Epidermal Necrolyses",[5187,5207],"Etanercept 50 mg sc day 1 and day 4",{"trials":5209,"activeCount":98},[],{"trials":5211,"activeCount":98},[],{"intervention":5207,"totalTrials":94,"cells":5213},{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5226,"NA":5228},{"trials":5215,"activeCount":98},[],{"trials":5217,"activeCount":98},[],{"trials":5219,"activeCount":98},[],{"trials":5221,"activeCount":98},[5222],{"nctId":5198,"briefTitle":5199,"status":446,"phases":5223,"primaryCompletion":5201,"completion":5201,"start":5202,"enrollment":506,"conditions":5224,"interventions":5225},[88],[5204,5205],[5187,5207],{"trials":5227,"activeCount":98},[],{"trials":5229,"activeCount":98},[],{"intervention":5231,"totalTrials":94,"cells":5232},"Nicotine metabolism",{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5239,"PHASE4":5255,"NA":5257},{"trials":5234,"activeCount":98},[],{"trials":5236,"activeCount":98},[],{"trials":5238,"activeCount":98},[],{"trials":5240,"activeCount":98},[5241],{"nctId":5242,"briefTitle":5243,"status":446,"phases":5244,"primaryCompletion":5245,"completion":5246,"start":5247,"enrollment":5248,"conditions":5249,"interventions":5251},"NCT03521141","PRecision Interventions for SMoking in the SCCS",[87,88],"2019-04-11","2019-04-25","2018-05-18",67,[5250],"Tobacco Use Cessation",[5252,5253,5231,5254],"Nicotine patch","Varenicline","Genetically-informed lung cancer risk score",{"trials":5256,"activeCount":98},[],{"trials":5258,"activeCount":98},[],{"intervention":5254,"totalTrials":94,"cells":5260},{"EARLY_PHASE1":5261,"PHASE1":5263,"PHASE2":5265,"PHASE3":5267,"PHASE4":5273,"NA":5275},{"trials":5262,"activeCount":98},[],{"trials":5264,"activeCount":98},[],{"trials":5266,"activeCount":98},[],{"trials":5268,"activeCount":98},[5269],{"nctId":5242,"briefTitle":5243,"status":446,"phases":5270,"primaryCompletion":5245,"completion":5246,"start":5247,"enrollment":5248,"conditions":5271,"interventions":5272},[87,88],[5250],[5252,5253,5231,5254],{"trials":5274,"activeCount":98},[],{"trials":5276,"activeCount":98},[],{"intervention":5278,"totalTrials":94,"cells":5279},"Dantrolene\u002FRyanodex",{"EARLY_PHASE1":5280,"PHASE1":5282,"PHASE2":5284,"PHASE3":5286,"PHASE4":5298,"NA":5300},{"trials":5281,"activeCount":98},[],{"trials":5283,"activeCount":98},[],{"trials":5285,"activeCount":98},[],{"trials":5287,"activeCount":98},[5288],{"nctId":5289,"briefTitle":5290,"status":446,"phases":5291,"primaryCompletion":5292,"completion":5293,"start":5294,"enrollment":698,"conditions":5295,"interventions":5297},"NCT04134845","A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.",[87,88],"2025-05-29","2025-08-29","2020-08-21",[5296],"Ventricular Tachycardia",[5278],{"trials":5299,"activeCount":98},[],{"trials":5301,"activeCount":98},[],{"intervention":5303,"totalTrials":506,"cells":5304},"Atomoxetine",{"EARLY_PHASE1":5305,"PHASE1":5307,"PHASE2":5316,"PHASE3":5327,"PHASE4":5329,"NA":5331},{"trials":5306,"activeCount":98},[],{"trials":5308,"activeCount":98},[5309],{"nctId":5310,"briefTitle":5311,"status":634,"phases":5312,"primaryCompletion":5313,"completion":5313,"start":4339,"enrollment":3209,"conditions":5314,"interventions":5315},"NCT03808740","Orthostatic Intolerance After Bariatric Surgery",[86],"2021-05-31",[2704],[5303],{"trials":5317,"activeCount":98},[5318],{"nctId":5319,"briefTitle":5320,"status":446,"phases":5321,"primaryCompletion":5322,"completion":5323,"start":5324,"enrollment":1037,"conditions":5325,"interventions":5326},"NCT02784535","Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)",[87],"2021-05-12","2023-06","2016-08-29",[2089],[5303],{"trials":5328,"activeCount":98},[],{"trials":5330,"activeCount":98},[],{"trials":5332,"activeCount":98},[],{"intervention":468,"totalTrials":506,"cells":5334},{"EARLY_PHASE1":5335,"PHASE1":5337,"PHASE2":5339,"PHASE3":5354,"PHASE4":5356,"NA":5358},{"trials":5336,"activeCount":98},[],{"trials":5338,"activeCount":98},[],{"trials":5340,"activeCount":98},[5341,5350],{"nctId":5342,"briefTitle":5343,"status":446,"phases":5344,"primaryCompletion":5345,"completion":5345,"start":4409,"enrollment":5346,"conditions":5347,"interventions":5349},"NCT02819440","PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction",[87],"2020-06",141,[2252,5348],"Obese",[468],{"nctId":458,"briefTitle":459,"status":446,"phases":5351,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":5352,"interventions":5353},[87],[466],[468,434],{"trials":5355,"activeCount":98},[],{"trials":5357,"activeCount":98},[],{"trials":5359,"activeCount":98},[],{"intervention":5361,"totalTrials":94,"cells":5362},"dulaglutide",{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5367,"PHASE3":5378,"PHASE4":5380,"NA":5382},{"trials":5364,"activeCount":98},[],{"trials":5366,"activeCount":98},[],{"trials":5368,"activeCount":98},[5369],{"nctId":5370,"briefTitle":5371,"status":446,"phases":5372,"primaryCompletion":5373,"completion":4383,"start":5374,"enrollment":1131,"conditions":5375,"interventions":5377},"NCT05254418","Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease",[87],"2024-05-01","2022-03-15",[5376],"Chronic Kidney Diseases",[5361],{"trials":5379,"activeCount":98},[],{"trials":5381,"activeCount":98},[],{"trials":5383,"activeCount":98},[],{"intervention":5385,"totalTrials":94,"cells":5386},"Magnesium Citrate plus probiotic",{"EARLY_PHASE1":5387,"PHASE1":5389,"PHASE2":5391,"PHASE3":5402,"PHASE4":5404,"NA":5406},{"trials":5388,"activeCount":98},[],{"trials":5390,"activeCount":98},[],{"trials":5392,"activeCount":98},[5393],{"nctId":5394,"briefTitle":5395,"status":634,"phases":5396,"primaryCompletion":5397,"completion":5397,"start":5398,"enrollment":9,"conditions":5399,"interventions":5401},"NCT04941703","\"CHANGE COVID-19 Severity\"",[86,87],"2022-06-25","2021-11-04",[5400],"COVID-19 Infection",[5385],{"trials":5403,"activeCount":98},[],{"trials":5405,"activeCount":98},[],{"trials":5407,"activeCount":98},[],{"intervention":5409,"totalTrials":94,"cells":5410},"Abatacept",{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5415,"PHASE3":5423,"PHASE4":5425,"NA":5427},{"trials":5412,"activeCount":98},[],{"trials":5414,"activeCount":98},[],{"trials":5416,"activeCount":98},[5417],{"nctId":5418,"briefTitle":5419,"status":634,"phases":5420,"primaryCompletion":891,"completion":891,"start":2681,"enrollment":94,"conditions":5421,"interventions":5422},"NCT02232880","Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation",[87],[18],[5409],{"trials":5424,"activeCount":98},[],{"trials":5426,"activeCount":98},[],{"trials":5428,"activeCount":98},[],{"intervention":5430,"totalTrials":94,"cells":5431},"Sildenafil",{"EARLY_PHASE1":5432,"PHASE1":5434,"PHASE2":5436,"PHASE3":5446,"PHASE4":5448,"NA":5450},{"trials":5433,"activeCount":98},[],{"trials":5435,"activeCount":98},[],{"trials":5437,"activeCount":98},[5438],{"nctId":5439,"briefTitle":5440,"status":446,"phases":5441,"primaryCompletion":5442,"completion":5442,"start":5443,"enrollment":624,"conditions":5444,"interventions":5445},"NCT01334554","Study of Sildenafil Citrate on Insulin Resistance in African American",[86,87],"2013-08","2011-04",[1319,15],[5430],{"trials":5447,"activeCount":98},[],{"trials":5449,"activeCount":98},[],{"trials":5451,"activeCount":98},[],{"intervention":1352,"totalTrials":94,"cells":5453},{"EARLY_PHASE1":5454,"PHASE1":5456,"PHASE2":5458,"PHASE3":5464,"PHASE4":5466,"NA":5468},{"trials":5455,"activeCount":98},[],{"trials":5457,"activeCount":98},[],{"trials":5459,"activeCount":98},[5460],{"nctId":1345,"briefTitle":1346,"status":446,"phases":5461,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":9,"conditions":5462,"interventions":5463},[86,87],[15],[1325,1352,1353],{"trials":5465,"activeCount":98},[],{"trials":5467,"activeCount":98},[],{"trials":5469,"activeCount":98},[],{"intervention":1353,"totalTrials":94,"cells":5471},{"EARLY_PHASE1":5472,"PHASE1":5474,"PHASE2":5476,"PHASE3":5482,"PHASE4":5484,"NA":5486},{"trials":5473,"activeCount":98},[],{"trials":5475,"activeCount":98},[],{"trials":5477,"activeCount":98},[5478],{"nctId":1345,"briefTitle":1346,"status":446,"phases":5479,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":9,"conditions":5480,"interventions":5481},[86,87],[15],[1325,1352,1353],{"trials":5483,"activeCount":98},[],{"trials":5485,"activeCount":98},[],{"trials":5487,"activeCount":98},[],{"intervention":5489,"totalTrials":94,"cells":5490},"Sildenafil Citrate in G allele carrier",{"EARLY_PHASE1":5491,"PHASE1":5493,"PHASE2":5495,"PHASE3":5506,"PHASE4":5508,"NA":5510},{"trials":5492,"activeCount":98},[],{"trials":5494,"activeCount":98},[],{"trials":5496,"activeCount":98},[5497],{"nctId":5498,"briefTitle":5499,"status":446,"phases":5500,"primaryCompletion":5501,"completion":5502,"start":1337,"enrollment":611,"conditions":5503,"interventions":5504},"NCT03012386","CD36 in Nutrient Delivery and Its Dysfunction",[86,87],"2021-07","2021-07-31",[2251,310],[5489,5505],"Sildenafil Citrate in non G allele carrier",{"trials":5507,"activeCount":98},[],{"trials":5509,"activeCount":98},[],{"trials":5511,"activeCount":98},[],{"intervention":5505,"totalTrials":94,"cells":5513},{"EARLY_PHASE1":5514,"PHASE1":5516,"PHASE2":5518,"PHASE3":5524,"PHASE4":5526,"NA":5528},{"trials":5515,"activeCount":98},[],{"trials":5517,"activeCount":98},[],{"trials":5519,"activeCount":98},[5520],{"nctId":5498,"briefTitle":5499,"status":446,"phases":5521,"primaryCompletion":5501,"completion":5502,"start":1337,"enrollment":611,"conditions":5522,"interventions":5523},[86,87],[2251,310],[5489,5505],{"trials":5525,"activeCount":98},[],{"trials":5527,"activeCount":98},[],{"trials":5529,"activeCount":98},[],{"intervention":5531,"totalTrials":94,"cells":5532},"Lisinopril",{"EARLY_PHASE1":5533,"PHASE1":5535,"PHASE2":5537,"PHASE3":5553,"PHASE4":5555,"NA":5557},{"trials":5534,"activeCount":98},[],{"trials":5536,"activeCount":98},[],{"trials":5538,"activeCount":98},[5539],{"nctId":5540,"briefTitle":5541,"status":634,"phases":5542,"primaryCompletion":5543,"completion":5544,"start":5545,"enrollment":5546,"conditions":5547,"interventions":5552},"NCT03201939","Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria",[87],"2021-11-30","2025-02-01","2021-04-01",66,[5548,5549,5550,5551],"HIV\u002FAIDS","Albuminuria","Kidney Diseases","Genetic Predisposition",[5531],{"trials":5554,"activeCount":98},[],{"trials":5556,"activeCount":98},[],{"trials":5558,"activeCount":98},[],{"intervention":5560,"totalTrials":94,"cells":5561},"Lopinavir\u002FRitonavir 400 mg\u002F100 mg",{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5578,"PHASE4":5580,"NA":5582},{"trials":5563,"activeCount":98},[],{"trials":5565,"activeCount":98},[],{"trials":5567,"activeCount":98},[5568],{"nctId":5569,"briefTitle":5570,"status":446,"phases":5571,"primaryCompletion":5572,"completion":5573,"start":5574,"enrollment":5575,"conditions":5576,"interventions":5577},"NCT04372628","Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19",[87],"2021-12-16","2022-01-18","2020-06-01",452,[5093],[5560],{"trials":5579,"activeCount":98},[],{"trials":5581,"activeCount":98},[],{"trials":5583,"activeCount":98},[],{"intervention":5585,"totalTrials":94,"cells":5586},"Rosuvastatin",{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5591,"PHASE3":5601,"PHASE4":5603,"NA":5605},{"trials":5588,"activeCount":98},[],{"trials":5590,"activeCount":98},[],{"trials":5592,"activeCount":98},[5593],{"nctId":5594,"briefTitle":5595,"status":446,"phases":5596,"primaryCompletion":5597,"completion":1157,"start":3065,"enrollment":386,"conditions":5598,"interventions":5600},"NCT00978419","Pilot Trial of Statin Use in Burn Patients",[87],"2011-02",[5599],"Burns",[5585],{"trials":5602,"activeCount":98},[],{"trials":5604,"activeCount":98},[],{"trials":5606,"activeCount":98},[],{"intervention":5608,"totalTrials":94,"cells":5609},"Tamoxifen",{"EARLY_PHASE1":5610,"PHASE1":5612,"PHASE2":5614,"PHASE3":5630,"PHASE4":5632,"NA":5634},{"trials":5611,"activeCount":98},[],{"trials":5613,"activeCount":98},[],{"trials":5615,"activeCount":98},[5616],{"nctId":5617,"briefTitle":5618,"status":446,"phases":5619,"primaryCompletion":5620,"completion":5620,"start":3133,"enrollment":2182,"conditions":5621,"interventions":5629},"NCT03528902","Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension",[87],"2023-06-14",[18,5622,5623,5624,5625,5608,5626,5627,5628],"Pulmonary Arterial Hypertension","Familial Primary Pulmonary Hypertension","Primary Pulmonary Hypertension","Lung Diseases","Estrogen Receptor Antagonist","Hormone Antagonists","Estrogens",[5608],{"trials":5631,"activeCount":98},[],{"trials":5633,"activeCount":98},[],{"trials":5635,"activeCount":98},[],{"intervention":5637,"totalTrials":94,"cells":5638},"Exenatide",{"EARLY_PHASE1":5639,"PHASE1":5641,"PHASE2":5643,"PHASE3":5654,"PHASE4":5656,"NA":5658},{"trials":5640,"activeCount":98},[],{"trials":5642,"activeCount":98},[],{"trials":5644,"activeCount":98},[5645],{"nctId":5646,"briefTitle":5647,"status":446,"phases":5648,"primaryCompletion":1349,"completion":1349,"start":5649,"enrollment":3209,"conditions":5650,"interventions":5653},"NCT01484873","Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor",[87],"2012-06",[15,5651,5652],"Overweight","Craniopharyngioma",[5637],{"trials":5655,"activeCount":98},[],{"trials":5657,"activeCount":98},[],{"trials":5659,"activeCount":98},[],{"intervention":5661,"totalTrials":94,"cells":5662},"GSK2256294",{"EARLY_PHASE1":5663,"PHASE1":5665,"PHASE2":5667,"PHASE3":5677,"PHASE4":5679,"NA":5681},{"trials":5664,"activeCount":98},[],{"trials":5666,"activeCount":98},[],{"trials":5668,"activeCount":98},[5669],{"nctId":5670,"briefTitle":5671,"status":446,"phases":5672,"primaryCompletion":5673,"completion":5673,"start":5674,"enrollment":2038,"conditions":5675,"interventions":5676},"NCT03486223","Soluble Epoxide Hydrolase Inhibition and Insulin Resistance",[87],"2021-11-18","2018-05-17",[3069,3070,3071,1288,15],[5661],{"trials":5678,"activeCount":98},[],{"trials":5680,"activeCount":98},[],{"trials":5682,"activeCount":98},[],{"intervention":5684,"totalTrials":94,"cells":5685},"Tadalafil 20 MG",{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5702,"PHASE4":5704,"NA":5706},{"trials":5687,"activeCount":98},[],{"trials":5689,"activeCount":98},[],{"trials":5691,"activeCount":98},[5692],{"nctId":5693,"briefTitle":5694,"status":446,"phases":5695,"primaryCompletion":5696,"completion":5697,"start":5698,"enrollment":5699,"conditions":5700,"interventions":5701},"NCT04684589","Effect of PDE5 Inhibition on Adipose Metabolism in Humans",[87],"2025-06-20","2025-06-24","2021-03-16",89,[15],[5684],{"trials":5703,"activeCount":98},[],{"trials":5705,"activeCount":98},[],{"trials":5707,"activeCount":98},[],{"intervention":589,"totalTrials":94,"cells":5709},{"EARLY_PHASE1":5710,"PHASE1":5712,"PHASE2":5714,"PHASE3":5720,"PHASE4":5722,"NA":5724},{"trials":5711,"activeCount":98},[],{"trials":5713,"activeCount":98},[],{"trials":5715,"activeCount":98},[5716],{"nctId":578,"briefTitle":579,"status":580,"phases":5717,"primaryCompletion":582,"completion":582,"start":583,"enrollment":98,"conditions":5718,"interventions":5719},[87],[585,586,587],[589,590,591,569],{"trials":5721,"activeCount":98},[],{"trials":5723,"activeCount":98},[],{"trials":5725,"activeCount":98},[],{"intervention":590,"totalTrials":94,"cells":5727},{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5732,"PHASE3":5738,"PHASE4":5740,"NA":5742},{"trials":5729,"activeCount":98},[],{"trials":5731,"activeCount":98},[],{"trials":5733,"activeCount":98},[5734],{"nctId":578,"briefTitle":579,"status":580,"phases":5735,"primaryCompletion":582,"completion":582,"start":583,"enrollment":98,"conditions":5736,"interventions":5737},[87],[585,586,587],[589,590,591,569],{"trials":5739,"activeCount":98},[],{"trials":5741,"activeCount":98},[],{"trials":5743,"activeCount":98},[],{"intervention":591,"totalTrials":94,"cells":5745},{"EARLY_PHASE1":5746,"PHASE1":5748,"PHASE2":5750,"PHASE3":5756,"PHASE4":5758,"NA":5760},{"trials":5747,"activeCount":98},[],{"trials":5749,"activeCount":98},[],{"trials":5751,"activeCount":98},[5752],{"nctId":578,"briefTitle":579,"status":580,"phases":5753,"primaryCompletion":582,"completion":582,"start":583,"enrollment":98,"conditions":5754,"interventions":5755},[87],[585,586,587],[589,590,591,569],{"trials":5757,"activeCount":98},[],{"trials":5759,"activeCount":98},[],{"trials":5761,"activeCount":98},[],{"intervention":5763,"totalTrials":94,"cells":5764},"Venlafaxine",{"EARLY_PHASE1":5765,"PHASE1":5767,"PHASE2":5769,"PHASE3":5779,"PHASE4":5781,"NA":5783},{"trials":5766,"activeCount":98},[],{"trials":5768,"activeCount":98},[],{"trials":5770,"activeCount":98},[5771],{"nctId":5772,"briefTitle":5773,"status":580,"phases":5774,"primaryCompletion":5775,"completion":5775,"start":795,"enrollment":98,"conditions":5776,"interventions":5778},"NCT05724849","Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer",[87],"2026-08-01",[5777,28],"Head and Neck Cancer",[5763],{"trials":5780,"activeCount":98},[],{"trials":5782,"activeCount":98},[],{"trials":5784,"activeCount":98},[],{"intervention":5786,"totalTrials":94,"cells":5787},"Low Dose Nicotine",{"EARLY_PHASE1":5788,"PHASE1":5790,"PHASE2":5792,"PHASE3":5803,"PHASE4":5805,"NA":5807},{"trials":5789,"activeCount":98},[],{"trials":5791,"activeCount":98},[],{"trials":5793,"activeCount":98},[5794],{"nctId":5795,"briefTitle":5796,"status":446,"phases":5797,"primaryCompletion":5798,"completion":5798,"start":4152,"enrollment":1131,"conditions":5799,"interventions":5801},"NCT01778946","Nicotine Treatment of Cognitive Decline in Down Syndrome",[86,87],"2021-02",[1672,5800],"Mild Cognitive Impairment",[5786,5802],"Moderate Dose Nicotine",{"trials":5804,"activeCount":98},[],{"trials":5806,"activeCount":98},[],{"trials":5808,"activeCount":98},[],{"intervention":5802,"totalTrials":94,"cells":5810},{"EARLY_PHASE1":5811,"PHASE1":5813,"PHASE2":5815,"PHASE3":5821,"PHASE4":5823,"NA":5825},{"trials":5812,"activeCount":98},[],{"trials":5814,"activeCount":98},[],{"trials":5816,"activeCount":98},[5817],{"nctId":5795,"briefTitle":5796,"status":446,"phases":5818,"primaryCompletion":5798,"completion":5798,"start":4152,"enrollment":1131,"conditions":5819,"interventions":5820},[86,87],[1672,5800],[5786,5802],{"trials":5822,"activeCount":98},[],{"trials":5824,"activeCount":98},[],{"trials":5826,"activeCount":98},[],{"intervention":5828,"totalTrials":94,"cells":5829},"Montelukast added to Hydroxyurea",{"EARLY_PHASE1":5830,"PHASE1":5832,"PHASE2":5834,"PHASE3":5845,"PHASE4":5847,"NA":5849},{"trials":5831,"activeCount":98},[],{"trials":5833,"activeCount":98},[],{"trials":5835,"activeCount":98},[5836],{"nctId":5837,"briefTitle":5838,"status":446,"phases":5839,"primaryCompletion":5840,"completion":5840,"start":5841,"enrollment":624,"conditions":5842,"interventions":5844},"NCT01960413","Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia",[87],"2018-03","2013-11",[5843],"Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)",[5828],{"trials":5846,"activeCount":98},[],{"trials":5848,"activeCount":98},[],{"trials":5850,"activeCount":98},[],{"intervention":5852,"totalTrials":94,"cells":5853},"Metformin",{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5858,"PHASE3":5871,"PHASE4":5873,"NA":5875},{"trials":5855,"activeCount":98},[],{"trials":5857,"activeCount":98},[],{"trials":5859,"activeCount":98},[5860],{"nctId":5861,"briefTitle":5862,"status":446,"phases":5863,"primaryCompletion":5864,"completion":5865,"start":5866,"enrollment":5867,"conditions":5868,"interventions":5870},"NCT03617458","Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension",[87],"2023-09-09","2025-08-19","2018-08-23",73,[5869],"Pulmonary Artery Hypertension",[5852],{"trials":5872,"activeCount":98},[],{"trials":5874,"activeCount":98},[],{"trials":5876,"activeCount":98},[],{"intervention":5878,"totalTrials":94,"cells":5879},"Misoprostol 100Mcg Tab",{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5895,"PHASE4":5897,"NA":5899},{"trials":5881,"activeCount":98},[],{"trials":5883,"activeCount":98},[],{"trials":5885,"activeCount":98},[5886],{"nctId":5887,"briefTitle":5888,"status":634,"phases":5889,"primaryCompletion":5890,"completion":5890,"start":5891,"enrollment":659,"conditions":5892,"interventions":5894},"NCT03617172","PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol",[87],"2021-09-22","2018-11-26",[5893],"Clostridium Difficile",[5878],{"trials":5896,"activeCount":98},[],{"trials":5898,"activeCount":98},[],{"trials":5900,"activeCount":98},[],{"intervention":5902,"totalTrials":94,"cells":5903},"Granulocyte Colony Stimulating Factor",{"EARLY_PHASE1":5904,"PHASE1":5906,"PHASE2":5908,"PHASE3":5918,"PHASE4":5920,"NA":5922},{"trials":5905,"activeCount":98},[],{"trials":5907,"activeCount":98},[],{"trials":5909,"activeCount":98},[5910],{"nctId":5911,"briefTitle":5912,"status":446,"phases":5913,"primaryCompletion":2372,"completion":5914,"start":4410,"enrollment":1131,"conditions":5915,"interventions":5917},"NCT01538862","Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa",[87],"2014-11",[5916],"Dystrophic Epidermolysis Bullosa",[5902],{"trials":5919,"activeCount":98},[],{"trials":5921,"activeCount":98},[],{"trials":5923,"activeCount":98},[],{"intervention":5925,"totalTrials":94,"cells":5926},"L-Dopa",{"EARLY_PHASE1":5927,"PHASE1":5929,"PHASE2":5931,"PHASE3":5947,"PHASE4":5949,"NA":5951},{"trials":5928,"activeCount":98},[],{"trials":5930,"activeCount":98},[],{"trials":5932,"activeCount":98},[5933],{"nctId":5934,"briefTitle":5935,"status":446,"phases":5936,"primaryCompletion":5937,"completion":5937,"start":5938,"enrollment":5939,"conditions":5940,"interventions":5946},"NCT04469959","Dopaminergic Dysfunction in Late-Life Depression",[87],"2026-04-29","2021-02-15",79,[5941,5942,5943,5944,5945],"Late Life Depression","Cognitive Decline","Depressive Disorder, Treatment-Resistant","Levodopa","Gait Impairment",[5925],{"trials":5948,"activeCount":98},[],{"trials":5950,"activeCount":98},[],{"trials":5952,"activeCount":98},[],{"intervention":5954,"totalTrials":94,"cells":5955},"Ranolazine",{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5960,"PHASE3":5972,"PHASE4":5974,"NA":5976},{"trials":5957,"activeCount":98},[],{"trials":5959,"activeCount":98},[],{"trials":5961,"activeCount":98},[5962],{"nctId":5963,"briefTitle":5964,"status":634,"phases":5965,"primaryCompletion":5966,"completion":5966,"start":5967,"enrollment":647,"conditions":5968,"interventions":5971},"NCT04456517","Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy",[87],"2024-04-11","2022-10-18",[5969,5970],"Crohn's Disease","Inflammatory Bowel Disease",[5954],{"trials":5973,"activeCount":98},[],{"trials":5975,"activeCount":98},[],{"trials":5977,"activeCount":98},[],{"intervention":5979,"totalTrials":94,"cells":5980},"Transdermal nicotine",{"EARLY_PHASE1":5981,"PHASE1":5983,"PHASE2":5985,"PHASE3":5999,"PHASE4":6001,"NA":6003},{"trials":5982,"activeCount":98},[],{"trials":5984,"activeCount":98},[],{"trials":5986,"activeCount":98},[5987],{"nctId":5988,"briefTitle":5989,"status":446,"phases":5990,"primaryCompletion":5991,"completion":5991,"start":2785,"enrollment":4340,"conditions":5992,"interventions":5998},"NCT02312934","Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study",[87],"2018-05",[5993,5994,5995,5996,5997],"Chemo Brain","Chemotherapy-related Cognitive Impairment","Chemo Fog","Breast Cancer","Chemobrain",[5979],{"trials":6000,"activeCount":98},[],{"trials":6002,"activeCount":98},[],{"trials":6004,"activeCount":98},[],{"intervention":6006,"totalTrials":94,"cells":6007},"Botox 200 UNT",{"EARLY_PHASE1":6008,"PHASE1":6010,"PHASE2":6012,"PHASE3":6022,"PHASE4":6024,"NA":6026},{"trials":6009,"activeCount":98},[],{"trials":6011,"activeCount":98},[],{"trials":6013,"activeCount":98},[6014],{"nctId":6015,"briefTitle":6016,"status":634,"phases":6017,"primaryCompletion":6018,"completion":6018,"start":6019,"enrollment":647,"conditions":6020,"interventions":6021},"NCT03991299","Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects",[86,87],"2022-02-11","2021-04-29",[5348,34],[6006],{"trials":6023,"activeCount":98},[],{"trials":6025,"activeCount":98},[],{"trials":6027,"activeCount":98},[],{"intervention":1177,"totalTrials":94,"cells":6029},{"EARLY_PHASE1":6030,"PHASE1":6032,"PHASE2":6034,"PHASE3":6040,"PHASE4":6042,"NA":6044},{"trials":6031,"activeCount":98},[],{"trials":6033,"activeCount":98},[],{"trials":6035,"activeCount":98},[6036],{"nctId":1168,"briefTitle":1169,"status":634,"phases":6037,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":857,"conditions":6038,"interventions":6039},[87],[1175],[1177,1121],{"trials":6041,"activeCount":98},[],{"trials":6043,"activeCount":98},[],{"trials":6045,"activeCount":98},[],{"intervention":6047,"totalTrials":94,"cells":6048},"Levetiracetam 500 mg",{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6053,"PHASE3":6064,"PHASE4":6066,"NA":6068},{"trials":6050,"activeCount":98},[],{"trials":6052,"activeCount":98},[],{"trials":6054,"activeCount":98},[6055],{"nctId":6056,"briefTitle":6057,"status":634,"phases":6058,"primaryCompletion":6059,"completion":6059,"start":6060,"enrollment":94,"conditions":6061,"interventions":6063},"NCT04277936","Pharmacologic Modulation of Hippocampal Activity in Psychosis",[87],"2020-08-31","2020-05-11",[6062],"Schizophrenia; Psychosis",[6047],{"trials":6065,"activeCount":98},[],{"trials":6067,"activeCount":98},[],{"trials":6069,"activeCount":98},[],{"intervention":6071,"totalTrials":94,"cells":6072},"2-HOBA",{"EARLY_PHASE1":6073,"PHASE1":6075,"PHASE2":6077,"PHASE3":6089,"PHASE4":6091,"NA":6093},{"trials":6074,"activeCount":98},[],{"trials":6076,"activeCount":98},[],{"trials":6078,"activeCount":98},[6079],{"nctId":6080,"briefTitle":6081,"status":446,"phases":6082,"primaryCompletion":6083,"completion":6083,"start":6084,"enrollment":6085,"conditions":6086,"interventions":6088},"NCT05274243","2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis",[87],"2025-05-28","2022-08-09",32,[6087],"Rheumatoid Arthritis",[6071],{"trials":6090,"activeCount":98},[],{"trials":6092,"activeCount":98},[],{"trials":6094,"activeCount":98},[],{"intervention":6096,"totalTrials":94,"cells":6097},"Levocarnitine",{"EARLY_PHASE1":6098,"PHASE1":6100,"PHASE2":6102,"PHASE3":6114,"PHASE4":6116,"NA":6118},{"trials":6099,"activeCount":98},[],{"trials":6101,"activeCount":98},[],{"trials":6103,"activeCount":98},[6104],{"nctId":6105,"briefTitle":6106,"status":446,"phases":6107,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":19,"conditions":6110,"interventions":6113},"NCT03953703","Levocarnitine for Dry Eye in Sjogren's Syndrome",[87],"2025-09-19","2021-11-17",[6111,6112],"Sjogren's Syndrome","Keratoconjunctivitis Sicca",[6096],{"trials":6115,"activeCount":98},[],{"trials":6117,"activeCount":98},[],{"trials":6119,"activeCount":98},[],{"intervention":6121,"totalTrials":94,"cells":6122},"PRP injection dose",{"EARLY_PHASE1":6123,"PHASE1":6125,"PHASE2":6127,"PHASE3":6137,"PHASE4":6139,"NA":6141},{"trials":6124,"activeCount":98},[],{"trials":6126,"activeCount":98},[],{"trials":6128,"activeCount":98},[6129],{"nctId":6130,"briefTitle":6131,"status":580,"phases":6132,"primaryCompletion":6133,"completion":6133,"start":6134,"enrollment":98,"conditions":6135,"interventions":6136},"NCT05330689","How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?",[87],"2022-09-07","2022-03-06",[282],[6121,6121,6121,6121],{"trials":6138,"activeCount":98},[],{"trials":6140,"activeCount":98},[],{"trials":6142,"activeCount":98},[],{"intervention":6144,"totalTrials":94,"cells":6145},"Memantine",{"EARLY_PHASE1":6146,"PHASE1":6148,"PHASE2":6150,"PHASE3":6161,"PHASE4":6163,"NA":6165},{"trials":6147,"activeCount":98},[],{"trials":6149,"activeCount":98},[],{"trials":6151,"activeCount":98},[6152],{"nctId":6153,"briefTitle":6154,"status":446,"phases":6155,"primaryCompletion":6156,"completion":6156,"start":5866,"enrollment":6157,"conditions":6158,"interventions":6160},"NCT03527472","Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus",[87],"2026-02-28",111,[6159],"Lupus Erythematosus, Systemic",[6144],{"trials":6162,"activeCount":98},[],{"trials":6164,"activeCount":98},[],{"trials":6166,"activeCount":98},[],{"intervention":6168,"totalTrials":94,"cells":6169},"Levetiracetam (LEV) 500 mg",{"EARLY_PHASE1":6170,"PHASE1":6172,"PHASE2":6174,"PHASE3":6184,"PHASE4":6186,"NA":6188},{"trials":6171,"activeCount":98},[],{"trials":6173,"activeCount":98},[],{"trials":6175,"activeCount":98},[6176],{"nctId":6177,"briefTitle":6178,"status":446,"phases":6179,"primaryCompletion":4126,"completion":4126,"start":6180,"enrollment":6181,"conditions":6182,"interventions":6183},"NCT04559529","Pharmacological Modulation of Hippocampal Activity in Psychosis 2",[87],"2020-09-23",62,[6062],[6168],{"trials":6185,"activeCount":98},[],{"trials":6187,"activeCount":98},[],{"trials":6189,"activeCount":98},[],{"intervention":6191,"totalTrials":506,"cells":6192},"Trimethaphan",{"EARLY_PHASE1":6193,"PHASE1":6195,"PHASE2":6215,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6194,"activeCount":98},[],{"trials":6196,"activeCount":98},[6197,6206],{"nctId":6198,"briefTitle":6199,"status":446,"phases":6200,"primaryCompletion":6201,"completion":6201,"start":6202,"enrollment":871,"conditions":6203,"interventions":6204},"NCT01122407","Pathophysiology of Cardiometabolic Risk Factors in African Americans",[86],"2016-11","2010-01",[15,18],[6205,6191],"L-NMMA",{"nctId":6207,"briefTitle":6208,"status":580,"phases":6209,"primaryCompletion":6210,"completion":6211,"start":6212,"enrollment":98,"conditions":6213,"interventions":6214},"NCT03028571","Autonomic Blockade and Endogenous Glucose Production",[86],"2022-12-31","2024-12-31","2017-04-17",[2251],[6191],{"trials":6216,"activeCount":98},[],{"trials":6218,"activeCount":98},[],{"trials":6220,"activeCount":98},[],{"trials":6222,"activeCount":98},[],{"intervention":1255,"totalTrials":94,"cells":6224},{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6233,"PHASE3":6235,"PHASE4":6237,"NA":6239},{"trials":6226,"activeCount":98},[],{"trials":6228,"activeCount":98},[6229],{"nctId":1246,"briefTitle":1247,"status":634,"phases":6230,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":506,"conditions":6231,"interventions":6232},[86],[1252,1253],[1255,885],{"trials":6234,"activeCount":98},[],{"trials":6236,"activeCount":98},[],{"trials":6238,"activeCount":98},[],{"trials":6240,"activeCount":98},[],{"intervention":6242,"totalTrials":94,"cells":6243},"Valganciclovir",{"EARLY_PHASE1":6244,"PHASE1":6246,"PHASE2":6257,"PHASE3":6259,"PHASE4":6261,"NA":6263},{"trials":6245,"activeCount":98},[],{"trials":6247,"activeCount":98},[6248],{"nctId":6249,"briefTitle":6250,"status":446,"phases":6251,"primaryCompletion":6252,"completion":6252,"start":6253,"enrollment":2087,"conditions":6254,"interventions":6256},"NCT02871401","A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)",[86],"2020-01-31","2018-01-03",[6255],"Idiopathic Pulmonary Fibrosis",[6242],{"trials":6258,"activeCount":98},[],{"trials":6260,"activeCount":98},[],{"trials":6262,"activeCount":98},[],{"trials":6264,"activeCount":98},[],{"intervention":6266,"totalTrials":94,"cells":6267},"Pramipexole",{"EARLY_PHASE1":6268,"PHASE1":6270,"PHASE2":6280,"PHASE3":6282,"PHASE4":6284,"NA":6286},{"trials":6269,"activeCount":98},[],{"trials":6271,"activeCount":98},[6272],{"nctId":6273,"briefTitle":6274,"status":446,"phases":6275,"primaryCompletion":4338,"completion":6276,"start":6277,"enrollment":2182,"conditions":6278,"interventions":6279},"NCT04249544","Social Decision Making in Parkinson's Disease",[86],"2022-09-01","2019-12-03",[23],[6266],{"trials":6281,"activeCount":98},[],{"trials":6283,"activeCount":98},[],{"trials":6285,"activeCount":98},[],{"trials":6287,"activeCount":98},[],{"intervention":6289,"totalTrials":94,"cells":6290},"SinuSurf irrigation twice daily",{"EARLY_PHASE1":6291,"PHASE1":6293,"PHASE2":6305,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6292,"activeCount":98},[],{"trials":6294,"activeCount":98},[6295],{"nctId":6296,"briefTitle":6297,"status":446,"phases":6298,"primaryCompletion":6299,"completion":6299,"start":6300,"enrollment":386,"conditions":6301,"interventions":6303},"NCT02728505","SinuSurf vs. Saline Solution in Normal Subjects",[86],"2017-01-20","2016-04-12",[6302],"Rhinosinusitis",[6289,6304],"NeilMed Sinus rinse irrigation twice daily",{"trials":6306,"activeCount":98},[],{"trials":6308,"activeCount":98},[],{"trials":6310,"activeCount":98},[],{"trials":6312,"activeCount":98},[],{"intervention":6304,"totalTrials":94,"cells":6314},{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6323,"PHASE3":6325,"PHASE4":6327,"NA":6329},{"trials":6316,"activeCount":98},[],{"trials":6318,"activeCount":98},[6319],{"nctId":6296,"briefTitle":6297,"status":446,"phases":6320,"primaryCompletion":6299,"completion":6299,"start":6300,"enrollment":386,"conditions":6321,"interventions":6322},[86],[6302],[6289,6304],{"trials":6324,"activeCount":98},[],{"trials":6326,"activeCount":98},[],{"trials":6328,"activeCount":98},[],{"trials":6330,"activeCount":98},[],{"intervention":3073,"totalTrials":94,"cells":6332},{"EARLY_PHASE1":6333,"PHASE1":6335,"PHASE2":6341,"PHASE3":6343,"PHASE4":6345,"NA":6347},{"trials":6334,"activeCount":98},[],{"trials":6336,"activeCount":98},[6337],{"nctId":3060,"briefTitle":3061,"status":446,"phases":6338,"primaryCompletion":3063,"completion":3064,"start":3065,"enrollment":3066,"conditions":6339,"interventions":6340},[86],[3068,3069,3070,3071],[3073,3053,3074,3075,3076],{"trials":6342,"activeCount":98},[],{"trials":6344,"activeCount":98},[],{"trials":6346,"activeCount":98},[],{"trials":6348,"activeCount":98},[],{"intervention":3074,"totalTrials":94,"cells":6350},{"EARLY_PHASE1":6351,"PHASE1":6353,"PHASE2":6359,"PHASE3":6361,"PHASE4":6363,"NA":6365},{"trials":6352,"activeCount":98},[],{"trials":6354,"activeCount":98},[6355],{"nctId":3060,"briefTitle":3061,"status":446,"phases":6356,"primaryCompletion":3063,"completion":3064,"start":3065,"enrollment":3066,"conditions":6357,"interventions":6358},[86],[3068,3069,3070,3071],[3073,3053,3074,3075,3076],{"trials":6360,"activeCount":98},[],{"trials":6362,"activeCount":98},[],{"trials":6364,"activeCount":98},[],{"trials":6366,"activeCount":98},[],{"intervention":3076,"totalTrials":94,"cells":6368},{"EARLY_PHASE1":6369,"PHASE1":6371,"PHASE2":6377,"PHASE3":6379,"PHASE4":6381,"NA":6383},{"trials":6370,"activeCount":98},[],{"trials":6372,"activeCount":98},[6373],{"nctId":3060,"briefTitle":3061,"status":446,"phases":6374,"primaryCompletion":3063,"completion":3064,"start":3065,"enrollment":3066,"conditions":6375,"interventions":6376},[86],[3068,3069,3070,3071],[3073,3053,3074,3075,3076],{"trials":6378,"activeCount":98},[],{"trials":6380,"activeCount":98},[],{"trials":6382,"activeCount":98},[],{"trials":6384,"activeCount":98},[],{"intervention":6205,"totalTrials":94,"cells":6386},{"EARLY_PHASE1":6387,"PHASE1":6389,"PHASE2":6395,"PHASE3":6397,"PHASE4":6399,"NA":6401},{"trials":6388,"activeCount":98},[],{"trials":6390,"activeCount":98},[6391],{"nctId":6198,"briefTitle":6199,"status":446,"phases":6392,"primaryCompletion":6201,"completion":6201,"start":6202,"enrollment":871,"conditions":6393,"interventions":6394},[86],[15,18],[6205,6191],{"trials":6396,"activeCount":98},[],{"trials":6398,"activeCount":98},[],{"trials":6400,"activeCount":98},[],{"trials":6402,"activeCount":98},[],{"intervention":6404,"totalTrials":94,"cells":6405},"Angiotensin II",{"EARLY_PHASE1":6406,"PHASE1":6408,"PHASE2":6418,"PHASE3":6420,"PHASE4":6422,"NA":6424},{"trials":6407,"activeCount":98},[],{"trials":6409,"activeCount":98},[6410],{"nctId":6411,"briefTitle":6412,"status":446,"phases":6413,"primaryCompletion":696,"completion":696,"start":6414,"enrollment":1265,"conditions":6415,"interventions":6417},"NCT00962949","The Renin-Aldosterone Axis in Postural Tachycardia Syndrome",[86],"2009-04",[6416],"Postural Orthostatic Tachycardia Syndrome (POTS)",[6404],{"trials":6419,"activeCount":98},[],{"trials":6421,"activeCount":98},[],{"trials":6423,"activeCount":98},[],{"trials":6425,"activeCount":98},[],{"intervention":6427,"totalTrials":94,"cells":6428},"Dose Escalation of VU319",{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6442,"PHASE3":6444,"PHASE4":6446,"NA":6448},{"trials":6430,"activeCount":98},[],{"trials":6432,"activeCount":98},[6433],{"nctId":6434,"briefTitle":6435,"status":580,"phases":6436,"primaryCompletion":6437,"completion":6437,"start":6437,"enrollment":98,"conditions":6438,"interventions":6440},"NCT04051801","Multiple Ascending Dose Putative Cognitive Enhancer VU319",[86],"2021-05-25",[6439],"Cognitive Impairment",[6427,6441],"Dose Escalation of Placebo",{"trials":6443,"activeCount":98},[],{"trials":6445,"activeCount":98},[],{"trials":6447,"activeCount":98},[],{"trials":6449,"activeCount":98},[],{"intervention":6441,"totalTrials":94,"cells":6451},{"EARLY_PHASE1":6452,"PHASE1":6454,"PHASE2":6460,"PHASE3":6462,"PHASE4":6464,"NA":6466},{"trials":6453,"activeCount":98},[],{"trials":6455,"activeCount":98},[6456],{"nctId":6434,"briefTitle":6435,"status":580,"phases":6457,"primaryCompletion":6437,"completion":6437,"start":6437,"enrollment":98,"conditions":6458,"interventions":6459},[86],[6439],[6427,6441],{"trials":6461,"activeCount":98},[],{"trials":6463,"activeCount":98},[],{"trials":6465,"activeCount":98},[],{"trials":6467,"activeCount":98},[],{"intervention":6469,"totalTrials":94,"cells":6470},"F-18",{"EARLY_PHASE1":6471,"PHASE1":6473,"PHASE2":6484,"PHASE3":6486,"PHASE4":6488,"NA":6490},{"trials":6472,"activeCount":98},[],{"trials":6474,"activeCount":98},[6475],{"nctId":6476,"briefTitle":6477,"status":446,"phases":6478,"primaryCompletion":6479,"completion":5649,"start":6480,"enrollment":1131,"conditions":6481,"interventions":6483},"NCT00801827","PET Imaging and Bariatric Surgery",[86],"2011-03","2007-01",[6482],"Obesity, Morbid",[6469],{"trials":6485,"activeCount":98},[],{"trials":6487,"activeCount":98},[],{"trials":6489,"activeCount":98},[],{"trials":6491,"activeCount":98},[],{"intervention":663,"totalTrials":94,"cells":6493},{"EARLY_PHASE1":6494,"PHASE1":6496,"PHASE2":6502,"PHASE3":6504,"PHASE4":6506,"NA":6508},{"trials":6495,"activeCount":98},[],{"trials":6497,"activeCount":98},[6498],{"nctId":654,"briefTitle":655,"status":634,"phases":6499,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":6500,"interventions":6501},[86],[21,661],[65,663],{"trials":6503,"activeCount":98},[],{"trials":6505,"activeCount":98},[],{"trials":6507,"activeCount":98},[],{"trials":6509,"activeCount":98},[],{"intervention":3011,"totalTrials":94,"cells":6511},{"EARLY_PHASE1":6512,"PHASE1":6514,"PHASE2":6520,"PHASE3":6522,"PHASE4":6524,"NA":6526},{"trials":6513,"activeCount":98},[],{"trials":6515,"activeCount":98},[6516],{"nctId":3004,"briefTitle":3005,"status":446,"phases":6517,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":506,"conditions":6518,"interventions":6519},[86],[2252],[3011,2997],{"trials":6521,"activeCount":98},[],{"trials":6523,"activeCount":98},[],{"trials":6525,"activeCount":98},[],{"trials":6527,"activeCount":98},[],{"intervention":6529,"totalTrials":94,"cells":6530},"Ga-EC2115",{"EARLY_PHASE1":6531,"PHASE1":6533,"PHASE2":6545,"PHASE3":6547,"PHASE4":6549,"NA":6551},{"trials":6532,"activeCount":98},[],{"trials":6534,"activeCount":98},[6535],{"nctId":6536,"briefTitle":6537,"status":634,"phases":6538,"primaryCompletion":6539,"completion":6540,"start":6541,"enrollment":29,"conditions":6542,"interventions":6544},"NCT03494114","Imaging Activated Macrophages in the Lungs",[86],"2019-11-20","2021-01-13","2018-11-29",[6543],"COPD",[6529],{"trials":6546,"activeCount":98},[],{"trials":6548,"activeCount":98},[],{"trials":6550,"activeCount":98},[],{"trials":6552,"activeCount":98},[],{"intervention":6554,"totalTrials":94,"cells":6555},"Benzocaine Infusion into Duodenum",{"EARLY_PHASE1":6556,"PHASE1":6558,"PHASE2":6569,"PHASE3":6571,"PHASE4":6573,"NA":6575},{"trials":6557,"activeCount":98},[],{"trials":6559,"activeCount":98},[6560],{"nctId":6561,"briefTitle":6562,"status":446,"phases":6563,"primaryCompletion":6564,"completion":6564,"start":6565,"enrollment":2038,"conditions":6566,"interventions":6568},"NCT01694004","Nutrient Sensing in the Duodenum",[86],"2014-10-27","2012-11",[6567],"The Effect of LCFA on Nutrient Absorption",[6554],{"trials":6570,"activeCount":98},[],{"trials":6572,"activeCount":98},[],{"trials":6574,"activeCount":98},[],{"trials":6576,"activeCount":98},[],{"intervention":6578,"totalTrials":94,"cells":6579},"Adenosine",{"EARLY_PHASE1":6580,"PHASE1":6582,"PHASE2":6593,"PHASE3":6595,"PHASE4":6597,"NA":6599},{"trials":6581,"activeCount":98},[],{"trials":6583,"activeCount":98},[6584],{"nctId":6585,"briefTitle":6586,"status":634,"phases":6587,"primaryCompletion":1337,"completion":1337,"start":6588,"enrollment":29,"conditions":6589,"interventions":6591},"NCT00179010","AMP as a Better Delivery System of Adenosine",[86],"2003-10",[6590],"Ischemia",[6578,6592],"Adenosine Mono Phosphate",{"trials":6594,"activeCount":98},[],{"trials":6596,"activeCount":98},[],{"trials":6598,"activeCount":98},[],{"trials":6600,"activeCount":98},[],{"intervention":6592,"totalTrials":94,"cells":6602},{"EARLY_PHASE1":6603,"PHASE1":6605,"PHASE2":6611,"PHASE3":6613,"PHASE4":6615,"NA":6617},{"trials":6604,"activeCount":98},[],{"trials":6606,"activeCount":98},[6607],{"nctId":6585,"briefTitle":6586,"status":634,"phases":6608,"primaryCompletion":1337,"completion":1337,"start":6588,"enrollment":29,"conditions":6609,"interventions":6610},[86],[6590],[6578,6592],{"trials":6612,"activeCount":98},[],{"trials":6614,"activeCount":98},[],{"trials":6616,"activeCount":98},[],{"trials":6618,"activeCount":98},[],{"intervention":3020,"totalTrials":94,"cells":6620},{"EARLY_PHASE1":6621,"PHASE1":6623,"PHASE2":6629,"PHASE3":6631,"PHASE4":6633,"NA":6635},{"trials":6622,"activeCount":98},[],{"trials":6624,"activeCount":98},[6625],{"nctId":3013,"briefTitle":3014,"status":446,"phases":6626,"primaryCompletion":3016,"completion":3016,"start":3017,"enrollment":9,"conditions":6627,"interventions":6628},[86],[34],[3020,3021],{"trials":6630,"activeCount":98},[],{"trials":6632,"activeCount":98},[],{"trials":6634,"activeCount":98},[],{"trials":6636,"activeCount":98},[],{"intervention":6638,"totalTrials":94,"cells":6639},"Polyethylene glycol",{"EARLY_PHASE1":6640,"PHASE1":6642,"PHASE2":6654,"PHASE3":6656,"PHASE4":6658,"NA":6660},{"trials":6641,"activeCount":98},[],{"trials":6643,"activeCount":98},[6644],{"nctId":6645,"briefTitle":6646,"status":446,"phases":6647,"primaryCompletion":6648,"completion":6648,"start":6649,"enrollment":6650,"conditions":6651,"interventions":6653},"NCT02359825","Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function",[86],"2026-05-21","2019-09-19",45,[6652],"Peripheral Nerve Injury",[6638],{"trials":6655,"activeCount":98},[],{"trials":6657,"activeCount":98},[],{"trials":6659,"activeCount":98},[],{"trials":6661,"activeCount":98},[],{"intervention":6663,"totalTrials":94,"cells":6664},"Glutamine",{"EARLY_PHASE1":6665,"PHASE1":6667,"PHASE2":6678,"PHASE3":6680,"PHASE4":6682,"NA":6684},{"trials":6666,"activeCount":98},[],{"trials":6668,"activeCount":98},[6669],{"nctId":6670,"briefTitle":6671,"status":446,"phases":6672,"primaryCompletion":5176,"completion":6673,"start":6674,"enrollment":435,"conditions":6675,"interventions":6677},"NCT04388371","Glutamine PET Imaging in LAM",[86],"2021-08-10","2019-10-18",[6676],"Lymphangioleiomyomatosis (LAM)",[6663],{"trials":6679,"activeCount":98},[],{"trials":6681,"activeCount":98},[],{"trials":6683,"activeCount":98},[],{"trials":6685,"activeCount":98},[],{"intervention":6687,"totalTrials":94,"cells":6688},"Insulin Glargine 0.5 u\u002Fkg body wt SC",{"EARLY_PHASE1":6689,"PHASE1":6691,"PHASE2":6704,"PHASE3":6706,"PHASE4":6708,"NA":6710},{"trials":6690,"activeCount":98},[],{"trials":6692,"activeCount":98},[6693],{"nctId":6694,"briefTitle":6695,"status":446,"phases":6696,"primaryCompletion":6697,"completion":6202,"start":3782,"enrollment":935,"conditions":6698,"interventions":6700},"NCT00574912","Characteristics of Glargine in Type 2 Diabetics",[86],"2009-09",[6699],"Type 2 Diabetes",[6687,6701,6702,6703],"Insulin Glargine 1.0 u\u002Fkg body wt SC","Insulin Glargine 1.5 u\u002Fkg body wt SC","Insulin Glargine 2.0 u\u002Fkg body wt SC",{"trials":6705,"activeCount":98},[],{"trials":6707,"activeCount":98},[],{"trials":6709,"activeCount":98},[],{"trials":6711,"activeCount":98},[],{"intervention":6701,"totalTrials":94,"cells":6713},{"EARLY_PHASE1":6714,"PHASE1":6716,"PHASE2":6722,"PHASE3":6724,"PHASE4":6726,"NA":6728},{"trials":6715,"activeCount":98},[],{"trials":6717,"activeCount":98},[6718],{"nctId":6694,"briefTitle":6695,"status":446,"phases":6719,"primaryCompletion":6697,"completion":6202,"start":3782,"enrollment":935,"conditions":6720,"interventions":6721},[86],[6699],[6687,6701,6702,6703],{"trials":6723,"activeCount":98},[],{"trials":6725,"activeCount":98},[],{"trials":6727,"activeCount":98},[],{"trials":6729,"activeCount":98},[],{"intervention":6702,"totalTrials":94,"cells":6731},{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6740,"PHASE3":6742,"PHASE4":6744,"NA":6746},{"trials":6733,"activeCount":98},[],{"trials":6735,"activeCount":98},[6736],{"nctId":6694,"briefTitle":6695,"status":446,"phases":6737,"primaryCompletion":6697,"completion":6202,"start":3782,"enrollment":935,"conditions":6738,"interventions":6739},[86],[6699],[6687,6701,6702,6703],{"trials":6741,"activeCount":98},[],{"trials":6743,"activeCount":98},[],{"trials":6745,"activeCount":98},[],{"trials":6747,"activeCount":98},[],{"intervention":6703,"totalTrials":94,"cells":6749},{"EARLY_PHASE1":6750,"PHASE1":6752,"PHASE2":6758,"PHASE3":6760,"PHASE4":6762,"NA":6764},{"trials":6751,"activeCount":98},[],{"trials":6753,"activeCount":98},[6754],{"nctId":6694,"briefTitle":6695,"status":446,"phases":6755,"primaryCompletion":6697,"completion":6202,"start":3782,"enrollment":935,"conditions":6756,"interventions":6757},[86],[6699],[6687,6701,6702,6703],{"trials":6759,"activeCount":98},[],{"trials":6761,"activeCount":98},[],{"trials":6763,"activeCount":98},[],{"trials":6765,"activeCount":98},[],{"intervention":6767,"totalTrials":94,"cells":6768},"phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine",{"EARLY_PHASE1":6769,"PHASE1":6771,"PHASE2":6782,"PHASE3":6784,"PHASE4":6786,"NA":6788},{"trials":6770,"activeCount":98},[],{"trials":6772,"activeCount":98},[6773],{"nctId":6774,"briefTitle":6775,"status":446,"phases":6776,"primaryCompletion":4588,"completion":4588,"start":6777,"enrollment":3209,"conditions":6778,"interventions":6780},"NCT00748059","The Pathophysiology of Orthostatic Hypotension",[86],"1996-12",[2703,2056,6779,2704],"Dopamine Beta-Hydroxylase Deficiency",[6767,6781],"clonidine,yohimbine,metoclopramide,alpha-methyldopa",{"trials":6783,"activeCount":98},[],{"trials":6785,"activeCount":98},[],{"trials":6787,"activeCount":98},[],{"trials":6789,"activeCount":98},[],{"intervention":6781,"totalTrials":94,"cells":6791},{"EARLY_PHASE1":6792,"PHASE1":6794,"PHASE2":6800,"PHASE3":6802,"PHASE4":6804,"NA":6806},{"trials":6793,"activeCount":98},[],{"trials":6795,"activeCount":98},[6796],{"nctId":6774,"briefTitle":6775,"status":446,"phases":6797,"primaryCompletion":4588,"completion":4588,"start":6777,"enrollment":3209,"conditions":6798,"interventions":6799},[86],[2703,2056,6779,2704],[6767,6781],{"trials":6801,"activeCount":98},[],{"trials":6803,"activeCount":98},[],{"trials":6805,"activeCount":98},[],{"trials":6807,"activeCount":98},[],{"intervention":1150,"totalTrials":94,"cells":6809},{"EARLY_PHASE1":6810,"PHASE1":6812,"PHASE2":6818,"PHASE3":6820,"PHASE4":6822,"NA":6824},{"trials":6811,"activeCount":98},[],{"trials":6813,"activeCount":98},[6814],{"nctId":1142,"briefTitle":1143,"status":446,"phases":6815,"primaryCompletion":1145,"completion":914,"start":1146,"enrollment":1147,"conditions":6816,"interventions":6817},[86],[15],[1150,1121],{"trials":6819,"activeCount":98},[],{"trials":6821,"activeCount":98},[],{"trials":6823,"activeCount":98},[],{"trials":6825,"activeCount":98},[],{"intervention":6827,"totalTrials":94,"cells":6828},"Ghrelin infusion to assess effects on insulin sensitivity",{"EARLY_PHASE1":6829,"PHASE1":6831,"PHASE2":6841,"PHASE3":6843,"PHASE4":6845,"NA":6847},{"trials":6830,"activeCount":98},[],{"trials":6832,"activeCount":98},[6833],{"nctId":6834,"briefTitle":6835,"status":446,"phases":6836,"primaryCompletion":6837,"completion":6837,"start":638,"enrollment":935,"conditions":6838,"interventions":6840},"NCT00884494","Ghrelin and Insulin Resistance",[86],"2014-05",[15,2251,6839],"Normal Weight,Healthy Controls",[6827],{"trials":6842,"activeCount":98},[],{"trials":6844,"activeCount":98},[],{"trials":6846,"activeCount":98},[],{"trials":6848,"activeCount":98},[],{"intervention":6850,"totalTrials":94,"cells":6851},"Donor Blood",{"EARLY_PHASE1":6852,"PHASE1":6863,"PHASE2":6865,"PHASE3":6867,"PHASE4":6869,"NA":6871},{"trials":6853,"activeCount":98},[6854],{"nctId":6855,"briefTitle":6856,"status":580,"phases":6857,"primaryCompletion":5501,"completion":5501,"start":4588,"enrollment":98,"conditions":6858,"interventions":6861},"NCT04383756","Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation",[85],[6859,6860],"Transfusion Related Complication","Liver Transplant",[6850,6862],"Banked Blood",{"trials":6864,"activeCount":98},[],{"trials":6866,"activeCount":98},[],{"trials":6868,"activeCount":98},[],{"trials":6870,"activeCount":98},[],{"trials":6872,"activeCount":98},[],{"intervention":6862,"totalTrials":94,"cells":6874},{"EARLY_PHASE1":6875,"PHASE1":6881,"PHASE2":6883,"PHASE3":6885,"PHASE4":6887,"NA":6889},{"trials":6876,"activeCount":98},[6877],{"nctId":6855,"briefTitle":6856,"status":580,"phases":6878,"primaryCompletion":5501,"completion":5501,"start":4588,"enrollment":98,"conditions":6879,"interventions":6880},[85],[6859,6860],[6850,6862],{"trials":6882,"activeCount":98},[],{"trials":6884,"activeCount":98},[],{"trials":6886,"activeCount":98},[],{"trials":6888,"activeCount":98},[],{"trials":6890,"activeCount":98},[],{"intervention":6892,"totalTrials":94,"cells":6893},"Amitriptyline",{"EARLY_PHASE1":6894,"PHASE1":6905,"PHASE2":6907,"PHASE3":6909,"PHASE4":6911,"NA":6913},{"trials":6895,"activeCount":98},[6896],{"nctId":6897,"briefTitle":6898,"status":580,"phases":6899,"primaryCompletion":6900,"completion":6900,"start":6901,"enrollment":98,"conditions":6902,"interventions":6904},"NCT06417684","Comparison of Amitriptyline to Lifestyle Modification as Intervention for Vestibular Migraine",[85],"2026-03-11","2024-06-19",[6903],"Vestibular Migraine",[6892],{"trials":6906,"activeCount":98},[],{"trials":6908,"activeCount":98},[],{"trials":6910,"activeCount":98},[],{"trials":6912,"activeCount":98},[],{"trials":6914,"activeCount":98},[],{"intervention":6916,"totalTrials":94,"cells":6917},"Ondansetron",{"EARLY_PHASE1":6918,"PHASE1":6930,"PHASE2":6932,"PHASE3":6934,"PHASE4":6936,"NA":6938},{"trials":6919,"activeCount":98},[6920],{"nctId":6921,"briefTitle":6922,"status":446,"phases":6923,"primaryCompletion":6924,"completion":6924,"start":6925,"enrollment":1722,"conditions":6926,"interventions":6928},"NCT03593811","Noninvasive Markers of Functional Nausea in Children",[85],"2021-04-02","2018-08-03",[6927],"Nausea",[6916,6929],"Cyproheptadine Oral",{"trials":6931,"activeCount":98},[],{"trials":6933,"activeCount":98},[],{"trials":6935,"activeCount":98},[],{"trials":6937,"activeCount":98},[],{"trials":6939,"activeCount":98},[],{"intervention":6929,"totalTrials":94,"cells":6941},{"EARLY_PHASE1":6942,"PHASE1":6948,"PHASE2":6950,"PHASE3":6952,"PHASE4":6954,"NA":6956},{"trials":6943,"activeCount":98},[6944],{"nctId":6921,"briefTitle":6922,"status":446,"phases":6945,"primaryCompletion":6924,"completion":6924,"start":6925,"enrollment":1722,"conditions":6946,"interventions":6947},[85],[6927],[6916,6929],{"trials":6949,"activeCount":98},[],{"trials":6951,"activeCount":98},[],{"trials":6953,"activeCount":98},[],{"trials":6955,"activeCount":98},[],{"trials":6957,"activeCount":98},[],{"intervention":1138,"totalTrials":94,"cells":6959},{"EARLY_PHASE1":6960,"PHASE1":6966,"PHASE2":6968,"PHASE3":6970,"PHASE4":6972,"NA":6974},{"trials":6961,"activeCount":98},[6962],{"nctId":1127,"briefTitle":1128,"status":634,"phases":6963,"primaryCompletion":1130,"completion":1130,"start":637,"enrollment":1131,"conditions":6964,"interventions":6965},[85],[1133,1134,1135,1136],[1138,1121],{"trials":6967,"activeCount":98},[],{"trials":6969,"activeCount":98},[],{"trials":6971,"activeCount":98},[],{"trials":6973,"activeCount":98},[],{"trials":6975,"activeCount":98},[],{"intervention":6977,"totalTrials":94,"cells":6978},"Nesiritide",{"EARLY_PHASE1":6979,"PHASE1":6990,"PHASE2":6992,"PHASE3":6994,"PHASE4":6996,"NA":6998},{"trials":6980,"activeCount":98},[6981],{"nctId":6982,"briefTitle":6983,"status":580,"phases":6984,"primaryCompletion":6985,"completion":6985,"enrollment":98,"conditions":6986,"interventions":6988},"NCT02642523","Natriuretic Peptides and Metabolic Risk in Obesity",[85],"2017-02",[15,6987],"Hyperinsulinemia",[6977,6989],"Insulin",{"trials":6991,"activeCount":98},[],{"trials":6993,"activeCount":98},[],{"trials":6995,"activeCount":98},[],{"trials":6997,"activeCount":98},[],{"trials":6999,"activeCount":98},[],{"intervention":6989,"totalTrials":94,"cells":7001},{"EARLY_PHASE1":7002,"PHASE1":7008,"PHASE2":7010,"PHASE3":7012,"PHASE4":7014,"NA":7016},{"trials":7003,"activeCount":98},[7004],{"nctId":6982,"briefTitle":6983,"status":580,"phases":7005,"primaryCompletion":6985,"completion":6985,"enrollment":98,"conditions":7006,"interventions":7007},[85],[15,6987],[6977,6989],{"trials":7009,"activeCount":98},[],{"trials":7011,"activeCount":98},[],{"trials":7013,"activeCount":98},[],{"trials":7015,"activeCount":98},[],{"trials":7017,"activeCount":98},[],{"intervention":7019,"totalTrials":94,"cells":7020},"CREON",{"EARLY_PHASE1":7021,"PHASE1":7031,"PHASE2":7033,"PHASE3":7035,"PHASE4":7037,"NA":7039},{"trials":7022,"activeCount":98},[7023],{"nctId":7024,"briefTitle":7025,"status":446,"phases":7026,"primaryCompletion":7027,"completion":7027,"start":7028,"enrollment":35,"conditions":7029,"interventions":7030},"NCT05266963","Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes",[85],"2024-03-22","2022-09-02",[1005],[7019],{"trials":7032,"activeCount":98},[],{"trials":7034,"activeCount":98},[],{"trials":7036,"activeCount":98},[],{"trials":7038,"activeCount":98},[],{"trials":7040,"activeCount":98},[],{"intervention":7042,"totalTrials":647,"cells":7043},"gene expression analysis",{"EARLY_PHASE1":7044,"PHASE1":7046,"PHASE2":7048,"PHASE3":7050,"PHASE4":7052,"NA":7054},{"trials":7045,"activeCount":98},[],{"trials":7047,"activeCount":98},[],{"trials":7049,"activeCount":98},[],{"trials":7051,"activeCount":98},[],{"trials":7053,"activeCount":98},[],{"trials":7055,"activeCount":98},[7056,7070,7080,7089],{"nctId":7057,"briefTitle":7058,"status":446,"phases":7059,"primaryCompletion":2785,"completion":7060,"start":7061,"enrollment":7062,"conditions":7063,"interventions":7065},"NCT00899028","Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants",[],"2016-08","2001-05",689,[7064],"Lung Cancer",[7066,7067,7042,7068,7069],"comparative genomic hybridization","fluorescence in situ hybridization","microarray analysis","protein expression analysis",{"nctId":7071,"briefTitle":7072,"status":446,"phases":7073,"primaryCompletion":3063,"completion":3063,"start":7074,"enrollment":1425,"conditions":7075,"interventions":7076},"NCT00482872","Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer",[],"2004-03",[5777],[7042,7077,7078,7079],"mutation analysis","polymerase chain reaction","polymorphism analysis",{"nctId":7081,"briefTitle":7082,"status":446,"phases":7083,"start":7084,"conditions":7085,"interventions":7086},"NCT00896948","Study of Proteins in Head and Neck Cancer Cells",[],"2005-05",[5777],[7087,7088,7042,7069],"Southern blotting","TdT-mediated dUTP nick end labeling assay",{"nctId":7090,"briefTitle":7091,"status":446,"phases":7092,"start":7093,"enrollment":386,"conditions":7094,"interventions":7095},"NCT00897988","DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx",[],"2006-04",[5777],[7042,7077,7096,7078,7069,7097],"polyacrylamide gel electrophoresis","reverse transcriptase-polymerase chain reaction",{"intervention":7069,"totalTrials":647,"cells":7099},{"EARLY_PHASE1":7100,"PHASE1":7102,"PHASE2":7104,"PHASE3":7106,"PHASE4":7108,"NA":7110},{"trials":7101,"activeCount":98},[],{"trials":7103,"activeCount":98},[],{"trials":7105,"activeCount":98},[],{"trials":7107,"activeCount":98},[],{"trials":7109,"activeCount":98},[],{"trials":7111,"activeCount":98},[7112,7116,7120,7124],{"nctId":7057,"briefTitle":7058,"status":446,"phases":7113,"primaryCompletion":2785,"completion":7060,"start":7061,"enrollment":7062,"conditions":7114,"interventions":7115},[],[7064],[7066,7067,7042,7068,7069],{"nctId":7081,"briefTitle":7082,"status":446,"phases":7117,"start":7084,"conditions":7118,"interventions":7119},[],[5777],[7087,7088,7042,7069],{"nctId":7090,"briefTitle":7091,"status":446,"phases":7121,"start":7093,"enrollment":386,"conditions":7122,"interventions":7123},[],[5777],[7042,7077,7096,7078,7069,7097],{"nctId":7125,"briefTitle":7126,"status":446,"phases":7127,"start":7128,"enrollment":769,"conditions":7129,"interventions":7130},"NCT00899769","Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers",[],"2005-04",[5777],[7069,7131],"proteomic profiling",{"intervention":535,"totalTrials":857,"cells":7133},{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7138,"PHASE3":7140,"PHASE4":7146,"NA":7148},{"trials":7135,"activeCount":98},[],{"trials":7137,"activeCount":98},[],{"trials":7139,"activeCount":98},[],{"trials":7141,"activeCount":98},[7142],{"nctId":680,"briefTitle":681,"status":446,"phases":7143,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":7144,"interventions":7145},[88],[687,21,688],[65,535],{"trials":7147,"activeCount":98},[],{"trials":7149,"activeCount":98},[7150,7154],{"nctId":525,"briefTitle":526,"status":446,"phases":7151,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7152,"interventions":7153},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"nctId":7155,"briefTitle":7156,"status":446,"phases":7157,"primaryCompletion":2113,"completion":7158,"start":7159,"enrollment":7160,"conditions":7161,"interventions":7164},"NCT02584452","Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction",[90],"2018-04-10","2015-11-03",59,[7162,7163],"Rupture of Anterior Cruciate Ligament","Tear of Anterior Cruciate Ligament",[561,7165,7166,535,7167],"Normal Saline as bolus followed by bupivacaine","ropivacaine and dexamethasone","Fentanyl",{"intervention":557,"totalTrials":857,"cells":7169},{"EARLY_PHASE1":7170,"PHASE1":7172,"PHASE2":7174,"PHASE3":7188,"PHASE4":7194,"NA":7196},{"trials":7171,"activeCount":98},[],{"trials":7173,"activeCount":98},[],{"trials":7175,"activeCount":98},[7176],{"nctId":7177,"briefTitle":7178,"status":446,"phases":7179,"primaryCompletion":7180,"completion":7181,"start":7182,"enrollment":7183,"conditions":7184,"interventions":7186},"NCT03865940","Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy",[87],"2023-10-04","2024-01-31","2019-11-04",37,[7185],"Trigeminal Neuralgia",[557,7187],"Guanfacine",{"trials":7189,"activeCount":98},[7190],{"nctId":3027,"briefTitle":3028,"status":446,"phases":7191,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":115,"conditions":7192,"interventions":7193},[88],[3033],[3035,2997,557],{"trials":7195,"activeCount":98},[],{"trials":7197,"activeCount":98},[7198],{"nctId":525,"briefTitle":526,"status":446,"phases":7199,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7200,"interventions":7201},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":7187,"totalTrials":857,"cells":7203},{"EARLY_PHASE1":7204,"PHASE1":7206,"PHASE2":7208,"PHASE3":7223,"PHASE4":7225,"NA":7227},{"trials":7205,"activeCount":98},[],{"trials":7207,"activeCount":98},[],{"trials":7209,"activeCount":98},[7210,7219],{"nctId":7211,"briefTitle":7212,"status":446,"phases":7213,"primaryCompletion":7214,"completion":7215,"start":7216,"enrollment":624,"conditions":7217,"interventions":7218},"NCT04742673","Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study",[87],"2024-03-30","2025-11-30","2021-05-04",[31,21,6439],[7187],{"nctId":7177,"briefTitle":7178,"status":446,"phases":7220,"primaryCompletion":7180,"completion":7181,"start":7182,"enrollment":7183,"conditions":7221,"interventions":7222},[87],[7185],[557,7187],{"trials":7224,"activeCount":98},[],{"trials":7226,"activeCount":98},[],{"trials":7228,"activeCount":98},[7229],{"nctId":7230,"briefTitle":7231,"status":446,"phases":7232,"primaryCompletion":6985,"completion":6985,"start":6201,"enrollment":7233,"conditions":7234,"interventions":7236},"NCT02882854","Guanfacine for PONV and Pain After Sinus Surgery",[90],84,[7235,2639],"Postoperative Nausea and Vomiting",[7187],{"intervention":541,"totalTrials":506,"cells":7238},{"EARLY_PHASE1":7239,"PHASE1":7241,"PHASE2":7243,"PHASE3":7245,"PHASE4":7247,"NA":7253},{"trials":7240,"activeCount":98},[],{"trials":7242,"activeCount":98},[],{"trials":7244,"activeCount":98},[],{"trials":7246,"activeCount":98},[],{"trials":7248,"activeCount":98},[7249],{"nctId":2677,"briefTitle":2678,"status":634,"phases":7250,"primaryCompletion":2680,"completion":2680,"start":2681,"enrollment":2682,"conditions":7251,"interventions":7252},[89],[2684,687,2685,2686,2687],[540,541],{"trials":7254,"activeCount":98},[7255],{"nctId":525,"briefTitle":526,"status":446,"phases":7256,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7257,"interventions":7258},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":560,"totalTrials":506,"cells":7260},{"EARLY_PHASE1":7261,"PHASE1":7263,"PHASE2":7265,"PHASE3":7267,"PHASE4":7269,"NA":7275},{"trials":7262,"activeCount":98},[],{"trials":7264,"activeCount":98},[],{"trials":7266,"activeCount":98},[],{"trials":7268,"activeCount":98},[],{"trials":7270,"activeCount":98},[7271],{"nctId":3039,"briefTitle":3040,"status":580,"phases":7272,"primaryCompletion":3042,"completion":3043,"start":3044,"enrollment":98,"conditions":7273,"interventions":7274},[89],[3046,3047,3048],[2997,560],{"trials":7276,"activeCount":98},[7277],{"nctId":525,"briefTitle":526,"status":446,"phases":7278,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7279,"interventions":7280},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":561,"totalTrials":506,"cells":7282},{"EARLY_PHASE1":7283,"PHASE1":7285,"PHASE2":7287,"PHASE3":7289,"PHASE4":7291,"NA":7293},{"trials":7284,"activeCount":98},[],{"trials":7286,"activeCount":98},[],{"trials":7288,"activeCount":98},[],{"trials":7290,"activeCount":98},[],{"trials":7292,"activeCount":98},[],{"trials":7294,"activeCount":98},[7295,7299],{"nctId":525,"briefTitle":526,"status":446,"phases":7296,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7297,"interventions":7298},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"nctId":7155,"briefTitle":7156,"status":446,"phases":7300,"primaryCompletion":2113,"completion":7158,"start":7159,"enrollment":7160,"conditions":7301,"interventions":7302},[90],[7162,7163],[561,7165,7166,535,7167],{"intervention":566,"totalTrials":506,"cells":7304},{"EARLY_PHASE1":7305,"PHASE1":7307,"PHASE2":7317,"PHASE3":7319,"PHASE4":7321,"NA":7323},{"trials":7306,"activeCount":98},[],{"trials":7308,"activeCount":98},[7309],{"nctId":7310,"briefTitle":7311,"status":446,"phases":7312,"primaryCompletion":7313,"completion":7313,"start":636,"enrollment":2510,"conditions":7314,"interventions":7315},"NCT02537314","Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans",[86],"2022-12-08",[15],[7316],"benzocaine",{"trials":7318,"activeCount":98},[],{"trials":7320,"activeCount":98},[],{"trials":7322,"activeCount":98},[],{"trials":7324,"activeCount":98},[7325],{"nctId":525,"briefTitle":526,"status":446,"phases":7326,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7327,"interventions":7328},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":5253,"totalTrials":506,"cells":7330},{"EARLY_PHASE1":7331,"PHASE1":7333,"PHASE2":7335,"PHASE3":7337,"PHASE4":7343,"NA":7345},{"trials":7332,"activeCount":98},[],{"trials":7334,"activeCount":98},[],{"trials":7336,"activeCount":98},[],{"trials":7338,"activeCount":98},[7339],{"nctId":5242,"briefTitle":5243,"status":446,"phases":7340,"primaryCompletion":5245,"completion":5246,"start":5247,"enrollment":5248,"conditions":7341,"interventions":7342},[87,88],[5250],[5252,5253,5231,5254],{"trials":7344,"activeCount":98},[],{"trials":7346,"activeCount":98},[7347],{"nctId":7348,"briefTitle":7349,"status":446,"phases":7350,"primaryCompletion":7351,"completion":2070,"start":7352,"enrollment":7353,"conditions":7354,"interventions":7356},"NCT03227679","Metabolism-informed Care for Smoking Cessation",[90],"2016-10-08","2016-05-18",82,[7355,5250],"Tobacco Use",[5253,7357,5252],"Bupropion",{"intervention":7357,"totalTrials":506,"cells":7359},{"EARLY_PHASE1":7360,"PHASE1":7362,"PHASE2":7364,"PHASE3":7366,"PHASE4":7368,"NA":7374},{"trials":7361,"activeCount":98},[],{"trials":7363,"activeCount":98},[],{"trials":7365,"activeCount":98},[],{"trials":7367,"activeCount":98},[],{"trials":7369,"activeCount":98},[7370],{"nctId":4149,"briefTitle":4150,"status":446,"phases":7371,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":1722,"conditions":7372,"interventions":7373},[89],[28],[4136,4156],{"trials":7375,"activeCount":98},[7376],{"nctId":7348,"briefTitle":7349,"status":446,"phases":7377,"primaryCompletion":7351,"completion":2070,"start":7352,"enrollment":7353,"conditions":7378,"interventions":7379},[90],[7355,5250],[5253,7357,5252],{"intervention":5252,"totalTrials":506,"cells":7381},{"EARLY_PHASE1":7382,"PHASE1":7384,"PHASE2":7386,"PHASE3":7388,"PHASE4":7394,"NA":7396},{"trials":7383,"activeCount":98},[],{"trials":7385,"activeCount":98},[],{"trials":7387,"activeCount":98},[],{"trials":7389,"activeCount":98},[7390],{"nctId":5242,"briefTitle":5243,"status":446,"phases":7391,"primaryCompletion":5245,"completion":5246,"start":5247,"enrollment":5248,"conditions":7392,"interventions":7393},[87,88],[5250],[5252,5253,5231,5254],{"trials":7395,"activeCount":98},[],{"trials":7397,"activeCount":98},[7398],{"nctId":7348,"briefTitle":7349,"status":446,"phases":7399,"primaryCompletion":7351,"completion":2070,"start":7352,"enrollment":7353,"conditions":7400,"interventions":7401},[90],[7355,5250],[5253,7357,5252],{"intervention":7077,"totalTrials":506,"cells":7403},{"EARLY_PHASE1":7404,"PHASE1":7406,"PHASE2":7408,"PHASE3":7410,"PHASE4":7412,"NA":7414},{"trials":7405,"activeCount":98},[],{"trials":7407,"activeCount":98},[],{"trials":7409,"activeCount":98},[],{"trials":7411,"activeCount":98},[],{"trials":7413,"activeCount":98},[],{"trials":7415,"activeCount":98},[7416,7420],{"nctId":7071,"briefTitle":7072,"status":446,"phases":7417,"primaryCompletion":3063,"completion":3063,"start":7074,"enrollment":1425,"conditions":7418,"interventions":7419},[],[5777],[7042,7077,7078,7079],{"nctId":7090,"briefTitle":7091,"status":446,"phases":7421,"start":7093,"enrollment":386,"conditions":7422,"interventions":7423},[],[5777],[7042,7077,7096,7078,7069,7097],{"intervention":7078,"totalTrials":506,"cells":7425},{"EARLY_PHASE1":7426,"PHASE1":7428,"PHASE2":7430,"PHASE3":7432,"PHASE4":7434,"NA":7436},{"trials":7427,"activeCount":98},[],{"trials":7429,"activeCount":98},[],{"trials":7431,"activeCount":98},[],{"trials":7433,"activeCount":98},[],{"trials":7435,"activeCount":98},[],{"trials":7437,"activeCount":98},[7438,7442],{"nctId":7071,"briefTitle":7072,"status":446,"phases":7439,"primaryCompletion":3063,"completion":3063,"start":7074,"enrollment":1425,"conditions":7440,"interventions":7441},[],[5777],[7042,7077,7078,7079],{"nctId":7090,"briefTitle":7091,"status":446,"phases":7443,"start":7093,"enrollment":386,"conditions":7444,"interventions":7445},[],[5777],[7042,7077,7096,7078,7069,7097],{"intervention":7447,"totalTrials":94,"cells":7448},"Normal Saline 0.9% Infusion Solution Bag",{"EARLY_PHASE1":7449,"PHASE1":7451,"PHASE2":7453,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7450,"activeCount":98},[],{"trials":7452,"activeCount":98},[],{"trials":7454,"activeCount":98},[],{"trials":7456,"activeCount":98},[],{"trials":7458,"activeCount":98},[],{"trials":7460,"activeCount":98},[7461],{"nctId":7462,"briefTitle":7463,"status":446,"phases":7464,"primaryCompletion":7465,"completion":7465,"start":7466,"enrollment":2182,"conditions":7467,"interventions":7468},"NCT04223531","The Natriuretic Peptide Response to Saline Infusion",[90],"2022-06-17","2020-10-26",[15],[7447],{"intervention":7470,"totalTrials":94,"cells":7471},"Influenza Vaccine Recipients",{"EARLY_PHASE1":7472,"PHASE1":7474,"PHASE2":7476,"PHASE3":7478,"PHASE4":7480,"NA":7482},{"trials":7473,"activeCount":98},[],{"trials":7475,"activeCount":98},[],{"trials":7477,"activeCount":98},[],{"trials":7479,"activeCount":98},[],{"trials":7481,"activeCount":98},[],{"trials":7483,"activeCount":98},[7484],{"nctId":7485,"briefTitle":7486,"status":446,"phases":7487,"primaryCompletion":2863,"completion":2863,"start":7488,"enrollment":3209,"conditions":7489,"interventions":7495},"NCT03743688","Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults",[],"2018-12-04",[1079,7490,4462,7491,7492,7493,7494],"Influenza, Human","Influenza A","Influenza Type B","Influenza A H1N1","Influenza A H3N2",[7470],{"intervention":7497,"totalTrials":94,"cells":7498},"Flecainide Acetate",{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7503,"PHASE3":7505,"PHASE4":7507,"NA":7509},{"trials":7500,"activeCount":98},[],{"trials":7502,"activeCount":98},[],{"trials":7504,"activeCount":98},[],{"trials":7506,"activeCount":98},[],{"trials":7508,"activeCount":98},[],{"trials":7510,"activeCount":98},[7511],{"nctId":7512,"briefTitle":7513,"status":446,"phases":7514,"primaryCompletion":4015,"completion":4015,"start":7515,"enrollment":24,"conditions":7516,"interventions":7518},"NCT01117454","Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia",[90],"2011-12",[7517],"Catecholaminergic Polymorphic Ventricular Tachycardia",[7497,7519],"Beta blocker",{"intervention":7519,"totalTrials":94,"cells":7521},{"EARLY_PHASE1":7522,"PHASE1":7524,"PHASE2":7526,"PHASE3":7528,"PHASE4":7530,"NA":7532},{"trials":7523,"activeCount":98},[],{"trials":7525,"activeCount":98},[],{"trials":7527,"activeCount":98},[],{"trials":7529,"activeCount":98},[],{"trials":7531,"activeCount":98},[],{"trials":7533,"activeCount":98},[7534],{"nctId":7512,"briefTitle":7513,"status":446,"phases":7535,"primaryCompletion":4015,"completion":4015,"start":7515,"enrollment":24,"conditions":7536,"interventions":7537},[90],[7517],[7497,7519],{"intervention":7066,"totalTrials":94,"cells":7539},{"EARLY_PHASE1":7540,"PHASE1":7542,"PHASE2":7544,"PHASE3":7546,"PHASE4":7548,"NA":7550},{"trials":7541,"activeCount":98},[],{"trials":7543,"activeCount":98},[],{"trials":7545,"activeCount":98},[],{"trials":7547,"activeCount":98},[],{"trials":7549,"activeCount":98},[],{"trials":7551,"activeCount":98},[7552],{"nctId":7057,"briefTitle":7058,"status":446,"phases":7553,"primaryCompletion":2785,"completion":7060,"start":7061,"enrollment":7062,"conditions":7554,"interventions":7555},[],[7064],[7066,7067,7042,7068,7069],{"intervention":7067,"totalTrials":94,"cells":7557},{"EARLY_PHASE1":7558,"PHASE1":7560,"PHASE2":7562,"PHASE3":7564,"PHASE4":7566,"NA":7568},{"trials":7559,"activeCount":98},[],{"trials":7561,"activeCount":98},[],{"trials":7563,"activeCount":98},[],{"trials":7565,"activeCount":98},[],{"trials":7567,"activeCount":98},[],{"trials":7569,"activeCount":98},[7570],{"nctId":7057,"briefTitle":7058,"status":446,"phases":7571,"primaryCompletion":2785,"completion":7060,"start":7061,"enrollment":7062,"conditions":7572,"interventions":7573},[],[7064],[7066,7067,7042,7068,7069],{"intervention":7068,"totalTrials":94,"cells":7575},{"EARLY_PHASE1":7576,"PHASE1":7578,"PHASE2":7580,"PHASE3":7582,"PHASE4":7584,"NA":7586},{"trials":7577,"activeCount":98},[],{"trials":7579,"activeCount":98},[],{"trials":7581,"activeCount":98},[],{"trials":7583,"activeCount":98},[],{"trials":7585,"activeCount":98},[],{"trials":7587,"activeCount":98},[7588],{"nctId":7057,"briefTitle":7058,"status":446,"phases":7589,"primaryCompletion":2785,"completion":7060,"start":7061,"enrollment":7062,"conditions":7590,"interventions":7591},[],[7064],[7066,7067,7042,7068,7069],{"intervention":536,"totalTrials":94,"cells":7593},{"EARLY_PHASE1":7594,"PHASE1":7596,"PHASE2":7598,"PHASE3":7600,"PHASE4":7602,"NA":7604},{"trials":7595,"activeCount":98},[],{"trials":7597,"activeCount":98},[],{"trials":7599,"activeCount":98},[],{"trials":7601,"activeCount":98},[],{"trials":7603,"activeCount":98},[],{"trials":7605,"activeCount":98},[7606],{"nctId":525,"briefTitle":526,"status":446,"phases":7607,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7608,"interventions":7609},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":537,"totalTrials":94,"cells":7611},{"EARLY_PHASE1":7612,"PHASE1":7614,"PHASE2":7616,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7613,"activeCount":98},[],{"trials":7615,"activeCount":98},[],{"trials":7617,"activeCount":98},[],{"trials":7619,"activeCount":98},[],{"trials":7621,"activeCount":98},[],{"trials":7623,"activeCount":98},[7624],{"nctId":525,"briefTitle":526,"status":446,"phases":7625,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7626,"interventions":7627},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":538,"totalTrials":94,"cells":7629},{"EARLY_PHASE1":7630,"PHASE1":7632,"PHASE2":7634,"PHASE3":7636,"PHASE4":7638,"NA":7640},{"trials":7631,"activeCount":98},[],{"trials":7633,"activeCount":98},[],{"trials":7635,"activeCount":98},[],{"trials":7637,"activeCount":98},[],{"trials":7639,"activeCount":98},[],{"trials":7641,"activeCount":98},[7642],{"nctId":525,"briefTitle":526,"status":446,"phases":7643,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7644,"interventions":7645},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":539,"totalTrials":94,"cells":7647},{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7658},{"trials":7649,"activeCount":98},[],{"trials":7651,"activeCount":98},[],{"trials":7653,"activeCount":98},[],{"trials":7655,"activeCount":98},[],{"trials":7657,"activeCount":98},[],{"trials":7659,"activeCount":98},[7660],{"nctId":525,"briefTitle":526,"status":446,"phases":7661,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7662,"interventions":7663},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":542,"totalTrials":94,"cells":7665},{"EARLY_PHASE1":7666,"PHASE1":7668,"PHASE2":7670,"PHASE3":7672,"PHASE4":7674,"NA":7676},{"trials":7667,"activeCount":98},[],{"trials":7669,"activeCount":98},[],{"trials":7671,"activeCount":98},[],{"trials":7673,"activeCount":98},[],{"trials":7675,"activeCount":98},[],{"trials":7677,"activeCount":98},[7678],{"nctId":525,"briefTitle":526,"status":446,"phases":7679,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7680,"interventions":7681},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":543,"totalTrials":94,"cells":7683},{"EARLY_PHASE1":7684,"PHASE1":7686,"PHASE2":7688,"PHASE3":7690,"PHASE4":7692,"NA":7694},{"trials":7685,"activeCount":98},[],{"trials":7687,"activeCount":98},[],{"trials":7689,"activeCount":98},[],{"trials":7691,"activeCount":98},[],{"trials":7693,"activeCount":98},[],{"trials":7695,"activeCount":98},[7696],{"nctId":525,"briefTitle":526,"status":446,"phases":7697,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7698,"interventions":7699},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":544,"totalTrials":94,"cells":7701},{"EARLY_PHASE1":7702,"PHASE1":7704,"PHASE2":7706,"PHASE3":7708,"PHASE4":7710,"NA":7712},{"trials":7703,"activeCount":98},[],{"trials":7705,"activeCount":98},[],{"trials":7707,"activeCount":98},[],{"trials":7709,"activeCount":98},[],{"trials":7711,"activeCount":98},[],{"trials":7713,"activeCount":98},[7714],{"nctId":525,"briefTitle":526,"status":446,"phases":7715,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7716,"interventions":7717},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":546,"totalTrials":94,"cells":7719},{"EARLY_PHASE1":7720,"PHASE1":7722,"PHASE2":7724,"PHASE3":7726,"PHASE4":7728,"NA":7730},{"trials":7721,"activeCount":98},[],{"trials":7723,"activeCount":98},[],{"trials":7725,"activeCount":98},[],{"trials":7727,"activeCount":98},[],{"trials":7729,"activeCount":98},[],{"trials":7731,"activeCount":98},[7732],{"nctId":525,"briefTitle":526,"status":446,"phases":7733,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7734,"interventions":7735},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":547,"totalTrials":94,"cells":7737},{"EARLY_PHASE1":7738,"PHASE1":7740,"PHASE2":7742,"PHASE3":7744,"PHASE4":7746,"NA":7748},{"trials":7739,"activeCount":98},[],{"trials":7741,"activeCount":98},[],{"trials":7743,"activeCount":98},[],{"trials":7745,"activeCount":98},[],{"trials":7747,"activeCount":98},[],{"trials":7749,"activeCount":98},[7750],{"nctId":525,"briefTitle":526,"status":446,"phases":7751,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7752,"interventions":7753},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":548,"totalTrials":94,"cells":7755},{"EARLY_PHASE1":7756,"PHASE1":7758,"PHASE2":7760,"PHASE3":7762,"PHASE4":7764,"NA":7766},{"trials":7757,"activeCount":98},[],{"trials":7759,"activeCount":98},[],{"trials":7761,"activeCount":98},[],{"trials":7763,"activeCount":98},[],{"trials":7765,"activeCount":98},[],{"trials":7767,"activeCount":98},[7768],{"nctId":525,"briefTitle":526,"status":446,"phases":7769,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7770,"interventions":7771},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":549,"totalTrials":94,"cells":7773},{"EARLY_PHASE1":7774,"PHASE1":7776,"PHASE2":7778,"PHASE3":7780,"PHASE4":7782,"NA":7784},{"trials":7775,"activeCount":98},[],{"trials":7777,"activeCount":98},[],{"trials":7779,"activeCount":98},[],{"trials":7781,"activeCount":98},[],{"trials":7783,"activeCount":98},[],{"trials":7785,"activeCount":98},[7786],{"nctId":525,"briefTitle":526,"status":446,"phases":7787,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7788,"interventions":7789},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":550,"totalTrials":94,"cells":7791},{"EARLY_PHASE1":7792,"PHASE1":7794,"PHASE2":7796,"PHASE3":7798,"PHASE4":7800,"NA":7802},{"trials":7793,"activeCount":98},[],{"trials":7795,"activeCount":98},[],{"trials":7797,"activeCount":98},[],{"trials":7799,"activeCount":98},[],{"trials":7801,"activeCount":98},[],{"trials":7803,"activeCount":98},[7804],{"nctId":525,"briefTitle":526,"status":446,"phases":7805,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7806,"interventions":7807},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":551,"totalTrials":94,"cells":7809},{"EARLY_PHASE1":7810,"PHASE1":7812,"PHASE2":7814,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7811,"activeCount":98},[],{"trials":7813,"activeCount":98},[],{"trials":7815,"activeCount":98},[],{"trials":7817,"activeCount":98},[],{"trials":7819,"activeCount":98},[],{"trials":7821,"activeCount":98},[7822],{"nctId":525,"briefTitle":526,"status":446,"phases":7823,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7824,"interventions":7825},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":552,"totalTrials":94,"cells":7827},{"EARLY_PHASE1":7828,"PHASE1":7830,"PHASE2":7832,"PHASE3":7834,"PHASE4":7836,"NA":7838},{"trials":7829,"activeCount":98},[],{"trials":7831,"activeCount":98},[],{"trials":7833,"activeCount":98},[],{"trials":7835,"activeCount":98},[],{"trials":7837,"activeCount":98},[],{"trials":7839,"activeCount":98},[7840],{"nctId":525,"briefTitle":526,"status":446,"phases":7841,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7842,"interventions":7843},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":553,"totalTrials":94,"cells":7845},{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7847,"activeCount":98},[],{"trials":7849,"activeCount":98},[],{"trials":7851,"activeCount":98},[],{"trials":7853,"activeCount":98},[],{"trials":7855,"activeCount":98},[],{"trials":7857,"activeCount":98},[7858],{"nctId":525,"briefTitle":526,"status":446,"phases":7859,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7860,"interventions":7861},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":554,"totalTrials":94,"cells":7863},{"EARLY_PHASE1":7864,"PHASE1":7866,"PHASE2":7868,"PHASE3":7870,"PHASE4":7872,"NA":7874},{"trials":7865,"activeCount":98},[],{"trials":7867,"activeCount":98},[],{"trials":7869,"activeCount":98},[],{"trials":7871,"activeCount":98},[],{"trials":7873,"activeCount":98},[],{"trials":7875,"activeCount":98},[7876],{"nctId":525,"briefTitle":526,"status":446,"phases":7877,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7878,"interventions":7879},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":555,"totalTrials":94,"cells":7881},{"EARLY_PHASE1":7882,"PHASE1":7884,"PHASE2":7886,"PHASE3":7888,"PHASE4":7890,"NA":7892},{"trials":7883,"activeCount":98},[],{"trials":7885,"activeCount":98},[],{"trials":7887,"activeCount":98},[],{"trials":7889,"activeCount":98},[],{"trials":7891,"activeCount":98},[],{"trials":7893,"activeCount":98},[7894],{"nctId":525,"briefTitle":526,"status":446,"phases":7895,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7896,"interventions":7897},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":556,"totalTrials":94,"cells":7899},{"EARLY_PHASE1":7900,"PHASE1":7902,"PHASE2":7904,"PHASE3":7906,"PHASE4":7908,"NA":7910},{"trials":7901,"activeCount":98},[],{"trials":7903,"activeCount":98},[],{"trials":7905,"activeCount":98},[],{"trials":7907,"activeCount":98},[],{"trials":7909,"activeCount":98},[],{"trials":7911,"activeCount":98},[7912],{"nctId":525,"briefTitle":526,"status":446,"phases":7913,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7914,"interventions":7915},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":558,"totalTrials":94,"cells":7917},{"EARLY_PHASE1":7918,"PHASE1":7920,"PHASE2":7922,"PHASE3":7924,"PHASE4":7926,"NA":7928},{"trials":7919,"activeCount":98},[],{"trials":7921,"activeCount":98},[],{"trials":7923,"activeCount":98},[],{"trials":7925,"activeCount":98},[],{"trials":7927,"activeCount":98},[],{"trials":7929,"activeCount":98},[7930],{"nctId":525,"briefTitle":526,"status":446,"phases":7931,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7932,"interventions":7933},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":559,"totalTrials":94,"cells":7935},{"EARLY_PHASE1":7936,"PHASE1":7938,"PHASE2":7940,"PHASE3":7942,"PHASE4":7944,"NA":7946},{"trials":7937,"activeCount":98},[],{"trials":7939,"activeCount":98},[],{"trials":7941,"activeCount":98},[],{"trials":7943,"activeCount":98},[],{"trials":7945,"activeCount":98},[],{"trials":7947,"activeCount":98},[7948],{"nctId":525,"briefTitle":526,"status":446,"phases":7949,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7950,"interventions":7951},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":562,"totalTrials":94,"cells":7953},{"EARLY_PHASE1":7954,"PHASE1":7956,"PHASE2":7958,"PHASE3":7960,"PHASE4":7962,"NA":7964},{"trials":7955,"activeCount":98},[],{"trials":7957,"activeCount":98},[],{"trials":7959,"activeCount":98},[],{"trials":7961,"activeCount":98},[],{"trials":7963,"activeCount":98},[],{"trials":7965,"activeCount":98},[7966],{"nctId":525,"briefTitle":526,"status":446,"phases":7967,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7968,"interventions":7969},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":563,"totalTrials":94,"cells":7971},{"EARLY_PHASE1":7972,"PHASE1":7974,"PHASE2":7976,"PHASE3":7978,"PHASE4":7980,"NA":7982},{"trials":7973,"activeCount":98},[],{"trials":7975,"activeCount":98},[],{"trials":7977,"activeCount":98},[],{"trials":7979,"activeCount":98},[],{"trials":7981,"activeCount":98},[],{"trials":7983,"activeCount":98},[7984],{"nctId":525,"briefTitle":526,"status":446,"phases":7985,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":7986,"interventions":7987},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":564,"totalTrials":94,"cells":7989},{"EARLY_PHASE1":7990,"PHASE1":7992,"PHASE2":7994,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7991,"activeCount":98},[],{"trials":7993,"activeCount":98},[],{"trials":7995,"activeCount":98},[],{"trials":7997,"activeCount":98},[],{"trials":7999,"activeCount":98},[],{"trials":8001,"activeCount":98},[8002],{"nctId":525,"briefTitle":526,"status":446,"phases":8003,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":8004,"interventions":8005},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":565,"totalTrials":94,"cells":8007},{"EARLY_PHASE1":8008,"PHASE1":8010,"PHASE2":8012,"PHASE3":8014,"PHASE4":8016,"NA":8018},{"trials":8009,"activeCount":98},[],{"trials":8011,"activeCount":98},[],{"trials":8013,"activeCount":98},[],{"trials":8015,"activeCount":98},[],{"trials":8017,"activeCount":98},[],{"trials":8019,"activeCount":98},[8020],{"nctId":525,"briefTitle":526,"status":446,"phases":8021,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":8022,"interventions":8023},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":567,"totalTrials":94,"cells":8025},{"EARLY_PHASE1":8026,"PHASE1":8028,"PHASE2":8030,"PHASE3":8032,"PHASE4":8034,"NA":8036},{"trials":8027,"activeCount":98},[],{"trials":8029,"activeCount":98},[],{"trials":8031,"activeCount":98},[],{"trials":8033,"activeCount":98},[],{"trials":8035,"activeCount":98},[],{"trials":8037,"activeCount":98},[8038],{"nctId":525,"briefTitle":526,"status":446,"phases":8039,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":8040,"interventions":8041},[90],[533],[535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,343,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567],{"intervention":8043,"totalTrials":94,"cells":8044},"Definity Suspension for",{"EARLY_PHASE1":8045,"PHASE1":8047,"PHASE2":8049,"PHASE3":8051,"PHASE4":8053,"NA":8055},{"trials":8046,"activeCount":98},[],{"trials":8048,"activeCount":98},[],{"trials":8050,"activeCount":98},[],{"trials":8052,"activeCount":98},[],{"trials":8054,"activeCount":98},[],{"trials":8056,"activeCount":98},[8057],{"nctId":8058,"briefTitle":8059,"status":446,"phases":8060,"primaryCompletion":8061,"completion":8062,"start":8063,"enrollment":2038,"conditions":8064,"interventions":8065},"NCT05135169","Multi-organ Transit Time Acquisition Using Contrast Ultrasound",[],"2023-06-16","2025-06-30","2022-03-03",[2252],[8043],{"intervention":8067,"totalTrials":94,"cells":8068},"Scopolamine Injectable Product",{"EARLY_PHASE1":8069,"PHASE1":8071,"PHASE2":8073,"PHASE3":8075,"PHASE4":8077,"NA":8079},{"trials":8070,"activeCount":98},[],{"trials":8072,"activeCount":98},[],{"trials":8074,"activeCount":98},[],{"trials":8076,"activeCount":98},[],{"trials":8078,"activeCount":98},[],{"trials":8080,"activeCount":98},[8081],{"nctId":8082,"briefTitle":8083,"status":446,"phases":8084,"primaryCompletion":1336,"completion":1336,"start":4015,"enrollment":4340,"conditions":8085,"interventions":8090},"NCT03244488","Mental Ability Challenge Study in Adults With and Without HIV",[],[8086,8087,6439,8088,8089],"HIV-1-infection","Aging, Premature","Memory Impairment","HIV-Associated Cognitive Motor Complex",[8067,8091],"Mecamylamine Pill",{"intervention":8091,"totalTrials":94,"cells":8093},{"EARLY_PHASE1":8094,"PHASE1":8096,"PHASE2":8098,"PHASE3":8100,"PHASE4":8102,"NA":8104},{"trials":8095,"activeCount":98},[],{"trials":8097,"activeCount":98},[],{"trials":8099,"activeCount":98},[],{"trials":8101,"activeCount":98},[],{"trials":8103,"activeCount":98},[],{"trials":8105,"activeCount":98},[8106],{"nctId":8082,"briefTitle":8083,"status":446,"phases":8107,"primaryCompletion":1336,"completion":1336,"start":4015,"enrollment":4340,"conditions":8108,"interventions":8109},[],[8086,8087,6439,8088,8089],[8067,8091],{"intervention":8111,"totalTrials":94,"cells":8112},"methotrexate",{"EARLY_PHASE1":8113,"PHASE1":8115,"PHASE2":8117,"PHASE3":8119,"PHASE4":8121,"NA":8123},{"trials":8114,"activeCount":98},[],{"trials":8116,"activeCount":98},[],{"trials":8118,"activeCount":98},[],{"trials":8120,"activeCount":98},[],{"trials":8122,"activeCount":98},[],{"trials":8124,"activeCount":98},[8125],{"nctId":8126,"briefTitle":8127,"status":446,"phases":8128,"primaryCompletion":3781,"start":4637,"enrollment":3209,"conditions":8129,"interventions":8132},"NCT00993135","Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia",[],[8130,8131],"Leukemia","Renal Toxicity",[8111],{"intervention":8134,"totalTrials":94,"cells":8135},"540,000 IU vitamin D3",{"EARLY_PHASE1":8136,"PHASE1":8138,"PHASE2":8140,"PHASE3":8142,"PHASE4":8144,"NA":8146},{"trials":8137,"activeCount":98},[],{"trials":8139,"activeCount":98},[],{"trials":8141,"activeCount":98},[],{"trials":8143,"activeCount":98},[],{"trials":8145,"activeCount":98},[],{"trials":8147,"activeCount":98},[8148],{"nctId":8149,"briefTitle":8150,"status":446,"phases":8151,"primaryCompletion":8152,"completion":8153,"start":8154,"enrollment":916,"conditions":8155,"interventions":8156},"NCT03733418","Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients",[],"2019-10-02","2020-02-21","2018-11-01",[5942],[8134],{"intervention":8158,"totalTrials":94,"cells":8159},"Atenolol",{"EARLY_PHASE1":8160,"PHASE1":8162,"PHASE2":8164,"PHASE3":8166,"PHASE4":8168,"NA":8170},{"trials":8161,"activeCount":98},[],{"trials":8163,"activeCount":98},[],{"trials":8165,"activeCount":98},[],{"trials":8167,"activeCount":98},[],{"trials":8169,"activeCount":98},[],{"trials":8171,"activeCount":98},[8172],{"nctId":8173,"briefTitle":8174,"status":446,"phases":8175,"primaryCompletion":1146,"completion":1146,"start":8176,"enrollment":3783,"conditions":8177,"interventions":8178},"NCT01719367","Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation",[90],"2013-01",[918],[8158],{"intervention":8180,"totalTrials":94,"cells":8181},"Optimal drug therapy",{"EARLY_PHASE1":8182,"PHASE1":8184,"PHASE2":8186,"PHASE3":8188,"PHASE4":8190,"NA":8192},{"trials":8183,"activeCount":98},[],{"trials":8185,"activeCount":98},[],{"trials":8187,"activeCount":98},[],{"trials":8189,"activeCount":98},[],{"trials":8191,"activeCount":98},[],{"trials":8193,"activeCount":98},[8194],{"nctId":8195,"briefTitle":8196,"status":446,"phases":8197,"primaryCompletion":3087,"completion":8198,"start":4613,"enrollment":7183,"conditions":8199,"interventions":8201},"NCT00282152","Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)",[90],"2015-10",[8200],"Parkinson's Disease",[8180],{"intervention":7079,"totalTrials":94,"cells":8203},{"EARLY_PHASE1":8204,"PHASE1":8206,"PHASE2":8208,"PHASE3":8210,"PHASE4":8212,"NA":8214},{"trials":8205,"activeCount":98},[],{"trials":8207,"activeCount":98},[],{"trials":8209,"activeCount":98},[],{"trials":8211,"activeCount":98},[],{"trials":8213,"activeCount":98},[],{"trials":8215,"activeCount":98},[8216],{"nctId":7071,"briefTitle":7072,"status":446,"phases":8217,"primaryCompletion":3063,"completion":3063,"start":7074,"enrollment":1425,"conditions":8218,"interventions":8219},[],[5777],[7042,7077,7078,7079],{"intervention":8221,"totalTrials":94,"cells":8222},"Procainamide",{"EARLY_PHASE1":8223,"PHASE1":8225,"PHASE2":8227,"PHASE3":8229,"PHASE4":8231,"NA":8233},{"trials":8224,"activeCount":98},[],{"trials":8226,"activeCount":98},[],{"trials":8228,"activeCount":98},[],{"trials":8230,"activeCount":98},[],{"trials":8232,"activeCount":98},[],{"trials":8234,"activeCount":98},[8235],{"nctId":8236,"briefTitle":8237,"status":446,"phases":8238,"primaryCompletion":891,"completion":891,"start":8239,"enrollment":8240,"conditions":8241,"interventions":8242},"NCT01205529","ST-segment Elevation as an AF Endophenotype",[90],"2010-11",161,[918],[8221],{"intervention":7087,"totalTrials":94,"cells":8244},{"EARLY_PHASE1":8245,"PHASE1":8247,"PHASE2":8249,"PHASE3":8251,"PHASE4":8253,"NA":8255},{"trials":8246,"activeCount":98},[],{"trials":8248,"activeCount":98},[],{"trials":8250,"activeCount":98},[],{"trials":8252,"activeCount":98},[],{"trials":8254,"activeCount":98},[],{"trials":8256,"activeCount":98},[8257],{"nctId":7081,"briefTitle":7082,"status":446,"phases":8258,"start":7084,"conditions":8259,"interventions":8260},[],[5777],[7087,7088,7042,7069],{"intervention":7088,"totalTrials":94,"cells":8262},{"EARLY_PHASE1":8263,"PHASE1":8265,"PHASE2":8267,"PHASE3":8269,"PHASE4":8271,"NA":8273},{"trials":8264,"activeCount":98},[],{"trials":8266,"activeCount":98},[],{"trials":8268,"activeCount":98},[],{"trials":8270,"activeCount":98},[],{"trials":8272,"activeCount":98},[],{"trials":8274,"activeCount":98},[8275],{"nctId":7081,"briefTitle":7082,"status":446,"phases":8276,"start":7084,"conditions":8277,"interventions":8278},[],[5777],[7087,7088,7042,7069],{"intervention":8280,"totalTrials":94,"cells":8281},"Walking Exercise Group",{"EARLY_PHASE1":8282,"PHASE1":8284,"PHASE2":8286,"PHASE3":8288,"PHASE4":8290,"NA":8292},{"trials":8283,"activeCount":98},[],{"trials":8285,"activeCount":98},[],{"trials":8287,"activeCount":98},[],{"trials":8289,"activeCount":98},[],{"trials":8291,"activeCount":98},[],{"trials":8293,"activeCount":98},[8294],{"nctId":8295,"briefTitle":8296,"status":446,"phases":8297,"primaryCompletion":8298,"completion":8298,"start":1231,"enrollment":1122,"conditions":8299,"interventions":8300},"NCT00937443","Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure",[],"2014-01",[626],[8280],{"intervention":7096,"totalTrials":94,"cells":8302},{"EARLY_PHASE1":8303,"PHASE1":8305,"PHASE2":8307,"PHASE3":8309,"PHASE4":8311,"NA":8313},{"trials":8304,"activeCount":98},[],{"trials":8306,"activeCount":98},[],{"trials":8308,"activeCount":98},[],{"trials":8310,"activeCount":98},[],{"trials":8312,"activeCount":98},[],{"trials":8314,"activeCount":98},[8315],{"nctId":7090,"briefTitle":7091,"status":446,"phases":8316,"start":7093,"enrollment":386,"conditions":8317,"interventions":8318},[],[5777],[7042,7077,7096,7078,7069,7097],{"intervention":7097,"totalTrials":94,"cells":8320},{"EARLY_PHASE1":8321,"PHASE1":8323,"PHASE2":8325,"PHASE3":8327,"PHASE4":8329,"NA":8331},{"trials":8322,"activeCount":98},[],{"trials":8324,"activeCount":98},[],{"trials":8326,"activeCount":98},[],{"trials":8328,"activeCount":98},[],{"trials":8330,"activeCount":98},[],{"trials":8332,"activeCount":98},[8333],{"nctId":7090,"briefTitle":7091,"status":446,"phases":8334,"start":7093,"enrollment":386,"conditions":8335,"interventions":8336},[],[5777],[7042,7077,7096,7078,7069,7097],{"intervention":8338,"totalTrials":94,"cells":8339},"Albuterol and Ipratropium Continuous Nebulizer",{"EARLY_PHASE1":8340,"PHASE1":8342,"PHASE2":8344,"PHASE3":8346,"PHASE4":8348,"NA":8350},{"trials":8341,"activeCount":98},[],{"trials":8343,"activeCount":98},[],{"trials":8345,"activeCount":98},[],{"trials":8347,"activeCount":98},[],{"trials":8349,"activeCount":98},[],{"trials":8351,"activeCount":98},[8352],{"nctId":8353,"briefTitle":8354,"status":580,"phases":8355,"primaryCompletion":8356,"completion":8356,"start":4408,"enrollment":98,"conditions":8357,"interventions":8358},"NCT02458482","Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children",[90],"2020-11-11",[1978],[8338],{"intervention":8360,"totalTrials":94,"cells":8361},"olopatadine",{"EARLY_PHASE1":8362,"PHASE1":8364,"PHASE2":8366,"PHASE3":8368,"PHASE4":8370,"NA":8372},{"trials":8363,"activeCount":98},[],{"trials":8365,"activeCount":98},[],{"trials":8367,"activeCount":98},[],{"trials":8369,"activeCount":98},[],{"trials":8371,"activeCount":98},[],{"trials":8373,"activeCount":98},[8374],{"nctId":8375,"briefTitle":8376,"status":446,"phases":8377,"primaryCompletion":8378,"completion":8378,"start":4016,"enrollment":1003,"conditions":8379,"interventions":8382},"NCT00775658","Olopatadine Eye Drops and Allergy Skin Testing",[90],"2008-06",[8380,8381],"Allergic Rhinitis","Allergic Conjunctivitis",[8360],{"intervention":8384,"totalTrials":94,"cells":8385},"Angiotensin Converting Enzyme Inhibitor",{"EARLY_PHASE1":8386,"PHASE1":8388,"PHASE2":8390,"PHASE3":8392,"PHASE4":8394,"NA":8396},{"trials":8387,"activeCount":98},[],{"trials":8389,"activeCount":98},[],{"trials":8391,"activeCount":98},[],{"trials":8393,"activeCount":98},[],{"trials":8395,"activeCount":98},[],{"trials":8397,"activeCount":98},[8398],{"nctId":8399,"briefTitle":8400,"status":446,"phases":8401,"primaryCompletion":4522,"completion":4522,"start":8402,"enrollment":2098,"conditions":8403,"interventions":8404},"NCT00848250","Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children",[90],"2008-09",[821],[8384],{"intervention":8406,"totalTrials":94,"cells":8407},"atorvastatin",{"EARLY_PHASE1":8408,"PHASE1":8410,"PHASE2":8412,"PHASE3":8414,"PHASE4":8416,"NA":8418},{"trials":8409,"activeCount":98},[],{"trials":8411,"activeCount":98},[],{"trials":8413,"activeCount":98},[],{"trials":8415,"activeCount":98},[],{"trials":8417,"activeCount":98},[],{"trials":8419,"activeCount":98},[8420],{"nctId":8421,"briefTitle":8422,"status":446,"phases":8423,"primaryCompletion":2372,"completion":4014,"start":1231,"enrollment":8424,"conditions":8425,"interventions":8430},"NCT00791648","Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery",[90],653,[8426,8427,8428,8429,21],"Acute Kidney Injury","Post-Operative Delirium","Icu Delirium","Acute Renal Failure",[8406],{"intervention":8432,"totalTrials":94,"cells":8433},"Nicotine Patch, 7 Mg\u002F24 Hr",{"EARLY_PHASE1":8434,"PHASE1":8436,"PHASE2":8438,"PHASE3":8440,"PHASE4":8442,"NA":8444},{"trials":8435,"activeCount":98},[],{"trials":8437,"activeCount":98},[],{"trials":8439,"activeCount":98},[],{"trials":8441,"activeCount":98},[],{"trials":8443,"activeCount":98},[],{"trials":8445,"activeCount":98},[8446],{"nctId":8447,"briefTitle":8448,"status":634,"phases":8449,"primaryCompletion":8450,"completion":8450,"start":8451,"enrollment":2182,"conditions":8452,"interventions":8455},"NCT03838484","Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia",[90],"2020-02-24","2019-05-10",[8453,8454],"Schizophrenia","Impulsive Behavior",[8432],{"intervention":8457,"totalTrials":94,"cells":8458},"ESR-specific PET scan",{"EARLY_PHASE1":8459,"PHASE1":8461,"PHASE2":8463,"PHASE3":8465,"PHASE4":8467,"NA":8469},{"trials":8460,"activeCount":98},[],{"trials":8462,"activeCount":98},[],{"trials":8464,"activeCount":98},[],{"trials":8466,"activeCount":98},[],{"trials":8468,"activeCount":98},[],{"trials":8470,"activeCount":98},[8471],{"nctId":8472,"briefTitle":8473,"status":580,"phases":8474,"primaryCompletion":4126,"completion":4126,"start":8475,"enrollment":98,"conditions":8476,"interventions":8477},"NCT04280523","TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH",[],"2021-01-05",[5622],[8457],{"intervention":8479,"totalTrials":94,"cells":8480},"Vancomycin powder",{"EARLY_PHASE1":8481,"PHASE1":8483,"PHASE2":8485,"PHASE3":8487,"PHASE4":8489,"NA":8491},{"trials":8482,"activeCount":98},[],{"trials":8484,"activeCount":98},[],{"trials":8486,"activeCount":98},[],{"trials":8488,"activeCount":98},[],{"trials":8490,"activeCount":98},[],{"trials":8492,"activeCount":98},[8493],{"nctId":8494,"briefTitle":8495,"status":580,"phases":8496,"primaryCompletion":4014,"completion":4014,"start":5649,"enrollment":98,"conditions":8497,"interventions":8499},"NCT01566422","Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients",[90],[8498],"Surgical Site Infection",[8479],{"intervention":8501,"totalTrials":94,"cells":8502},"PrEP",{"EARLY_PHASE1":8503,"PHASE1":8505,"PHASE2":8507,"PHASE3":8509,"PHASE4":8511,"NA":8513},{"trials":8504,"activeCount":98},[],{"trials":8506,"activeCount":98},[],{"trials":8508,"activeCount":98},[],{"trials":8510,"activeCount":98},[],{"trials":8512,"activeCount":98},[],{"trials":8514,"activeCount":98},[8515],{"nctId":8516,"briefTitle":8517,"status":446,"phases":8518,"primaryCompletion":8519,"completion":8519,"start":8520,"enrollment":8521,"conditions":8522,"interventions":8524},"NCT04071470","Storytelling to Increase Family Support for Pre Exposure Prophylaxis Use",[90],"2023-06-20","2021-01-01",128,[8523],"HIV Infections",[8501],{"intervention":1237,"totalTrials":94,"cells":8526},{"EARLY_PHASE1":8527,"PHASE1":8529,"PHASE2":8531,"PHASE3":8533,"PHASE4":8535,"NA":8537},{"trials":8528,"activeCount":98},[],{"trials":8530,"activeCount":98},[],{"trials":8532,"activeCount":98},[],{"trials":8534,"activeCount":98},[],{"trials":8536,"activeCount":98},[],{"trials":8538,"activeCount":98},[8539],{"nctId":1228,"briefTitle":1229,"status":446,"phases":8540,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":253,"conditions":8541,"interventions":8542},[90],[1235],[1237,1238],{"intervention":7131,"totalTrials":94,"cells":8544},{"EARLY_PHASE1":8545,"PHASE1":8547,"PHASE2":8549,"PHASE3":8551,"PHASE4":8553,"NA":8555},{"trials":8546,"activeCount":98},[],{"trials":8548,"activeCount":98},[],{"trials":8550,"activeCount":98},[],{"trials":8552,"activeCount":98},[],{"trials":8554,"activeCount":98},[],{"trials":8556,"activeCount":98},[8557],{"nctId":7125,"briefTitle":7126,"status":446,"phases":8558,"start":7128,"enrollment":769,"conditions":8559,"interventions":8560},[],[5777],[7069,7131],{"intervention":7165,"totalTrials":94,"cells":8562},{"EARLY_PHASE1":8563,"PHASE1":8565,"PHASE2":8567,"PHASE3":8569,"PHASE4":8571,"NA":8573},{"trials":8564,"activeCount":98},[],{"trials":8566,"activeCount":98},[],{"trials":8568,"activeCount":98},[],{"trials":8570,"activeCount":98},[],{"trials":8572,"activeCount":98},[],{"trials":8574,"activeCount":98},[8575],{"nctId":7155,"briefTitle":7156,"status":446,"phases":8576,"primaryCompletion":2113,"completion":7158,"start":7159,"enrollment":7160,"conditions":8577,"interventions":8578},[90],[7162,7163],[561,7165,7166,535,7167],{"intervention":7166,"totalTrials":94,"cells":8580},{"EARLY_PHASE1":8581,"PHASE1":8583,"PHASE2":8585,"PHASE3":8587,"PHASE4":8589,"NA":8591},{"trials":8582,"activeCount":98},[],{"trials":8584,"activeCount":98},[],{"trials":8586,"activeCount":98},[],{"trials":8588,"activeCount":98},[],{"trials":8590,"activeCount":98},[],{"trials":8592,"activeCount":98},[8593],{"nctId":7155,"briefTitle":7156,"status":446,"phases":8594,"primaryCompletion":2113,"completion":7158,"start":7159,"enrollment":7160,"conditions":8595,"interventions":8596},[90],[7162,7163],[561,7165,7166,535,7167],{"intervention":7167,"totalTrials":94,"cells":8598},{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8603,"PHASE3":8605,"PHASE4":8607,"NA":8609},{"trials":8600,"activeCount":98},[],{"trials":8602,"activeCount":98},[],{"trials":8604,"activeCount":98},[],{"trials":8606,"activeCount":98},[],{"trials":8608,"activeCount":98},[],{"trials":8610,"activeCount":98},[8611],{"nctId":7155,"briefTitle":7156,"status":446,"phases":8612,"primaryCompletion":2113,"completion":7158,"start":7159,"enrollment":7160,"conditions":8613,"interventions":8614},[90],[7162,7163],[561,7165,7166,535,7167],{"intervention":8616,"totalTrials":94,"cells":8617},"Chlorhexidine irrigation",{"EARLY_PHASE1":8618,"PHASE1":8620,"PHASE2":8622,"PHASE3":8624,"PHASE4":8626,"NA":8628},{"trials":8619,"activeCount":98},[],{"trials":8621,"activeCount":98},[],{"trials":8623,"activeCount":98},[],{"trials":8625,"activeCount":98},[],{"trials":8627,"activeCount":98},[],{"trials":8629,"activeCount":98},[8630],{"nctId":8631,"briefTitle":8632,"status":446,"phases":8633,"primaryCompletion":4588,"completion":4588,"start":4015,"enrollment":8634,"conditions":8635,"interventions":8636},"NCT02395614","Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation",[90],88,[5996],[8616,8637],"triple antibiotic irrigation",{"intervention":8637,"totalTrials":94,"cells":8639},{"EARLY_PHASE1":8640,"PHASE1":8642,"PHASE2":8644,"PHASE3":8646,"PHASE4":8648,"NA":8650},{"trials":8641,"activeCount":98},[],{"trials":8643,"activeCount":98},[],{"trials":8645,"activeCount":98},[],{"trials":8647,"activeCount":98},[],{"trials":8649,"activeCount":98},[],{"trials":8651,"activeCount":98},[8652],{"nctId":8631,"briefTitle":8632,"status":446,"phases":8653,"primaryCompletion":4588,"completion":4588,"start":4015,"enrollment":8634,"conditions":8654,"interventions":8655},[90],[5996],[8616,8637],{"intervention":8657,"totalTrials":94,"cells":8658},"Standard of Care",{"EARLY_PHASE1":8659,"PHASE1":8661,"PHASE2":8663,"PHASE3":8665,"PHASE4":8667,"NA":8669},{"trials":8660,"activeCount":98},[],{"trials":8662,"activeCount":98},[],{"trials":8664,"activeCount":98},[],{"trials":8666,"activeCount":98},[],{"trials":8668,"activeCount":98},[],{"trials":8670,"activeCount":98},[8671],{"nctId":8672,"briefTitle":8673,"status":446,"phases":8674,"primaryCompletion":8675,"completion":8676,"start":8677,"enrollment":8678,"conditions":8679,"interventions":8680},"NCT03076359","Traditional Healers as Adherence Partners for Persons Living With HIV in Rural Mozambique",[90],"2019-05-30","2019-06-30","2015-06-10",320,[5548],[8657],{"intervention":8682,"totalTrials":94,"cells":8683},"Vaginal Misoprostol",{"EARLY_PHASE1":8684,"PHASE1":8686,"PHASE2":8688,"PHASE3":8690,"PHASE4":8692,"NA":8694},{"trials":8685,"activeCount":98},[],{"trials":8687,"activeCount":98},[],{"trials":8689,"activeCount":98},[],{"trials":8691,"activeCount":98},[],{"trials":8693,"activeCount":98},[],{"trials":8695,"activeCount":98},[8696],{"nctId":8697,"briefTitle":8698,"status":446,"phases":8699,"primaryCompletion":6837,"completion":6837,"start":3063,"enrollment":8700,"conditions":8701,"interventions":8703},"NCT01634854","A Study Comparing Vaginal Misoprostol and Intravenous Oxytocin for Induction of Labor",[90],130,[8702],"Induction of Labor in Multiparous Women",[8682,8704],"Intravenous Oxytocin",{"intervention":8704,"totalTrials":94,"cells":8706},{"EARLY_PHASE1":8707,"PHASE1":8709,"PHASE2":8711,"PHASE3":8713,"PHASE4":8715,"NA":8717},{"trials":8708,"activeCount":98},[],{"trials":8710,"activeCount":98},[],{"trials":8712,"activeCount":98},[],{"trials":8714,"activeCount":98},[],{"trials":8716,"activeCount":98},[],{"trials":8718,"activeCount":98},[8719],{"nctId":8697,"briefTitle":8698,"status":446,"phases":8720,"primaryCompletion":6837,"completion":6837,"start":3063,"enrollment":8700,"conditions":8721,"interventions":8722},[90],[8702],[8682,8704],{"intervention":8724,"totalTrials":94,"cells":8725},"Magnevist",{"EARLY_PHASE1":8726,"PHASE1":8728,"PHASE2":8730,"PHASE3":8732,"PHASE4":8734,"NA":8736},{"trials":8727,"activeCount":98},[],{"trials":8729,"activeCount":98},[],{"trials":8731,"activeCount":98},[],{"trials":8733,"activeCount":98},[],{"trials":8735,"activeCount":98},[],{"trials":8737,"activeCount":98},[8738],{"nctId":8739,"briefTitle":8740,"status":446,"phases":8741,"primaryCompletion":3043,"completion":3043,"start":8742,"enrollment":8743,"conditions":8744,"interventions":8746},"NCT03910114","Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography",[],"1990-07-01",500,[8745],"Magnetic Resonance Imaging Contrast Agents",[8724,8747,8748],"Dotarem","Gadovist",{"intervention":8747,"totalTrials":94,"cells":8750},{"EARLY_PHASE1":8751,"PHASE1":8753,"PHASE2":8755,"PHASE3":8757,"PHASE4":8759,"NA":8761},{"trials":8752,"activeCount":98},[],{"trials":8754,"activeCount":98},[],{"trials":8756,"activeCount":98},[],{"trials":8758,"activeCount":98},[],{"trials":8760,"activeCount":98},[],{"trials":8762,"activeCount":98},[8763],{"nctId":8739,"briefTitle":8740,"status":446,"phases":8764,"primaryCompletion":3043,"completion":3043,"start":8742,"enrollment":8743,"conditions":8765,"interventions":8766},[],[8745],[8724,8747,8748],{"intervention":8748,"totalTrials":94,"cells":8768},{"EARLY_PHASE1":8769,"PHASE1":8771,"PHASE2":8773,"PHASE3":8775,"PHASE4":8777,"NA":8779},{"trials":8770,"activeCount":98},[],{"trials":8772,"activeCount":98},[],{"trials":8774,"activeCount":98},[],{"trials":8776,"activeCount":98},[],{"trials":8778,"activeCount":98},[],{"trials":8780,"activeCount":98},[8781],{"nctId":8739,"briefTitle":8740,"status":446,"phases":8782,"primaryCompletion":3043,"completion":3043,"start":8742,"enrollment":8743,"conditions":8783,"interventions":8784},[],[8745],[8724,8747,8748],{"intervention":2790,"totalTrials":94,"cells":8786},{"EARLY_PHASE1":8787,"PHASE1":8789,"PHASE2":8791,"PHASE3":8793,"PHASE4":8795,"NA":8797},{"trials":8788,"activeCount":98},[],{"trials":8790,"activeCount":98},[],{"trials":8792,"activeCount":98},[],{"trials":8794,"activeCount":98},[],{"trials":8796,"activeCount":98},[],{"trials":8798,"activeCount":98},[8799],{"nctId":2781,"briefTitle":2782,"status":446,"phases":8800,"primaryCompletion":2784,"completion":2784,"start":2785,"enrollment":2786,"conditions":8801,"interventions":8802},[90],[2788],[2790,2791]]